doi	section	ITC num	Ind studies num	questions	decision	PMID
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Medical Condition of Interest Name	thyroid eye disease	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of last author affiliations	XXXX	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 1	teprotumumab	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 2	intravenous methylprednisolone	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Anchored comparison?	No	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in proptosis in mm	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	419	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	79	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Other(s)	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: unadjusted treatment effect	-2.38	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.49;-1.27]	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: adjusted treatment effect	-2.31	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.45;-1.17]	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Patient-level data used	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Clinical Trial	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01868997	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Patient-level data used	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Clinical Trial	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01868997	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Patient-level data used	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Clinical Trial	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03298867	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Patient-level data used	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Clinical Trial	Yes	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03298867	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Patient-level data used	No	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Clinical Trial	No	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	meta-analysis of clinical trials from 12 articles	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Number of treatment arms (clinical trial only)	NA	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Patient-level data used	No	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Clinical Trial	XXXX	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	bartalena at al., 2012	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Number of treatment arms (clinical trial only)	XXXX	NA
10.1002/edm2.259	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes	NA
10.1002/edm2.259	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1002/edm2.259	general_information	NA	NA	Countries of last author affiliations	denmark	NA
10.1002/edm2.259	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1002/edm2.259	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1002/edm2.259	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1002/edm2.259	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1002/edm2.259	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1002/edm2.259	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1002/edm2.259	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1002/edm2.259	general_information	NA	NA	Countries of last author affiliations	XXXX	NA
10.1002/edm2.259	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1002/edm2.259	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1002/edm2.259	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1002/edm2.259	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1002/edm2.259	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1002/edm2.259	methodology	1	NA	Treatment name 1	semaglutide 0.5  +  1 mg	NA
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1002/edm2.259	methodology	1	NA	Treatment name 2	dulaglutide 1.5 mg	NA
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1002/edm2.259	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1002/edm2.259	methodology	1	NA	Anchored comparison?	Yes	NA
10.1002/edm2.259	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1002/edm2.259	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1002/edm2.259	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	3 point mace (cardiovascular death, non-fatal myocardial infraction, non-fatal stroke)	NA
10.1002/edm2.259	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1002/edm2.259	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1002/edm2.259	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1002/edm2.259	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1002/edm2.259	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1002/edm2.259	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1002/edm2.259	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1002/edm2.259	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1002/edm2.259	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1002/edm2.259	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1002/edm2.259	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1002/edm2.259	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1002/edm2.259	results	1	NA	Primary outcome: adjusted treatment effect	0.74	NA
10.1002/edm2.259	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.06	NA
10.1002/edm2.259	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	NA
10.1002/edm2.259	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	NA
10.1002/edm2.259	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	NA
10.1002/edm2.259	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	NA
10.1002/edm2.259	study_information	NA	1	Patient-level data used	Yes	NA
10.1002/edm2.259	study_information	NA	1	Clinical Trial	Yes	NA
10.1002/edm2.259	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01720446	NA
10.1002/edm2.259	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1002/edm2.259	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1002/edm2.259	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1002/edm2.259	study_information	NA	1	Patient-level data used	Yes	NA
10.1002/edm2.259	study_information	NA	1	Clinical Trial	Yes	NA
10.1002/edm2.259	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01720446	NA
10.1002/edm2.259	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1002/edm2.259	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1002/edm2.259	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1002/edm2.259	study_information	NA	2	Patient-level data used	No	NA
10.1002/edm2.259	study_information	NA	2	Clinical Trial	Yes	NA
10.1002/edm2.259	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01394952	NA
10.1002/edm2.259	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1002/edm2.259	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1002/edm2.259	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1002/edm2.259	study_information	NA	2	Patient-level data used	XXXX	NA
10.1002/edm2.259	study_information	NA	2	Clinical Trial	Yes	NA
10.1002/edm2.259	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01394952	NA
10.1002/edm2.259	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1002/edm2.259	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1002/edm2.259	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/bf03261873	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder	NA
10.1007/bf03261873	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/bf03261873	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/bf03261873	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/bf03261873	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/bf03261873	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/bf03261873	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/bf03261873	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/bf03261873	methodology	1	NA	Treatment name 1	guanfacine extended-release low dose	23113551
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	23113551
10.1007/bf03261873	methodology	1	NA	Treatment name 2	atomoxetine	23113551
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 2	3	23113551
10.1007/bf03261873	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	23113551
10.1007/bf03261873	methodology	1	NA	Anchored comparison?	No	23113551
10.1007/bf03261873	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	23113551
10.1007/bf03261873	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	23113551
10.1007/bf03261873	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23113551
10.1007/bf03261873	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	23113551
10.1007/bf03261873	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23113551
10.1007/bf03261873	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23113551
10.1007/bf03261873	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23113551
10.1007/bf03261873	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	23113551
10.1007/bf03261873	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23113551
10.1007/bf03261873	methodology	2	NA	Treatment name 1	guanfacine extended-release mid dose	23113551
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	23113551
10.1007/bf03261873	methodology	2	NA	Treatment name 2	atomoxetine	23113551
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 2	3	23113551
10.1007/bf03261873	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	23113551
10.1007/bf03261873	methodology	2	NA	Anchored comparison?	No	23113551
10.1007/bf03261873	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	23113551
10.1007/bf03261873	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	23113551
10.1007/bf03261873	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23113551
10.1007/bf03261873	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	23113551
10.1007/bf03261873	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23113551
10.1007/bf03261873	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23113551
10.1007/bf03261873	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23113551
10.1007/bf03261873	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	23113551
10.1007/bf03261873	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23113551
10.1007/bf03261873	methodology	3	NA	Treatment name 1	guanfacine extended-release high dose	23113551
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 1	1;2	23113551
10.1007/bf03261873	methodology	3	NA	Treatment name 2	atomoxetine	23113551
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 2	3	23113551
10.1007/bf03261873	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	23113551
10.1007/bf03261873	methodology	3	NA	Anchored comparison?	No	23113551
10.1007/bf03261873	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	23113551
10.1007/bf03261873	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	23113551
10.1007/bf03261873	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23113551
10.1007/bf03261873	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	23113551
10.1007/bf03261873	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23113551
10.1007/bf03261873	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23113551
10.1007/bf03261873	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23113551
10.1007/bf03261873	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	23113551
10.1007/bf03261873	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23113551
10.1007/bf03261873	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84	23113551
10.1007/bf03261873	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	147	23113551
10.1007/bf03261873	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	49	23113551
10.1007/bf03261873	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23113551
10.1007/bf03261873	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23113551
10.1007/bf03261873	results	1	NA	Number of covariates adjusted for/matched on	6	23113551
10.1007/bf03261873	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	23113551
10.1007/bf03261873	results	1	NA	Primary outcome: treatment effect contrast	Means difference	23113551
10.1007/bf03261873	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	23113551
10.1007/bf03261873	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	23113551
10.1007/bf03261873	results	1	NA	Primary outcome: adjusted treatment effect	NA	23113551
10.1007/bf03261873	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	84	23113551
10.1007/bf03261873	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	46	23113551
10.1007/bf03261873	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	16	23113551
10.1007/bf03261873	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23113551
10.1007/bf03261873	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23113551
10.1007/bf03261873	results	2	NA	Number of covariates adjusted for/matched on	6	23113551
10.1007/bf03261873	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	23113551
10.1007/bf03261873	results	2	NA	Primary outcome: treatment effect contrast	Means difference	23113551
10.1007/bf03261873	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02	23113551
10.1007/bf03261873	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	23113551
10.1007/bf03261873	results	2	NA	Primary outcome: adjusted treatment effect	NA	23113551
10.1007/bf03261873	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	84	23113551
10.1007/bf03261873	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	82	23113551
10.1007/bf03261873	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38	23113551
10.1007/bf03261873	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23113551
10.1007/bf03261873	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23113551
10.1007/bf03261873	results	3	NA	Number of covariates adjusted for/matched on	6	23113551
10.1007/bf03261873	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	23113551
10.1007/bf03261873	results	3	NA	Primary outcome: treatment effect contrast	Means difference	23113551
10.1007/bf03261873	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	23113551
10.1007/bf03261873	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	23113551
10.1007/bf03261873	results	3	NA	Primary outcome: adjusted treatment effect	NA	23113551
10.1007/bf03261873	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/bf03261873	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/bf03261873	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009	NA
10.1007/bf03261873	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/bf03261873	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/bf03261873	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1007/bf03261873	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/bf03261873	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/bf03261873	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618	NA
10.1007/bf03261873	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/bf03261873	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/bf03261873	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/bf03261873	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/bf03261873	study_information	NA	3	Patient-level data used	No	NA
10.1007/bf03261873	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/bf03261873	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	michelson et al. (2001)	NA
10.1007/bf03261873	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/bf03261873	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Mentioned sources of funding	No fundings	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Mentioned sources of funding	XXXX	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	XXXX	NA
10.1007/s00432-021-03602-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 1	regorafenib	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 2	cabozantinib	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s00432-021-03602-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s00432-021-03602-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	331	NA
10.1007/s00432-021-03602-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	278	NA
10.1007/s00432-021-03602-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s00432-021-03602-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No	NA
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s00432-021-03602-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: unadjusted treatment effect	0.8	NA
10.1007/s00432-021-03602-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.66;0.97]	NA
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: adjusted treatment effect	0.83	NA
10.1007/s00432-021-03602-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.62;1.09]	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Clinical Trial	No	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from unknown origin	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Clinical Trial	No	NA
10.1007/s00432-021-03602-w	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	unspecified real-world data	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Patient-level data used	No	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s00432-021-03602-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Patient-level data used	No	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s00432-021-03602-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s00432-021-03602-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Mentioned sources of funding	No fundings	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Mentioned sources of funding	XXXX	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s11523-021-00803-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 1	lenvatinib	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s11523-021-00803-8	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s11523-021-00803-8	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	336	NA
10.1007/s11523-021-00803-8	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	455	NA
10.1007/s11523-021-00803-8	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s11523-021-00803-8	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s11523-021-00803-8	results	1	NA	Number of covariates adjusted for/matched on	12	NA
10.1007/s11523-021-00803-8	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1007/s11523-021-00803-8	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s11523-021-00803-8	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1007/s11523-021-00803-8	results	1	NA	Primary outcome: adjusted treatment effect	0.59	NA
10.1007/s11523-021-00803-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;0.75]	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Clinical Trial	No	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from 12 japanese centers from march 2018 to may 2020	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Clinical Trial	No	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	Multi-center japanese observational cohort	NA
10.1007/s11523-021-00803-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Patient-level data used	No	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s11523-021-00803-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Patient-level data used	No	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s11523-021-00803-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s11523-021-00803-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-014-0167-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 1	fingolimod	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 2	dimethyl fumarate	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Anchored comparison?	Yes	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s12325-014-0167-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 1	fingolimod	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 2	teriflunomide 7 mg	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 2	5	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Anchored comparison?	Yes	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s12325-014-0167-z	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 1	fingolimod	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 2	teriflunomide 14 mg	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 2	5	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Anchored comparison?	Yes	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s12325-014-0167-z	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-014-0167-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	769	NA
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	771	NA
10.1007/s12325-014-0167-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	783	NA
10.1007/s12325-014-0167-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783	NA
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-014-0167-z	results	1	NA	Number of covariates adjusted for/matched on	2	NA
10.1007/s12325-014-0167-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Past treatments for the disease of interest	NA
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: treatment effect contrast	RR	NA
10.1007/s12325-014-0167-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: unadjusted treatment effect	1.58	NA
10.1007/s12325-014-0167-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.00;2.50]	NA
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: adjusted treatment effect	1.67	NA
10.1007/s12325-014-0167-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.08;2.57]	NA
10.1007/s12325-014-0167-z	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	365	NA
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	363	NA
10.1007/s12325-014-0167-z	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	783	NA
10.1007/s12325-014-0167-z	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783	NA
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-014-0167-z	results	2	NA	Number of covariates adjusted for/matched on	1	NA
10.1007/s12325-014-0167-z	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age	NA
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: treatment effect contrast	RR	NA
10.1007/s12325-014-0167-z	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: unadjusted treatment effect	2.18	NA
10.1007/s12325-014-0167-z	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.46;3.25]	NA
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: adjusted treatment effect	2.01	NA
10.1007/s12325-014-0167-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.38;2.93]	NA
10.1007/s12325-014-0167-z	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	358	NA
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	363	NA
10.1007/s12325-014-0167-z	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	783	NA
10.1007/s12325-014-0167-z	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783	NA
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773	NA
10.1007/s12325-014-0167-z	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-014-0167-z	results	3	NA	Number of covariates adjusted for/matched on	1	NA
10.1007/s12325-014-0167-z	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age	NA
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: treatment effect contrast	RR	NA
10.1007/s12325-014-0167-z	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: unadjusted treatment effect	1.75	NA
10.1007/s12325-014-0167-z	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.18;2.57]	NA
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: adjusted treatment effect	1.61	NA
10.1007/s12325-014-0167-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.12;2.31]	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Patient-level data used	No	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s12325-014-0167-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-014-0167-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of first author affiliations	belgium	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-017-0564-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 1	NA	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 1	1	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 2	obinutuzumab + chlorambucil	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 2	2	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Anchored comparison?	Yes	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Primary outcome: variable type	Time-to-event	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	28573505
10.1007/s12325-017-0564-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	28573505
10.1007/s12325-017-0564-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	28573505
10.1007/s12325-017-0564-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	28573505
10.1007/s12325-017-0564-1	results	1	NA	Number of covariates adjusted for/matched on	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	28573505
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: treatment effect contrast	HR	28573505
10.1007/s12325-017-0564-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	28573505
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: unadjusted treatment effect	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: adjusted treatment effect	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	28573505
10.1007/s12325-017-0564-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	28573505
10.1007/s12325-017-0564-1	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-017-0564-1	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-017-0564-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487	NA
10.1007/s12325-017-0564-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-017-0564-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-017-0564-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-017-0564-1	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-017-0564-1	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-017-0564-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01010061	NA
10.1007/s12325-017-0564-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-017-0564-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-017-0564-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small-cell lung cancer	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-018-0734-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 1	dabrafenib + trametinib	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 2	nivolumab	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Anchored comparison?	NA	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-018-0734-9	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-018-0734-9	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	290	NA
10.1007/s12325-018-0734-9	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	57	NA
10.1007/s12325-018-0734-9	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s12325-018-0734-9	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-018-0734-9	results	1	NA	Number of covariates adjusted for/matched on	10	NA
10.1007/s12325-018-0734-9	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1007/s12325-018-0734-9	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	34	NA
10.1007/s12325-018-0734-9	results	1	NA	Primary outcome: treatment effect contrast	NA	NA
10.1007/s12325-018-0734-9	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	NA
10.1007/s12325-018-0734-9	results	1	NA	Primary outcome: adjusted treatment effect	NA	NA
10.1007/s12325-018-0734-9	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01336634	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01336634	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01673867	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-018-0734-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01673867	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-018-0734-9	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-00991-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 1	inotuzumab ozogamicin	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 2	blinatumomab	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Anchored comparison?	Yes	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-019-00991-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 1	inotuzumab ozogamicin	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 2	blinatumomab	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Anchored comparison?	Yes	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	complete remission rate	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-019-00991-w	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-019-00991-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	271	NA
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	134	NA
10.1007/s12325-019-00991-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	164	NA
10.1007/s12325-019-00991-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70	NA
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	162	NA
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	53	NA
10.1007/s12325-019-00991-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s12325-019-00991-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-019-00991-w	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1007/s12325-019-00991-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	NA
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1007/s12325-019-00991-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: unadjusted treatment effect	2.63	NA
10.1007/s12325-019-00991-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.35;5.12]	NA
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: adjusted treatment effect	2.81	NA
10.1007/s12325-019-00991-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.12;7.05]	NA
10.1007/s12325-019-00991-w	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	271	NA
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	134	NA
10.1007/s12325-019-00991-w	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	164	NA
10.1007/s12325-019-00991-w	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	138	NA
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	162	NA
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	133	NA
10.1007/s12325-019-00991-w	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-019-00991-w	results	2	NA	Number of covariates adjusted for/matched on	6	NA
10.1007/s12325-019-00991-w	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	NA
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: treatment effect contrast	OR	NA
10.1007/s12325-019-00991-w	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: unadjusted treatment effect	2.63	NA
10.1007/s12325-019-00991-w	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.35;5.12]	NA
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: adjusted treatment effect	3.91	NA
10.1007/s12325-019-00991-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.53;9.99]	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-00991-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-00991-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-00991-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-01156-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 1	apalutamide	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 1	1	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 2	enzalutamide	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 2	2	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Anchored comparison?	Yes	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Primary outcome: variable type	Time-to-event	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31813086
10.1007/s12325-019-01156-5	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31813086
10.1007/s12325-019-01156-5	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	933	31813086
10.1007/s12325-019-01156-5	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468	31813086
10.1007/s12325-019-01156-5	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	806	31813086
10.1007/s12325-019-01156-5	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	401	31813086
10.1007/s12325-019-01156-5	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31813086
10.1007/s12325-019-01156-5	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31813086
10.1007/s12325-019-01156-5	results	1	NA	Number of covariates adjusted for/matched on	7	31813086
10.1007/s12325-019-01156-5	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	31813086
10.1007/s12325-019-01156-5	results	1	NA	Primary outcome: treatment effect contrast	HR	31813086
10.1007/s12325-019-01156-5	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31813086
10.1007/s12325-019-01156-5	results	1	NA	Primary outcome: adjusted treatment effect	0.91	31813086
10.1007/s12325-019-01156-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	31813086
10.1007/s12325-019-01156-5	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-01156-5	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-01156-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1007/s12325-019-01156-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01156-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01156-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01156-5	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-01156-5	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-01156-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924	NA
10.1007/s12325-019-01156-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01156-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01156-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-01157-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 1	apalutamide	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 2	enzalutamide	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Anchored comparison?	Yes	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	fatigue occurrence	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-019-01157-4	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-019-01157-4	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	933	NA
10.1007/s12325-019-01157-4	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468	NA
10.1007/s12325-019-01157-4	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	806	NA
10.1007/s12325-019-01157-4	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	401	NA
10.1007/s12325-019-01157-4	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s12325-019-01157-4	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-019-01157-4	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1007/s12325-019-01157-4	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.1007/s12325-019-01157-4	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1007/s12325-019-01157-4	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-019-01157-4	results	1	NA	Primary outcome: adjusted treatment effect	0.57	NA
10.1007/s12325-019-01157-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.37;0.88]	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01157-4	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-01157-4	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-01157-4	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Medical Condition of Interest Name	atrial fibrillation	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Medical Condition of Interest Name	atrial fibrillation	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-01173-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 1	ratiofrequency catheter ablation with ablation index	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 2	ratiofrequency catheter ablation with cryoballoon	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	arrhythmia recurrence	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-019-01173-4	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-019-01173-4	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	155	NA
10.1007/s12325-019-01173-4	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	132	NA
10.1007/s12325-019-01173-4	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	125	NA
10.1007/s12325-019-01173-4	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1007/s12325-019-01173-4	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-019-01173-4	results	1	NA	Number of covariates adjusted for/matched on	1	NA
10.1007/s12325-019-01173-4	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age	NA
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s12325-019-01173-4	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: unadjusted treatment effect	0.42	NA
10.1007/s12325-019-01173-4	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.21;0.86]	NA
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: adjusted treatment effect	0.41	NA
10.1007/s12325-019-01173-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.85]	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	solimene et al. doi: 10.1007/s10840-018-0420-5	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	solimene et al. doi: 10.1007/s10840-018-0420-5	NA
10.1007/s12325-019-01173-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	jourda et al.	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	jourda et al.	NA
10.1007/s12325-019-01173-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	giovanni et al. 10.1111/jce.12409	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	belgium	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	giovanni et al. 10.1111/jce.12409	NA
10.1007/s12325-019-01173-4	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	zhao et al. doi: 10.1016/j.acvd.2017.01.015	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Clinical Trial	No	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	zhao et al. doi: 10.1016/j.acvd.2017.01.015	NA
10.1007/s12325-019-01173-4	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-019-0873-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 1	blinatumomab	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 1	1	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 2	inotuzumab ozogamicin	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 2	2	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Anchored comparison?	Yes	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Primary outcome: variable type	Time-to-event	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30758745
10.1007/s12325-019-0873-7	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 1	blinatumomab	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 1	1	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 2	inotuzumab ozogamicin	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 2	2	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Anchored comparison?	No	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Primary outcome: variable type	Time-to-event	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30758745
10.1007/s12325-019-0873-7	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30758745
10.1007/s12325-019-0873-7	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	164	30758745
10.1007/s12325-019-0873-7	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162	30758745
10.1007/s12325-019-0873-7	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	203	30758745
10.1007/s12325-019-0873-7	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	30758745
10.1007/s12325-019-0873-7	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30758745
10.1007/s12325-019-0873-7	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30758745
10.1007/s12325-019-0873-7	results	1	NA	Number of covariates adjusted for/matched on	9	30758745
10.1007/s12325-019-0873-7	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	30758745
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: treatment effect contrast	NA	30758745
10.1007/s12325-019-0873-7	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30758745
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: unadjusted treatment effect	1.02	30758745
10.1007/s12325-019-0873-7	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.16	30758745
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: adjusted treatment effect	1.62	30758745
10.1007/s12325-019-0873-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.04	30758745
10.1007/s12325-019-0873-7	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30758745
10.1007/s12325-019-0873-7	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	164	30758745
10.1007/s12325-019-0873-7	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	203	30758745
10.1007/s12325-019-0873-7	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30758745
10.1007/s12325-019-0873-7	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30758745
10.1007/s12325-019-0873-7	results	2	NA	Number of covariates adjusted for/matched on	9	30758745
10.1007/s12325-019-0873-7	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	30758745
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: treatment effect contrast	NA	30758745
10.1007/s12325-019-0873-7	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30758745
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: unadjusted treatment effect	-0.18	30758745
10.1007/s12325-019-0873-7	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.69	30758745
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: adjusted treatment effect	0.15	30758745
10.1007/s12325-019-0873-7	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.76	30758745
10.1007/s12325-019-0873-7	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-019-0873-7	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-019-0873-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167	NA
10.1007/s12325-019-0873-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-0873-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-0873-7	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-019-0873-7	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-019-0873-7	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-019-0873-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784	NA
10.1007/s12325-019-0873-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-019-0873-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-019-0873-7	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Medical Condition of Interest Name	age-related macular degeneration	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of first author affiliations	japan	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of first author affiliations	japan	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-020-01298-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 1	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 2	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	number of etdrs (early treatment diabetic retinopathy study) letters gained vs baseline after 2 years	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-020-01298-x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-020-01298-x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	607	NA
10.1007/s12325-020-01298-x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	124	NA
10.1007/s12325-020-01298-x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s12325-020-01298-x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-020-01298-x	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1007/s12325-020-01298-x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1007/s12325-020-01298-x	results	1	NA	Primary outcome: treatment effect contrast	Median difference	NA
10.1007/s12325-020-01298-x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1007/s12325-020-01298-x	results	1	NA	Primary outcome: adjusted treatment effect	-0.99	NA
10.1007/s12325-020-01298-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.90;1.93]	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02305238	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02305238	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	XXXX	NA
10.1007/s12325-020-01298-x	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00509795	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00509795	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01298-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00637377	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-020-01298-x	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00637377	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01298-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-020-01378-y	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 1	cabozantinib	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 1	1	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 2	regorafenib	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 2	2	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Anchored comparison?	No	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Primary outcome: variable type	NA	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32424805
10.1007/s12325-020-01378-y	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Treatment name 1	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Study 'number(s)' for treatment 1	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Treatment name 2	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Study 'number(s)' for treatment 2	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Type of population-adjusted indirect comparisons performed	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Anchored comparison?	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Form of the indirect comparison	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Primary outcome: variable type	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	32424805
10.1007/s12325-020-01378-y	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	379	32424805
10.1007/s12325-020-01378-y	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	187	32424805
10.1007/s12325-020-01378-y	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32424805
10.1007/s12325-020-01378-y	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32424805
10.1007/s12325-020-01378-y	results	1	NA	Number of covariates adjusted for/matched on	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	32424805
10.1007/s12325-020-01378-y	results	1	NA	Primary outcome: treatment effect contrast	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	Primary outcome: adjusted treatment effect	NA	32424805
10.1007/s12325-020-01378-y	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3474	32424805
10.1007/s12325-020-01378-y	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Number of covariates adjusted for/matched on	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Primary outcome: treatment effect contrast	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Primary outcome: unadjusted treatment effect	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	Primary outcome: adjusted treatment effect	NA	32424805
10.1007/s12325-020-01378-y	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32424805
10.1007/s12325-020-01378-y	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-020-01378-y	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-020-01378-y	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.1007/s12325-020-01378-y	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01378-y	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01378-y	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01378-y	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-020-01378-y	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-020-01378-y	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01774344	NA
10.1007/s12325-020-01378-y	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01378-y	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01378-y	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Medical Condition of Interest Name	haemophilia a	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of first author affiliations	sweden	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of last author affiliations	sweden	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-020-01599-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 1	NA	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 1	1	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 2	NA	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 2	2	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Anchored comparison?	No	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	33377987
10.1007/s12325-020-01599-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 1	NA	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 1	1	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 2	NA	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 2	2	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Anchored comparison?	No	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	33377987
10.1007/s12325-020-01599-1	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 1	NA	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 1	1	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 2	NA	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 2	2	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Anchored comparison?	No	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	33377987
10.1007/s12325-020-01599-1	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 1	NA	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 1	1	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 2	NA	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 2	2	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Anchored comparison?	No	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	33377987
10.1007/s12325-020-01599-1	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33377987
10.1007/s12325-020-01599-1	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	110	33377987
10.1007/s12325-020-01599-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33377987
10.1007/s12325-020-01599-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	81	33377987
10.1007/s12325-020-01599-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33377987
10.1007/s12325-020-01599-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33377987
10.1007/s12325-020-01599-1	results	1	NA	Number of covariates adjusted for/matched on	6	33377987
10.1007/s12325-020-01599-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	33377987
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: treatment effect contrast	Means difference	33377987
10.1007/s12325-020-01599-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33377987
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: unadjusted treatment effect	-2	33377987
10.1007/s12325-020-01599-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.5;-0.4]	33377987
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: adjusted treatment effect	-1.9	33377987
10.1007/s12325-020-01599-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.5;-0.4]	33377987
10.1007/s12325-020-01599-1	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	24	33377987
10.1007/s12325-020-01599-1	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33377987
10.1007/s12325-020-01599-1	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	62	33377987
10.1007/s12325-020-01599-1	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33377987
10.1007/s12325-020-01599-1	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33377987
10.1007/s12325-020-01599-1	results	2	NA	Number of covariates adjusted for/matched on	6	33377987
10.1007/s12325-020-01599-1	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	33377987
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: treatment effect contrast	Means difference	33377987
10.1007/s12325-020-01599-1	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33377987
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: unadjusted treatment effect	-2	33377987
10.1007/s12325-020-01599-1	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33377987
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: adjusted treatment effect	-1.6	33377987
10.1007/s12325-020-01599-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-4.2;1.1]	33377987
10.1007/s12325-020-01599-1	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	43	33377987
10.1007/s12325-020-01599-1	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33377987
10.1007/s12325-020-01599-1	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	33377987
10.1007/s12325-020-01599-1	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33377987
10.1007/s12325-020-01599-1	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33377987
10.1007/s12325-020-01599-1	results	3	NA	Number of covariates adjusted for/matched on	6	33377987
10.1007/s12325-020-01599-1	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	33377987
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: treatment effect contrast	Means difference	33377987
10.1007/s12325-020-01599-1	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33377987
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: unadjusted treatment effect	-0.4	33377987
10.1007/s12325-020-01599-1	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.9;1.1]	33377987
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: adjusted treatment effect	-0.6	33377987
10.1007/s12325-020-01599-1	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-2.0;0.8]	33377987
10.1007/s12325-020-01599-1	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	43	33377987
10.1007/s12325-020-01599-1	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33377987
10.1007/s12325-020-01599-1	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	45	33377987
10.1007/s12325-020-01599-1	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33377987
10.1007/s12325-020-01599-1	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33377987
10.1007/s12325-020-01599-1	results	4	NA	Number of covariates adjusted for/matched on	6	33377987
10.1007/s12325-020-01599-1	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	33377987
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: treatment effect contrast	Means difference	33377987
10.1007/s12325-020-01599-1	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33377987
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: unadjusted treatment effect	-3.5	33377987
10.1007/s12325-020-01599-1	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-6.6;-0.4]	33377987
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: adjusted treatment effect	-3.3	33377987
10.1007/s12325-020-01599-1	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33377987
10.1007/s12325-020-01599-1	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-020-01599-1	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-020-01599-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128	NA
10.1007/s12325-020-01599-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01599-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-020-01599-1	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-020-01599-1	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-020-01599-1	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-020-01599-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293	NA
10.1007/s12325-020-01599-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-020-01599-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1007/s12325-020-01599-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01700-2	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 1	cabozantinib	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 1	1	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 2	ramucirumab	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 2	2	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Anchored comparison?	No	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Primary outcome: variable type	NA	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33822328
10.1007/s12325-021-01700-2	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	33822328
10.1007/s12325-021-01700-2	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	197	33822328
10.1007/s12325-021-01700-2	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	114	33822328
10.1007/s12325-021-01700-2	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63	33822328
10.1007/s12325-021-01700-2	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	33822328
10.1007/s12325-021-01700-2	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33822328
10.1007/s12325-021-01700-2	results	1	NA	Number of covariates adjusted for/matched on	9	33822328
10.1007/s12325-021-01700-2	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	33822328
10.1007/s12325-021-01700-2	results	1	NA	Primary outcome: treatment effect contrast	NA	33822328
10.1007/s12325-021-01700-2	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	33822328
10.1007/s12325-021-01700-2	results	1	NA	Primary outcome: adjusted treatment effect	NA	33822328
10.1007/s12325-021-01700-2	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.104	33822328
10.1007/s12325-021-01700-2	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01700-2	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01700-2	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.1007/s12325-021-01700-2	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01700-2	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-021-01700-2	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01700-2	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01700-2	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01700-2	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435433	NA
10.1007/s12325-021-01700-2	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01700-2	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-021-01700-2	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory diffuse large b-cell lymphoma	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01756-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 1	1	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 2	salvage chemotherapy	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 2	2	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Anchored comparison?	No	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33970454
10.1007/s12325-021-01756-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33970454
10.1007/s12325-021-01756-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	523	33970454
10.1007/s12325-021-01756-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	248	33970454
10.1007/s12325-021-01756-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	33970454
10.1007/s12325-021-01756-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33970454
10.1007/s12325-021-01756-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33970454
10.1007/s12325-021-01756-0	results	1	NA	Number of covariates adjusted for/matched on	7	33970454
10.1007/s12325-021-01756-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	33970454
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: treatment effect contrast	OR	33970454
10.1007/s12325-021-01756-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33970454
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: unadjusted treatment effect	7.7	33970454
10.1007/s12325-021-01756-0	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33970454
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: adjusted treatment effect	7	33970454
10.1007/s12325-021-01756-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33970454
10.1007/s12325-021-01756-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01756-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01756-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044	NA
10.1007/s12325-021-01756-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s12325-021-01756-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1007/s12325-021-01756-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01756-0	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01756-0	study_information	NA	2	Clinical Trial	No	NA
10.1007/s12325-021-01756-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	scholar-1	NA
10.1007/s12325-021-01756-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Medical Condition of Interest Name	persistent atrial fibrillation	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Medical Condition of Interest Name	persistent atrial fibrillation	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01846-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 1	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 2	second-generation cryoballoon (cb)	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 2	5;6;7;8	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	arrhythmia recurrence	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-021-01846-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	389	NA
10.1007/s12325-021-01846-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	191	NA
10.1007/s12325-021-01846-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	156	NA
10.1007/s12325-021-01846-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1007/s12325-021-01846-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-021-01846-z	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.1007/s12325-021-01846-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s12325-021-01846-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: unadjusted treatment effect	0.39	NA
10.1007/s12325-021-01846-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.27;0.56]	NA
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: adjusted treatment effect	0.35	NA
10.1007/s12325-021-01846-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.23;0.52]	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	hussein et al. (2017)	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	hussein et al. (2017)	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02628730	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Clinical Trial	XXXX	NA
10.1007/s12325-021-01846-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02628730	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	2	Number of treatment arms (clinical trial only)	XXXX	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	solimene et al. (2019)	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	solimene et al. (2019)	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03277976	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	stabile et al. (2020)	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Patient-level data used	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03277976	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s12325-021-01846-z	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	gramlich et al. (2019)	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	gramlich et al. (2019)	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Clinical Trial	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213731	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Clinical Trial	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213731	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	6	Number of treatment arms (clinical trial only)	XXXX	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	circonte et al. (2015)	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Clinical Trial	No	NA
10.1007/s12325-021-01846-z	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	circonte et al. (2015)	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Clinical Trial	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03012841	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Patient-level data used	No	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Clinical Trial	Yes	NA
10.1007/s12325-021-01846-z	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03012841	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01846-z	study_information	NA	8	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Medical Condition of Interest Name	severe haemophilia a	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of first author affiliations	spain	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of last author affiliations	portugal	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01853-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 1	NA	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 1	1	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 2	NA	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 2	2	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Anchored comparison?	No	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34368918
10.1007/s12325-021-01853-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 1	NA	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 1	1	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 2	NA	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 2	3	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Anchored comparison?	No	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34368918
10.1007/s12325-021-01853-0	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 1	NA	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 1	1	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 2	NA	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 2	4	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Anchored comparison?	No	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34368918
10.1007/s12325-021-01853-0	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34368918
10.1007/s12325-021-01853-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	111	34368918
10.1007/s12325-021-01853-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	146	34368918
10.1007/s12325-021-01853-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	34368918
10.1007/s12325-021-01853-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34368918
10.1007/s12325-021-01853-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34368918
10.1007/s12325-021-01853-0	results	1	NA	Number of covariates adjusted for/matched on	4	34368918
10.1007/s12325-021-01853-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)	34368918
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: treatment effect contrast	RR	34368918
10.1007/s12325-021-01853-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34368918
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: unadjusted treatment effect	0.55	34368918
10.1007/s12325-021-01853-0	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.17;3.12]	34368918
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: adjusted treatment effect	0.74	34368918
10.1007/s12325-021-01853-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34368918
10.1007/s12325-021-01853-0	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	32	34368918
10.1007/s12325-021-01853-0	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	146	34368918
10.1007/s12325-021-01853-0	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	79	34368918
10.1007/s12325-021-01853-0	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34368918
10.1007/s12325-021-01853-0	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	34368918
10.1007/s12325-021-01853-0	results	2	NA	Number of covariates adjusted for/matched on	2	34368918
10.1007/s12325-021-01853-0	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity	34368918
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: treatment effect contrast	Means difference	34368918
10.1007/s12325-021-01853-0	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34368918
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: unadjusted treatment effect	0.07	34368918
10.1007/s12325-021-01853-0	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.09;3.23]	34368918
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: adjusted treatment effect	0.01	34368918
10.1007/s12325-021-01853-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34368918
10.1007/s12325-021-01853-0	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	118	34368918
10.1007/s12325-021-01853-0	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	146	34368918
10.1007/s12325-021-01853-0	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	123.6	34368918
10.1007/s12325-021-01853-0	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34368918
10.1007/s12325-021-01853-0	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34368918
10.1007/s12325-021-01853-0	results	3	NA	Number of covariates adjusted for/matched on	4	34368918
10.1007/s12325-021-01853-0	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)	34368918
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: treatment effect contrast	RR	34368918
10.1007/s12325-021-01853-0	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34368918
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: unadjusted treatment effect	1.14	34368918
10.1007/s12325-021-01853-0	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.82;1.57]	34368918
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: adjusted treatment effect	1.18	34368918
10.1007/s12325-021-01853-0	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34368918
10.1007/s12325-021-01853-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01853-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01853-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01486927	NA
10.1007/s12325-021-01853-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01853-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 3	NA
10.1007/s12325-021-01853-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01853-0	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01853-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01853-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x	NA
10.1007/s12325-021-01853-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01853-0	study_information	NA	2	Number of treatment arms (clinical trial only)	??	NA
10.1007/s12325-021-01853-0	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-021-01853-0	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-021-01853-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386	NA
10.1007/s12325-021-01853-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01853-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	4	NA
10.1007/s12325-021-01853-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01853-0	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-021-01853-0	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s12325-021-01853-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128	NA
10.1007/s12325-021-01853-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01853-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-021-01853-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01884-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 1	belantamab mafodotin	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 2	selinexor + dexamethasone	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-021-01884-7	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s12325-021-01884-7	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	122	NA
10.1007/s12325-021-01884-7	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	95	NA
10.1007/s12325-021-01884-7	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63.46	NA
10.1007/s12325-021-01884-7	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1007/s12325-021-01884-7	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-021-01884-7	results	1	NA	Number of covariates adjusted for/matched on	8	NA
10.1007/s12325-021-01884-7	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s12325-021-01884-7	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: unadjusted treatment effect	0.6	NA
10.1007/s12325-021-01884-7	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.01	NA
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: adjusted treatment effect	0.53	NA
10.1007/s12325-021-01884-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.005	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-021-01884-7	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01884-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-021-01884-7	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-021-01885-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 1	NA	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 1	1	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 2	NA	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 2	2	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Anchored comparison?	Yes	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	metastasis-free survival	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Primary outcome: variable type	Time-to-event	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34797506
10.1007/s12325-021-01885-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34797506
10.1007/s12325-021-01885-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34797506
10.1007/s12325-021-01885-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34797506
10.1007/s12325-021-01885-6	results	1	NA	Number of covariates adjusted for/matched on	9	34797506
10.1007/s12325-021-01885-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	34797506
10.1007/s12325-021-01885-6	results	1	NA	Primary outcome: treatment effect contrast	HR	34797506
10.1007/s12325-021-01885-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34797506
10.1007/s12325-021-01885-6	results	1	NA	Primary outcome: adjusted treatment effect	0.7	34797506
10.1007/s12325-021-01885-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34797506
10.1007/s12325-021-01885-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34797506
10.1007/s12325-021-01885-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	34797506
10.1007/s12325-021-01885-6	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-021-01885-6	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-021-01885-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1007/s12325-021-01885-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01885-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-021-01885-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-021-01885-6	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-021-01885-6	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-021-01885-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614	NA
10.1007/s12325-021-01885-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-021-01885-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-021-01885-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory follicular lymphoma	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-022-02054-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 1	tazemetostat	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 1	1	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 2	idelalisib	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 2	2	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Anchored comparison?	No	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35157216
10.1007/s12325-022-02054-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 1	tazemetostat	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 1	1	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 2	duvelisib	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 2	3	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Anchored comparison?	No	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35157216
10.1007/s12325-022-02054-z	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 1	tazemetostat	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 1	1	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 2	copanlisib	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 2	4	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Anchored comparison?	No	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35157216
10.1007/s12325-022-02054-z	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 1	tazemetostat	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 1	1	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 2	umbralisib	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 2	5	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Anchored comparison?	No	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35157216
10.1007/s12325-022-02054-z	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35157216
10.1007/s12325-022-02054-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	72	35157216
10.1007/s12325-022-02054-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	99	35157216
10.1007/s12325-022-02054-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36	35157216
10.1007/s12325-022-02054-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35157216
10.1007/s12325-022-02054-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35157216
10.1007/s12325-022-02054-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35157216
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: treatment effect contrast	RR	35157216
10.1007/s12325-022-02054-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35157216
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: unadjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: adjusted treatment effect	0.45	35157216
10.1007/s12325-022-02054-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	1	NA	Number of covariates adjusted for/matched on	NA	35157216
10.1007/s12325-022-02054-z	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	129	35157216
10.1007/s12325-022-02054-z	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	99	35157216
10.1007/s12325-022-02054-z	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24	35157216
10.1007/s12325-022-02054-z	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35157216
10.1007/s12325-022-02054-z	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35157216
10.1007/s12325-022-02054-z	results	2	NA	Number of covariates adjusted for/matched on	NA	35157216
10.1007/s12325-022-02054-z	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35157216
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: treatment effect contrast	RR	35157216
10.1007/s12325-022-02054-z	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35157216
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: unadjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: adjusted treatment effect	0.35	35157216
10.1007/s12325-022-02054-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	142	35157216
10.1007/s12325-022-02054-z	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	99	35157216
10.1007/s12325-022-02054-z	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	66	35157216
10.1007/s12325-022-02054-z	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35157216
10.1007/s12325-022-02054-z	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35157216
10.1007/s12325-022-02054-z	results	3	NA	Number of covariates adjusted for/matched on	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: treatment effect contrast	RR	35157216
10.1007/s12325-022-02054-z	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35157216
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: unadjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: adjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	208	35157216
10.1007/s12325-022-02054-z	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	99	35157216
10.1007/s12325-022-02054-z	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	60	35157216
10.1007/s12325-022-02054-z	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35157216
10.1007/s12325-022-02054-z	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35157216
10.1007/s12325-022-02054-z	results	4	NA	Number of covariates adjusted for/matched on	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: treatment effect contrast	RR	35157216
10.1007/s12325-022-02054-z	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35157216
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: unadjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: adjusted treatment effect	NA	35157216
10.1007/s12325-022-02054-z	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35157216
10.1007/s12325-022-02054-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01897571	NA
10.1007/s12325-022-02054-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02054-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1007/s12325-022-02054-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-022-02054-z	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-022-02054-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01282424	NA
10.1007/s12325-022-02054-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02054-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-022-02054-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-022-02054-z	study_information	NA	3	Patient-level data used	No	NA
10.1007/s12325-022-02054-z	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02054-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-022-02054-z	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-022-02054-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01882803	NA
10.1007/s12325-022-02054-z	study_information	NA	4	Patient-level data used	No	NA
10.1007/s12325-022-02054-z	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01660451	NA
10.1007/s12325-022-02054-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02054-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-022-02054-z	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1007/s12325-022-02054-z	study_information	NA	5	Patient-level data used	No	NA
10.1007/s12325-022-02054-z	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s12325-022-02054-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02793583	NA
10.1007/s12325-022-02054-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02054-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s12325-022-02054-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of last author affiliations	france	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of last author affiliations	france	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s12325-022-02099-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 1	transarterial radioembolization	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Anchored comparison?	Yes	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to deterioration in quality of life	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes	NA
10.1007/s12325-022-02099-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	336	NA
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	165	NA
10.1007/s12325-022-02099-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	94	NA
10.1007/s12325-022-02099-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53	NA
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	123	NA
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	78	NA
10.1007/s12325-022-02099-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s12325-022-02099-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s12325-022-02099-0	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.1007/s12325-022-02099-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score	NA
10.1007/s12325-022-02099-0	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s12325-022-02099-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s12325-022-02099-0	results	1	NA	Primary outcome: adjusted treatment effect	1.06	NA
10.1007/s12325-022-02099-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.725	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01482442	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01482442	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-022-02099-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Patient-level data used	No	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s12325-022-02099-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s12325-022-02099-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Medical Condition of Interest Name	mild-to-moderate atopic dermatitis	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of last author affiliations	denmark	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Medical Condition of Interest Name	mild-to-moderate atopic dermatitis	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of last author affiliations	XXXX	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	XXXX	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s13555-021-00646-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 1	crisaborole ointment 2%	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 2	pimecrolimus 1%	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6;7	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	investigators static global assessment improvement score of 01	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s13555-021-00646-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 1	crisaborole	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 2	tacrolimus 0.03%	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 2	3;4;5;8;9	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Anchored comparison?	No	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	investigators static global assessment improvement score of 01	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s13555-021-00646-1	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Treatment name 1	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Study 'number(s)' for treatment 1	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Treatment name 2	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Study 'number(s)' for treatment 2	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Type of population-adjusted indirect comparisons performed	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Anchored comparison?	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Form of the indirect comparison	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Primary outcome: variable type	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	NA
10.1007/s13555-021-00646-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1021	NA
10.1007/s13555-021-00646-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	627	NA
10.1007/s13555-021-00646-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1007/s13555-021-00646-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s13555-021-00646-1	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1007/s13555-021-00646-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest	NA
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1007/s13555-021-00646-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: unadjusted treatment effect	2.04	NA
10.1007/s13555-021-00646-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.47;2.82]	NA
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: adjusted treatment effect	2.03	NA
10.1007/s13555-021-00646-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.45;2.85]	NA
10.1007/s13555-021-00646-1	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	1021	NA
10.1007/s13555-021-00646-1	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	311	NA
10.1007/s13555-021-00646-1	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1007/s13555-021-00646-1	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s13555-021-00646-1	results	2	NA	Number of covariates adjusted for/matched on	7	NA
10.1007/s13555-021-00646-1	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest	NA
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: treatment effect contrast	OR	NA
10.1007/s13555-021-00646-1	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: unadjusted treatment effect	1.31	NA
10.1007/s13555-021-00646-1	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.02;1.69]	NA
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: adjusted treatment effect	1.5	NA
10.1007/s13555-021-00646-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.09;2.05]	NA
10.1007/s13555-021-00646-1	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Number of covariates adjusted for/matched on	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Primary outcome: treatment effect contrast	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Primary outcome: unadjusted treatment effect	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	Primary outcome: adjusted treatment effect	NA	NA
10.1007/s13555-021-00646-1	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118766	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118766	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s13555-021-00646-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118792	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118792	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s13555-021-00646-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	schachner et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	schachner et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	kempers et al. (2004)	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	kempers et al. (2004)	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00667160	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Phase of the clinical trial (clinical trial only)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	paller et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Phase of the clinical trial (clinical trial only)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	abramovits et al. (2008)	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Patient-level data used	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Phase of the clinical trial (clinical trial only)	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	abramovits et al. (2008)	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	eichenfield et al. (2002)	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	eichenfield et al. (2002)	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	chapman et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	chapman et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s13555-021-00646-1	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Phase of the clinical trial (clinical trial only)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Data source name (only if observational study or clinical trial without NCT)	levy et al. (2005)	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Patient-level data used	No	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Clinical Trial	Yes	NA
10.1007/s13555-021-00646-1	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Phase of the clinical trial (clinical trial only)	XXXX	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s13555-021-00646-1	study_information	NA	9	Data source name (only if observational study or clinical trial without NCT)	levy et al. (2005)	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed and/or refractory multiple myeloma	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of first author affiliations	the netherlands	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40258-016-0271-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 1	panobinostat + bortezomib + dexamethasone	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 1	1	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 2	lenalidomide + dexamethasone	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Anchored comparison?	No	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Primary outcome: variable type	Time-to-event	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	27550239
10.1007/s40258-016-0271-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	27550239
10.1007/s40258-016-0271-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	220	27550239
10.1007/s40258-016-0271-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	142	27550239
10.1007/s40258-016-0271-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	138	27550239
10.1007/s40258-016-0271-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	27550239
10.1007/s40258-016-0271-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	27550239
10.1007/s40258-016-0271-0	results	1	NA	Number of covariates adjusted for/matched on	NA	27550239
10.1007/s40258-016-0271-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	27550239
10.1007/s40258-016-0271-0	results	1	NA	Primary outcome: treatment effect contrast	HR	27550239
10.1007/s40258-016-0271-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	27550239
10.1007/s40258-016-0271-0	results	1	NA	Primary outcome: adjusted treatment effect	0.96	27550239
10.1007/s40258-016-0271-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.72;1.28]	27550239
10.1007/s40258-016-0271-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40258-016-0271-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40258-016-0271-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01023308	NA
10.1007/s40258-016-0271-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40258-016-0271-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40258-016-0271-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40258-016-0271-0	study_information	NA	2	Patient-level data used	No	NA
10.1007/s40258-016-0271-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40258-016-0271-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00056160	NA
10.1007/s40258-016-0271-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40258-016-0271-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40258-016-0271-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40258-016-0271-0	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40258-016-0271-0	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40258-016-0271-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00424047	NA
10.1007/s40258-016-0271-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40258-016-0271-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40258-016-0271-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder in children and adolescents	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40263-013-0102-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 1	guanfacine extended release	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 2	atomoxetine	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 2	3	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Anchored comparison?	NA	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Form of the indirect comparison	NA	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	23975660
10.1007/s40263-013-0102-x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23975660
10.1007/s40263-013-0102-x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84	23975660
10.1007/s40263-013-0102-x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	82	23975660
10.1007/s40263-013-0102-x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23975660
10.1007/s40263-013-0102-x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23975660
10.1007/s40263-013-0102-x	results	1	NA	Number of covariates adjusted for/matched on	NA	23975660
10.1007/s40263-013-0102-x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	23975660
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: treatment effect contrast	Means difference	23975660
10.1007/s40263-013-0102-x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	23975660
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: unadjusted treatment effect	-9.2	23975660
10.1007/s40263-013-0102-x	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.01	23975660
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: adjusted treatment effect	-7	23975660
10.1007/s40263-013-0102-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.01	23975660
10.1007/s40263-013-0102-x	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	23975660
10.1007/s40263-013-0102-x	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	23975660
10.1007/s40263-013-0102-x	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40263-013-0102-x	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40263-013-0102-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009	NA
10.1007/s40263-013-0102-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-013-0102-x	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-013-0102-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40263-013-0102-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s40263-013-0102-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40263-013-0102-x	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40263-013-0102-x	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40263-013-0102-x	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	spencer et al. (2002)	NA
10.1007/s40263-013-0102-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Medical Condition of Interest Name	postpartum depression	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40263-019-00672-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 1	brexanolone	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 2	placebo	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 2	4	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Anchored comparison?	No	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	31642037
10.1007/s40263-019-00672-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31642037
10.1007/s40263-019-00672-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	30	31642037
10.1007/s40263-019-00672-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63.2	31642037
10.1007/s40263-019-00672-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31642037
10.1007/s40263-019-00672-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31642037
10.1007/s40263-019-00672-w	results	1	NA	Number of covariates adjusted for/matched on	3	31642037
10.1007/s40263-019-00672-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Past treatments for the disease of interest	31642037
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: treatment effect contrast	Means difference	31642037
10.1007/s40263-019-00672-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31642037
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: unadjusted treatment effect	NA	31642037
10.1007/s40263-019-00672-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	31642037
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: adjusted treatment effect	NA	31642037
10.1007/s40263-019-00672-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	31642037
10.1007/s40263-019-00672-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614547	NA
10.1007/s40263-019-00672-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40263-019-00672-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s40263-019-00672-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-019-00672-w	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942004	NA
10.1007/s40263-019-00672-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40263-019-00672-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-019-00672-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-019-00672-w	study_information	NA	3	Patient-level data used	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942017	NA
10.1007/s40263-019-00672-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40263-019-00672-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-019-00672-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-019-00672-w	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40263-019-00672-w	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40263-019-00672-w	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	yonkers et al. (2008)	NA
10.1007/s40263-019-00672-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40263-019-00672-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-019-00672-w	study_information	NA	5	Patient-level data used	NA	NA
10.1007/s40263-019-00672-w	study_information	NA	5	Clinical Trial	NA	NA
10.1007/s40263-019-00672-w	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s40263-019-00672-w	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1007/s40263-019-00672-w	study_information	NA	5	Number of treatment arms (clinical trial only)	NA	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40263-021-00805-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 1	ozanimod	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 2	dimethyl fumarate	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s40263-021-00805-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	769	NA
10.1007/s40263-021-00805-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	880	NA
10.1007/s40263-021-00805-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	744	NA
10.1007/s40263-021-00805-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1007/s40263-021-00805-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s40263-021-00805-0	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1007/s40263-021-00805-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	NA
10.1007/s40263-021-00805-0	results	1	NA	Primary outcome: treatment effect contrast	RR	NA
10.1007/s40263-021-00805-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s40263-021-00805-0	results	1	NA	Primary outcome: adjusted treatment effect	0.8	NA
10.1007/s40263-021-00805-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;0.97]	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40263-021-00805-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40263-021-00805-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Medical Condition of Interest Name	anaplastic lymphoma kinase (alk)-positive non-small-cell lung cancer	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of first author affiliations	sweden	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of first author affiliations	sweden	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40273-021-01015-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 1	lorlatinib	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 2	pemetrexed or docetaxel	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Anchored comparison?	No	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s40273-021-01015-8	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 1	lorlatinib	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 2	systemic therapy	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Study 'number(s)' for treatment 2	NA	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Anchored comparison?	No	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1007/s40273-021-01015-8	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1007/s40273-021-01015-8	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	151	NA
10.1007/s40273-021-01015-8	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	59	NA
10.1007/s40273-021-01015-8	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53.4	NA
10.1007/s40273-021-01015-8	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s40273-021-01015-8	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1007/s40273-021-01015-8	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.1007/s40273-021-01015-8	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1007/s40273-021-01015-8	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s40273-021-01015-8	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s40273-021-01015-8	results	1	NA	Primary outcome: adjusted treatment effect	0.224	NA
10.1007/s40273-021-01015-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.154;0.312]	NA
10.1007/s40273-021-01015-8	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	37	NA
10.1007/s40273-021-01015-8	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	59	NA
10.1007/s40273-021-01015-8	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24.5	NA
10.1007/s40273-021-01015-8	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1007/s40273-021-01015-8	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	NA
10.1007/s40273-021-01015-8	results	2	NA	Number of covariates adjusted for/matched on	4	NA
10.1007/s40273-021-01015-8	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1007/s40273-021-01015-8	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1007/s40273-021-01015-8	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1007/s40273-021-01015-8	results	2	NA	Primary outcome: adjusted treatment effect	0.159	NA
10.1007/s40273-021-01015-8	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.052;0.356]	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01970865	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01970865	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1007/s40273-021-01015-8	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02604342	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02604342	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40273-021-01015-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828112	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828112	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40273-021-01015-8	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s40273-021-01015-8	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1007/s40273-021-01015-8	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Patient-level data used	No	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Clinical Trial	Yes	NA
10.1007/s40273-021-01015-8	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.1007/s40273-021-01015-8	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40744-017-0070-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 1	adalimumab	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 1	1	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 2	secukinumab 150 mg	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Anchored comparison?	Yes	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	28762213
10.1007/s40744-017-0070-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 1	adalimumab	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 1	1	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 2	secukinumab 300 mg	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 2	2;3	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Anchored comparison?	Yes	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	28762213
10.1007/s40744-017-0070-6	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	28762213
10.1007/s40744-017-0070-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	302	28762213
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	300	28762213
10.1007/s40744-017-0070-6	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	134	28762213
10.1007/s40744-017-0070-6	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	49	28762213
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	147	28762213
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	79	28762213
10.1007/s40744-017-0070-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	28762213
10.1007/s40744-017-0070-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	28762213
10.1007/s40744-017-0070-6	results	1	NA	Number of covariates adjusted for/matched on	10	28762213
10.1007/s40744-017-0070-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	28762213
10.1007/s40744-017-0070-6	results	1	NA	Primary outcome: treatment effect contrast	NA	28762213
10.1007/s40744-017-0070-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	28762213
10.1007/s40744-017-0070-6	results	1	NA	Primary outcome: adjusted treatment effect	NA	28762213
10.1007/s40744-017-0070-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.176	28762213
10.1007/s40744-017-0070-6	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	100	28762213
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	300	28762213
10.1007/s40744-017-0070-6	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	134	28762213
10.1007/s40744-017-0070-6	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	76	28762213
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	147	28762213
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	79	28762213
10.1007/s40744-017-0070-6	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	28762213
10.1007/s40744-017-0070-6	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	28762213
10.1007/s40744-017-0070-6	results	2	NA	Number of covariates adjusted for/matched on	10	28762213
10.1007/s40744-017-0070-6	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	28762213
10.1007/s40744-017-0070-6	results	2	NA	Primary outcome: treatment effect contrast	NA	28762213
10.1007/s40744-017-0070-6	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	28762213
10.1007/s40744-017-0070-6	results	2	NA	Primary outcome: adjusted treatment effect	NA	28762213
10.1007/s40744-017-0070-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.507	28762213
10.1007/s40744-017-0070-6	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40744-017-0070-6	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40744-017-0070-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689	NA
10.1007/s40744-017-0070-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40744-017-0070-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-017-0070-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-017-0070-6	study_information	NA	2	Patient-level data used	No	NA
10.1007/s40744-017-0070-6	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40744-017-0070-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01392326	NA
10.1007/s40744-017-0070-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-017-0070-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-017-0070-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-017-0070-6	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40744-017-0070-6	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40744-017-0070-6	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634	NA
10.1007/s40744-017-0070-6	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-017-0070-6	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-017-0070-6	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of first author affiliations	australia	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40744-018-0106-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 1	secukinumab 150 mg	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 1	1	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 2	adalimumab	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 2	2	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Anchored comparison?	Yes	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29605841
10.1007/s40744-018-0106-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 1	secukinumab 300 mg	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 1	1	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 2	adalimumab	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 2	2	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Anchored comparison?	Yes	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29605841
10.1007/s40744-018-0106-6	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 1	secukinumab 150 mg	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 1	1	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 2	adalimumab	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 2	2	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Anchored comparison?	No	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29605841
10.1007/s40744-018-0106-6	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 1	secukinumab 300 mg	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 1	1	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 2	adalimumab	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 2	2	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Anchored comparison?	NA	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29605841
10.1007/s40744-018-0106-6	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29605841
10.1007/s40744-018-0106-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	151	29605841
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162	29605841
10.1007/s40744-018-0106-6	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	100	29605841
10.1007/s40744-018-0106-6	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36	29605841
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	98	29605841
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	27	29605841
10.1007/s40744-018-0106-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29605841
10.1007/s40744-018-0106-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29605841
10.1007/s40744-018-0106-6	results	1	NA	Number of covariates adjusted for/matched on	NA	29605841
10.1007/s40744-018-0106-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	29605841
10.1007/s40744-018-0106-6	results	1	NA	Primary outcome: treatment effect contrast	RR	29605841
10.1007/s40744-018-0106-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29605841
10.1007/s40744-018-0106-6	results	1	NA	Primary outcome: adjusted treatment effect	0.69	29605841
10.1007/s40744-018-0106-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.34;1.43]	29605841
10.1007/s40744-018-0106-6	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	151	29605841
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162	29605841
10.1007/s40744-018-0106-6	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	100	29605841
10.1007/s40744-018-0106-6	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38	29605841
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	98	29605841
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	27	29605841
10.1007/s40744-018-0106-6	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29605841
10.1007/s40744-018-0106-6	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29605841
10.1007/s40744-018-0106-6	results	2	NA	Number of covariates adjusted for/matched on	NA	29605841
10.1007/s40744-018-0106-6	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	29605841
10.1007/s40744-018-0106-6	results	2	NA	Primary outcome: treatment effect contrast	RR	29605841
10.1007/s40744-018-0106-6	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29605841
10.1007/s40744-018-0106-6	results	2	NA	Primary outcome: adjusted treatment effect	0.61	29605841
10.1007/s40744-018-0106-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29605841
10.1007/s40744-018-0106-6	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	151	29605841
10.1007/s40744-018-0106-6	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	100	29605841
10.1007/s40744-018-0106-6	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36	29605841
10.1007/s40744-018-0106-6	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29605841
10.1007/s40744-018-0106-6	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29605841
10.1007/s40744-018-0106-6	results	3	NA	Number of covariates adjusted for/matched on	NA	29605841
10.1007/s40744-018-0106-6	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	29605841
10.1007/s40744-018-0106-6	results	3	NA	Primary outcome: treatment effect contrast	RR	29605841
10.1007/s40744-018-0106-6	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29605841
10.1007/s40744-018-0106-6	results	3	NA	Primary outcome: adjusted treatment effect	1.34	29605841
10.1007/s40744-018-0106-6	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29605841
10.1007/s40744-018-0106-6	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	151	29605841
10.1007/s40744-018-0106-6	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	100	29605841
10.1007/s40744-018-0106-6	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38	29605841
10.1007/s40744-018-0106-6	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29605841
10.1007/s40744-018-0106-6	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29605841
10.1007/s40744-018-0106-6	results	4	NA	Number of covariates adjusted for/matched on	NA	29605841
10.1007/s40744-018-0106-6	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	29605841
10.1007/s40744-018-0106-6	results	4	NA	Primary outcome: treatment effect contrast	RR	29605841
10.1007/s40744-018-0106-6	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29605841
10.1007/s40744-018-0106-6	results	4	NA	Primary outcome: adjusted treatment effect	NA	29605841
10.1007/s40744-018-0106-6	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29605841
10.1007/s40744-018-0106-6	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40744-018-0106-6	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40744-018-0106-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634	NA
10.1007/s40744-018-0106-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-018-0106-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-018-0106-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-018-0106-6	study_information	NA	2	Patient-level data used	No	NA
10.1007/s40744-018-0106-6	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40744-018-0106-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689	NA
10.1007/s40744-018-0106-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1007/s40744-018-0106-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-018-0106-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe rheumatoid arthritis	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1007/s40744-020-00257-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 1	NA	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 1	1	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 2	tofacitinib + methotrexate	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 2	3	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Anchored comparison?	Yes	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Primary outcome: variable type	NA	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33244703
10.1007/s40744-020-00257-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 1	upadacitinib + methotrexate	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 1	2	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 2	tofacitinib + methotrexate	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 2	4	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Anchored comparison?	Yes	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Primary outcome: variable type	NA	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33244703
10.1007/s40744-020-00257-w	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33244703
10.1007/s40744-020-00257-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	204	33244703
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	108	33244703
10.1007/s40744-020-00257-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33244703
10.1007/s40744-020-00257-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	173	33244703
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	216	33244703
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	158	33244703
10.1007/s40744-020-00257-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33244703
10.1007/s40744-020-00257-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33244703
10.1007/s40744-020-00257-w	results	1	NA	Number of covariates adjusted for/matched on	7	33244703
10.1007/s40744-020-00257-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	33244703
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: treatment effect contrast	Means difference	33244703
10.1007/s40744-020-00257-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33244703
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: unadjusted treatment effect	NA	33244703
10.1007/s40744-020-00257-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.018	33244703
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: adjusted treatment effect	NA	33244703
10.1007/s40744-020-00257-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.019	33244703
10.1007/s40744-020-00257-w	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	376	33244703
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	386	33244703
10.1007/s40744-020-00257-w	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	647	33244703
10.1007/s40744-020-00257-w	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480	33244703
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	324	33244703
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	228	33244703
10.1007/s40744-020-00257-w	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33244703
10.1007/s40744-020-00257-w	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33244703
10.1007/s40744-020-00257-w	results	2	NA	Number of covariates adjusted for/matched on	7	33244703
10.1007/s40744-020-00257-w	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	33244703
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: treatment effect contrast	Means difference	33244703
10.1007/s40744-020-00257-w	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33244703
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: unadjusted treatment effect	NA	33244703
10.1007/s40744-020-00257-w	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.008	33244703
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: adjusted treatment effect	NA	33244703
10.1007/s40744-020-00257-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.011	33244703
10.1007/s40744-020-00257-w	study_information	NA	1	Patient-level data used	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	1	Clinical Trial	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02706951	NA
10.1007/s40744-020-00257-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-020-00257-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-020-00257-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-020-00257-w	study_information	NA	2	Patient-level data used	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	2	Clinical Trial	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02629159	NA
10.1007/s40744-020-00257-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-020-00257-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-020-00257-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-020-00257-w	study_information	NA	3	Patient-level data used	No	NA
10.1007/s40744-020-00257-w	study_information	NA	3	Clinical Trial	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00853385	NA
10.1007/s40744-020-00257-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-020-00257-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1007/s40744-020-00257-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1007/s40744-020-00257-w	study_information	NA	4	Patient-level data used	No	NA
10.1007/s40744-020-00257-w	study_information	NA	4	Clinical Trial	Yes	NA
10.1007/s40744-020-00257-w	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02187055	NA
10.1007/s40744-020-00257-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1007/s40744-020-00257-w	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3, 4	NA
10.1007/s40744-020-00257-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory large b cell lymphoma	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory large b cell lymphoma	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 1	axicabtagene ciloleucel	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 2	tisagenlecleucel	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Overall Survival	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Treatment name 1	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Study 'number(s)' for treatment 1	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Treatment name 2	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Study 'number(s)' for treatment 2	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Type of population-adjusted indirect comparisons performed	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Anchored comparison?	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Form of the indirect comparison	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Primary outcome: variable type	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	115	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	101	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	39.59	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: unadjusted treatment effect	0.68	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.47;0.98]	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: adjusted treatment effect	0.51	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.31;0.83]	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Number of covariates adjusted for/matched on	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Primary outcome: treatment effect contrast	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Primary outcome: unadjusted treatment effect	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	Primary outcome: adjusted treatment effect	NA	NA
10.1016/j.bbmt.2020.06.008	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Medical Condition of Interest Name	locally advanced or metastatic urothelial carcinoma	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 1	pembrolizumab	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 1	1	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 2	NA	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Anchored comparison?	No	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Primary outcome: variable type	Time-to-event	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32826180
10.1016/j.clgc.2020.07.006	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	Primary outcome: treatment effect contrast	HR	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	Primary outcome: adjusted treatment effect	2.34	32826180
10.1016/j.clgc.2020.07.006	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32826180
10.1016/j.clgc.2020.07.006	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clgc.2020.07.006	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clgc.2020.07.006	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424	NA
10.1016/j.clgc.2020.07.006	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clgc.2020.07.006	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clgc.2020.07.006	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clgc.2020.07.006	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clgc.2020.07.006	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clgc.2020.07.006	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)	NA
10.1016/j.clgc.2020.07.006	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1016/j.clgc.2020.07.006	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clgc.2020.07.006	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clgc.2020.07.006	study_information	NA	3	Clinical Trial	No	NA
10.1016/j.clgc.2020.07.006	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)	NA
10.1016/j.clgc.2020.07.006	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	spain	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1016/j.clgc.2020.07.006	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2004)	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	greece	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clgc.2020.07.006	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Medical Condition of Interest Name	metastatic advanced renal cell carcinoma	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Medical Condition of Interest Name	metastatic advanced renal cell carcinoma	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 1	everolimus	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 2	axitinib	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	194	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	43	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	Primary outcome: treatment effect contrast	NA	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00410124	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Clinical Trial	XXXX	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00410124	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Medical Condition of Interest Name	chronic hepatitis c coinfected with hiv	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response at week 12 post-treatment	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	455	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	91	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Number of covariates adjusted for/matched on	11	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: unadjusted treatment effect	0.12	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.002	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: adjusted treatment effect	0.15	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032888	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032888	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01667731	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01667731	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01783678	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01783678	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Medical Condition of Interest Name	relapsed-refractory multiple myeloma	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Medical Condition of Interest Name	relapsed-refractory multiple myeloma	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 1	pomalidomide + dexamethasone	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 2	daratumumab	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 1	pomalidomide + dexamethasone	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 2	carfilzomib	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Anchored comparison?	No	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Number of covariates adjusted for/matched on	8	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	Primary outcome: adjusted treatment effect	0.945	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.749	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Number of covariates adjusted for/matched on	8	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	Primary outcome: adjusted treatment effect	0.833	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.238	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833833	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833833	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00511238	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00511238	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory mantle cell lymphoma	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 2	ibrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 2	bortezomib	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 2	5	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 2	lenalidomide	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 2	6;7	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 2	temsirolimus	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 2	2;8;9	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 2	ibrutinib + rituximab	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 2	10	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 2	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 2	11	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 1	acalabrutinib	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 1	1	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 2	lenalidomide + rituximab	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 2	12	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Anchored comparison?	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Primary outcome: variable type	Binary (eg rates)	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31699438
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	370	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	123	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	45	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: unadjusted treatment effect	10.2	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.05	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: adjusted treatment effect	9.3	31699438
10.1016/j.clinthera.2019.09.012	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	155	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	124	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: unadjusted treatment effect	46	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: adjusted treatment effect	50.6	31699438
10.1016/j.clinthera.2019.09.012	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	304	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	122	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	28	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Number of covariates adjusted for/matched on	12	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: unadjusted treatment effect	39.7	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: adjusted treatment effect	38.1	31699438
10.1016/j.clinthera.2019.09.012	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	242	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	123	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	120	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: unadjusted treatment effect	40.9	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: adjusted treatment effect	40.7	31699438
10.1016/j.clinthera.2019.09.012	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	50	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	84	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	16	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: unadjusted treatment effect	-14.2	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.05	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: adjusted treatment effect	-10.6	31699438
10.1016/j.clinthera.2019.09.012	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.09	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	121	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: unadjusted treatment effect	-7	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.31	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: adjusted treatment effect	-9.8	31699438
10.1016/j.clinthera.2019.09.012	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.22	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	44	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	64	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Number of covariates adjusted for/matched on	NA	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: treatment effect contrast	Rate difference	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: unadjusted treatment effect	16.3	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.06	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: adjusted treatment effect	14.1	31699438
10.1016/j.clinthera.2019.09.012	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.13	31699438
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213926	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01880567	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	czuczman 2015	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00294632	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646021	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01236391	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01599949	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	pinnacle	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00875667	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00737529	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00117598	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Patient-level data used	No	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Clinical Trial	Yes	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01180049	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Phase of the clinical trial (clinical trial only)	4	NA
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable gastroenteropancreatic neuroendocrine tumours	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 1	[177lu]lu-dota-tate	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 2	everolimus	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 2	2	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 1	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 2	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 2	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 1	[177lu]lu-dota-tate	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 2	sunitinib	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 2	4	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 1	[177lu]lu-dota-tate	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 2	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 2	4	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 1	[177lu]lu-dota-tate	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 2	everolimus	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 2	3	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 1	[177lu]lu-dota-tate	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 1	1	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 2	NA	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 2	3	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Anchored comparison?	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Primary outcome: variable type	Time-to-event	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34912478
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	118	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	111	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	105	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Number of covariates adjusted for/matched on	1	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	Primary outcome: adjusted treatment effect	0.38	34912478
10.1016/j.ejcsup.2021.06.002	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.25;0.58]	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	57	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	111	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	95	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Number of covariates adjusted for/matched on	1	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	Primary outcome: adjusted treatment effect	0.35	34912478
10.1016/j.ejcsup.2021.06.002	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	86	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	62	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	48	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Number of covariates adjusted for/matched on	4	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	Primary outcome: adjusted treatment effect	0.36	34912478
10.1016/j.ejcsup.2021.06.002	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.70]	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	85	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	62	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	35	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Number of covariates adjusted for/matched on	4	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	Primary outcome: adjusted treatment effect	0.13	34912478
10.1016/j.ejcsup.2021.06.002	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.08;0.22]	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	207	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	62	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	22	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Number of covariates adjusted for/matched on	4	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	Primary outcome: adjusted treatment effect	0.46	34912478
10.1016/j.ejcsup.2021.06.002	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.30;0.71]	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	203	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	62	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	18	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Number of covariates adjusted for/matched on	4	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Primary outcome: treatment effect contrast	HR	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	Primary outcome: adjusted treatment effect	0.21	34912478
10.1016/j.ejcsup.2021.06.002	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.32]	34912478
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	erasmus study	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	the netherlands	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01524783	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Medical Condition of Interest Name	braf v600-mutant advanced melanoma	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 2	dabrafenib + trametinib	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 2	encorafenib + binimetinib	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 2	4	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Anchored comparison?	No	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.esmoop.2021.100050	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 1	nivolumab + ipilimumab	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 2	vemurafenib + cobimetinib	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 2	5	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Anchored comparison?	No	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.esmoop.2021.100050	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	563	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	103	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	91.68	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Number of covariates adjusted for/matched on	5	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.esmoop.2021.100050	results	1	NA	Primary outcome: adjusted treatment effect	0.53	NA
10.1016/j.esmoop.2021.100050	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.39;0.73]	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	192	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	103	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	93.81	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.esmoop.2021.100050	results	2	NA	Primary outcome: adjusted treatment effect	0.6	NA
10.1016/j.esmoop.2021.100050	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.42;0.85]	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	247	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	103	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	91.69	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Number of covariates adjusted for/matched on	5	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.esmoop.2021.100050	results	3	NA	Primary outcome: adjusted treatment effect	0.5	NA
10.1016/j.esmoop.2021.100050	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.36;0.70]	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01909453	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01909453	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.esmoop.2021.100050	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable, or metastatic urothelial cancer	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of last author affiliations	the netherlands	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable, or metastatic urothelial cancer	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of last author affiliations	XXXX	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 1	pembrolizumab	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 2	2;4;5;6	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.euo.2018.09.009	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 1	pembrolizumab	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 2	gemcitabine	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Anchored comparison?	No	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.euo.2018.09.009	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.euo.2018.09.009	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.euo.2018.09.009	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.euo.2018.09.009	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1016/j.euo.2018.09.009	results	1	NA	Primary outcome: adjusted treatment effect	2.78	NA
10.1016/j.euo.2018.09.009	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.29;3.38]	NA
10.1016/j.euo.2018.09.009	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1016/j.euo.2018.09.009	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1016/j.euo.2018.09.009	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.euo.2018.09.009	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1016/j.euo.2018.09.009	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1016/j.euo.2018.09.009	results	2	NA	Primary outcome: adjusted treatment effect	2.94	NA
10.1016/j.euo.2018.09.009	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.42;3.57]	NA
10.1016/j.euo.2018.09.009	results	2	NA	Number of covariates adjusted for/matched on	3	NA
10.1016/j.euo.2018.09.009	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.euo.2018.09.009	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1016/j.euo.2018.09.009	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	getug v01	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	getug v01	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.euo.2018.09.009	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	greece	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	greece	NA
10.1016/j.euo.2018.09.009	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	spain	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	spain	NA
10.1016/j.euo.2018.09.009	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2003)	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	greece	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Patient-level data used	No	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Clinical Trial	Yes	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2003)	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	greece	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.euo.2018.09.009	study_information	NA	6	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small cell lung cancer	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of first author affiliations	singapore	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 1	NA	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 2	crizotinib	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Anchored comparison?	No	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Primary outcome: variable type	Time-to-event	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	27288979
10.1016/j.jtho.2016.05.029	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	557	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	189	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	143	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Number of covariates adjusted for/matched on	6	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: treatment effect contrast	HR	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: unadjusted treatment effect	NA	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: adjusted treatment effect	0.59	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	27288979
10.1016/j.jtho.2016.05.029	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	27288979
10.1016/j.jtho.2016.05.029	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516	NA
10.1016/j.jtho.2016.05.029	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jtho.2016.05.029	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	Patient-level data used	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685138	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.jtho.2016.05.029	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.1016/j.jtho.2016.05.029	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.jtho.2016.05.029	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Medical Condition of Interest Name	tremor	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of last author affiliations	israel	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Medical Condition of Interest Name	tremor	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of last author affiliations	israel	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 1	magnetic resonance-guided focused ultrasound	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 2	unilateral deep brain stimulation	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	clinical rating scale for tremor part c at 1 month	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 1	magnetic resonance-guided focused ultrasound	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 2	unilateral deep brain stimulation (dbs)	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Anchored comparison?	No	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	clinical rating scale for tremor part c at 1 month	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.jval.2018.03.015	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	22	NA
10.1016/j.jval.2018.03.015	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	56	NA
10.1016/j.jval.2018.03.015	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	35.8	NA
10.1016/j.jval.2018.03.015	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1016/j.jval.2018.03.015	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.jval.2018.03.015	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1016/j.jval.2018.03.015	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1016/j.jval.2018.03.015	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: unadjusted treatment effect	0.35	NA
10.1016/j.jval.2018.03.015	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-2.17;2.87]	NA
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: adjusted treatment effect	1.92	NA
10.1016/j.jval.2018.03.015	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.94;4.79]	NA
10.1016/j.jval.2018.03.015	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	22	NA
10.1016/j.jval.2018.03.015	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	56	NA
10.1016/j.jval.2018.03.015	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56	NA
10.1016/j.jval.2018.03.015	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.jval.2018.03.015	results	2	NA	Number of covariates adjusted for/matched on	3	NA
10.1016/j.jval.2018.03.015	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1016/j.jval.2018.03.015	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: unadjusted treatment effect	0.35	NA
10.1016/j.jval.2018.03.015	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-2.17;2.87]	NA
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: adjusted treatment effect	1.67	NA
10.1016/j.jval.2018.03.015	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.74;4.08]	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01827904	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01827904	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.jval.2018.03.015	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Clinical Trial	No	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	putzke et al. (2005)	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Number of treatment arms (clinical trial only)	NA	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Patient-level data used	No	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Clinical Trial	No	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	putzke et al. (2005)	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1016/j.jval.2018.03.015	study_information	NA	2	Number of treatment arms (clinical trial only)	NA	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 2	atezolizumab + chemotherapy	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Study 'number(s)' for treatment 2	NA	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Anchored comparison?	No	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Primary outcome: variable type	Time-to-event	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33839603
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 1	pembrolizumab + chemotherapy	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 2	NA	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 2	NA	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Anchored comparison?	No	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Primary outcome: variable type	Time-to-event	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33839603
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	451	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	469	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	428	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Number of covariates adjusted for/matched on	6	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: treatment effect contrast	HR	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: unadjusted treatment effect	0.8	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.009	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: adjusted treatment effect	0.8	33839603
10.1016/j.lungcan.2021.03.020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.012	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	356	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	469	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	389	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Number of covariates adjusted for/matched on	6	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: treatment effect contrast	HR	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: unadjusted treatment effect	0.84	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.04	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: adjusted treatment effect	0.86	33839603
10.1016/j.lungcan.2021.03.020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.099	33839603
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	International	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Patient-level data used	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02367781	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02366143	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1016/j.msard.2021.102972	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 1	ozanimod	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 2	teriflunomide	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5;6;7;8	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Anchored comparison?	No	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1016/j.msard.2021.102972	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1016/j.msard.2021.102972	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	2290	NA
10.1016/j.msard.2021.102972	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	880	NA
10.1016/j.msard.2021.102972	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	663.53	NA
10.1016/j.msard.2021.102972	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1016/j.msard.2021.102972	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1016/j.msard.2021.102972	results	1	NA	Number of covariates adjusted for/matched on	9	NA
10.1016/j.msard.2021.102972	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	NA
10.1016/j.msard.2021.102972	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	NA
10.1016/j.msard.2021.102972	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1016/j.msard.2021.102972	results	1	NA	Primary outcome: adjusted treatment effect	0.73	NA
10.1016/j.msard.2021.102972	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.62;0.84]	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Patient-level data used	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Patient-level data used	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Patient-level data used	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792218	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792218	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792231	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792231	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00751881	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00751881	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425644	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425644	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00883337	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Patient-level data used	No	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Clinical Trial	Yes	NA
10.1016/j.msard.2021.102972	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00883337	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.1016/j.msard.2021.102972	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Medical Condition of Interest Name	multiple sclerosis	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Medical Condition of Interest Name	multiple sclerosis	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2016.1248380	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 1	dimethyl fumarate	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 2	fingolimod	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Anchored comparison?	Yes	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2016.1248380	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2016.1248380	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	783	NA
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	773	NA
10.1080/03007995.2016.1248380	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	769	NA
10.1080/03007995.2016.1248380	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	587	NA
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	771	NA
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	599	NA
10.1080/03007995.2016.1248380	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/03007995.2016.1248380	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2016.1248380	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1080/03007995.2016.1248380	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	NA
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: treatment effect contrast	RR	NA
10.1080/03007995.2016.1248380	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: unadjusted treatment effect	1.07	NA
10.1080/03007995.2016.1248380	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.5501	NA
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: adjusted treatment effect	1.11	NA
10.1080/03007995.2016.1248380	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3893	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Patient-level data used	No	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Patient-level data used	No	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/03007995.2016.1248380	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2016.1248380	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2018.1510225	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 1	ponatinib	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 2	bosutinib	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Anchored comparison?	No	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	cytogenetic response rate	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2018.1510225	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2018.1510225	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	119	NA
10.1080/03007995.2018.1510225	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	97	NA
10.1080/03007995.2018.1510225	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70	NA
10.1080/03007995.2018.1510225	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/03007995.2018.1510225	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2018.1510225	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1080/03007995.2018.1510225	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1080/03007995.2018.1510225	results	1	NA	Primary outcome: treatment effect contrast	NA	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01207440	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01207440	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2018.1510225	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1510225	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Medical Condition of Interest Name	NA	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Medical Condition of Interest Name	crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2018.1520696	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 1	brigatinib	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 2	ceritinib	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Anchored comparison?	No	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2018.1520696	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 1	brigatinib	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 2	ceritinib	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Anchored comparison?	No	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2018.1520696	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 1	brigatinib	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 2	alectinib	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 2	4	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Anchored comparison?	No	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2018.1520696	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 1	brigatinib	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 2	alectinib	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 2	5	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Anchored comparison?	No	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2018.1520696	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2018.1520696	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	163	NA
10.1080/03007995.2018.1520696	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	110	NA
10.1080/03007995.2018.1520696	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75.8	NA
10.1080/03007995.2018.1520696	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2018.1520696	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2018.1520696	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/03007995.2018.1520696	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2018.1520696	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: unadjusted treatment effect	0.96	NA
10.1080/03007995.2018.1520696	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.872	NA
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: adjusted treatment effect	0.88	NA
10.1080/03007995.2018.1520696	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.659	NA
10.1080/03007995.2018.1520696	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	140	NA
10.1080/03007995.2018.1520696	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	110	NA
10.1080/03007995.2018.1520696	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	50.8	NA
10.1080/03007995.2018.1520696	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2018.1520696	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2018.1520696	results	2	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/03007995.2018.1520696	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2018.1520696	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: unadjusted treatment effect	2.16	NA
10.1080/03007995.2018.1520696	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.003	NA
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: adjusted treatment effect	2.17	NA
10.1080/03007995.2018.1520696	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02	NA
10.1080/03007995.2018.1520696	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	87	NA
10.1080/03007995.2018.1520696	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	110	NA
10.1080/03007995.2018.1520696	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	77.5	NA
10.1080/03007995.2018.1520696	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2018.1520696	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2018.1520696	results	3	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/03007995.2018.1520696	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2018.1520696	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: unadjusted treatment effect	1.78	NA
10.1080/03007995.2018.1520696	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.047	NA
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: adjusted treatment effect	1.69	NA
10.1080/03007995.2018.1520696	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.096	NA
10.1080/03007995.2018.1520696	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	138	NA
10.1080/03007995.2018.1520696	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	110	NA
10.1080/03007995.2018.1520696	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70.7	NA
10.1080/03007995.2018.1520696	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2018.1520696	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2018.1520696	results	4	NA	Number of covariates adjusted for/matched on	8	NA
10.1080/03007995.2018.1520696	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2018.1520696	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: unadjusted treatment effect	1.47	NA
10.1080/03007995.2018.1520696	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.133	NA
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: adjusted treatment effect	1.44	NA
10.1080/03007995.2018.1520696	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.212	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02094573	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02094573	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1520696	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685060	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685060	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2018.1520696	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01871805	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01871805	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1520696	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01801111	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Patient-level data used	No	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/03007995.2018.1520696	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01801111	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2018.1520696	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Medical Condition of Interest Name	advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2018.1541443	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 1	ceritinib	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 1	1	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 2	crizotinib	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 2	2	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Anchored comparison?	No	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Primary outcome: variable type	Time-to-event	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30362839
10.1080/03007995.2018.1541443	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30362839
10.1080/03007995.2018.1541443	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	30362839
10.1080/03007995.2018.1541443	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	30362839
10.1080/03007995.2018.1541443	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30362839
10.1080/03007995.2018.1541443	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	30362839
10.1080/03007995.2018.1541443	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30362839
10.1080/03007995.2018.1541443	results	1	NA	Number of covariates adjusted for/matched on	8	30362839
10.1080/03007995.2018.1541443	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30362839
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: treatment effect contrast	HR	30362839
10.1080/03007995.2018.1541443	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30362839
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: unadjusted treatment effect	0.68	30362839
10.1080/03007995.2018.1541443	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.01	30362839
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: adjusted treatment effect	0.64	30362839
10.1080/03007995.2018.1541443	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004	30362839
10.1080/03007995.2018.1541443	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2018.1541443	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2018.1541443	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099	NA
10.1080/03007995.2018.1541443	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1541443	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2018.1541443	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2018.1541443	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2018.1541443	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2018.1541443	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140	NA
10.1080/03007995.2018.1541443	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2018.1541443	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2018.1541443	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Medical Condition of Interest Name	active relapsing-remitting multiple sclerosis	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Medical Condition of Interest Name	active relapsing-remitting multiple sclerosis	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2019.1585779	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 1	cladribine	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 2	alemtuzumab	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Anchored comparison?	No	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	confirmed disability progression	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2019.1585779	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2019.1585779	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	426	NA
10.1080/03007995.2019.1585779	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	113	NA
10.1080/03007995.2019.1585779	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	41	NA
10.1080/03007995.2019.1585779	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2019.1585779	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2019.1585779	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1080/03007995.2019.1585779	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	NA
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/03007995.2019.1585779	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: unadjusted treatment effect	0.96	NA
10.1080/03007995.2019.1585779	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.51;1.80]	NA
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: adjusted treatment effect	1	NA
10.1080/03007995.2019.1585779	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.44;2.27]	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00213135	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00213135	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2019.1585779	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00548405	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2019.1585779	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00548405	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2019.1585779	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2019.1605239	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 1	bosutinib	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 1	1	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 2	dasatinib	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 2	2	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Anchored comparison?	No	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Primary outcome: variable type	Time-to-event	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30964361
10.1080/03007995.2019.1605239	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 1	bosutinib	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 1	1	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 2	nilotinib	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 2	3	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Anchored comparison?	No	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Primary outcome: variable type	Time-to-event	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30964361
10.1080/03007995.2019.1605239	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30964361
10.1080/03007995.2019.1605239	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	167	30964361
10.1080/03007995.2019.1605239	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	283	30964361
10.1080/03007995.2019.1605239	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30964361
10.1080/03007995.2019.1605239	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30964361
10.1080/03007995.2019.1605239	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30964361
10.1080/03007995.2019.1605239	results	1	NA	Number of covariates adjusted for/matched on	NA	30964361
10.1080/03007995.2019.1605239	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30964361
10.1080/03007995.2019.1605239	results	1	NA	Primary outcome: treatment effect contrast	HR	30964361
10.1080/03007995.2019.1605239	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30964361
10.1080/03007995.2019.1605239	results	1	NA	Primary outcome: adjusted treatment effect	0.82	30964361
10.1080/03007995.2019.1605239	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.37	30964361
10.1080/03007995.2019.1605239	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	321	30964361
10.1080/03007995.2019.1605239	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	283	30964361
10.1080/03007995.2019.1605239	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30964361
10.1080/03007995.2019.1605239	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30964361
10.1080/03007995.2019.1605239	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30964361
10.1080/03007995.2019.1605239	results	2	NA	Number of covariates adjusted for/matched on	3	30964361
10.1080/03007995.2019.1605239	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30964361
10.1080/03007995.2019.1605239	results	2	NA	Primary outcome: treatment effect contrast	HR	30964361
10.1080/03007995.2019.1605239	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30964361
10.1080/03007995.2019.1605239	results	2	NA	Primary outcome: adjusted treatment effect	0.72	30964361
10.1080/03007995.2019.1605239	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.16	30964361
10.1080/03007995.2019.1605239	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2019.1605239	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2019.1605239	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846	NA
10.1080/03007995.2019.1605239	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1605239	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2019.1605239	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2019.1605239	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2019.1605239	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2019.1605239	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00123474	NA
10.1080/03007995.2019.1605239	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1605239	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2019.1605239	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2019.1605239	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2019.1605239	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2019.1605239	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109707	NA
10.1080/03007995.2019.1605239	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2019.1605239	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2019.1605239	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Medical Condition of Interest Name	secondary progressive multiple sclerosis	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2020.1747999	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 2	ifn-1b 250 g once every other day (q2d)	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 2	4	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 2	ifn-1a 22 g once weekly (qw)	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 2	3	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 2	natalizumab	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 2	2	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Primary outcome: variable type	NA	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 2	sc ifn-1a 22 g three times weekly	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 2	6	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 2	sc ifn-1a 44 g three times weekly	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 2	6	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Anchored comparison?	NA	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 2	ifn-1b 8 miu once every other day	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 2	7	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 1	siponimod	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 1	1	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 2	im ifn-1a 60 g once weekly	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 2	5	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Anchored comparison?	Yes	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Primary outcome: variable type	Time-to-event	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32220214
10.1080/03007995.2020.1747999	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32220214
10.1080/03007995.2020.1747999	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	1	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	1	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	1	NA	Primary outcome: adjusted treatment effect	0.55	32220214
10.1080/03007995.2020.1747999	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.33;0.91]	32220214
10.1080/03007995.2020.1747999	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	2	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	2	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	2	NA	Primary outcome: adjusted treatment effect	0.43	32220214
10.1080/03007995.2020.1747999	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.93]	32220214
10.1080/03007995.2020.1747999	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	3	NA	Number of covariates adjusted for/matched on	10	32220214
10.1080/03007995.2020.1747999	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	3	NA	Primary outcome: treatment effect contrast	NA	32220214
10.1080/03007995.2020.1747999	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	3	NA	Primary outcome: adjusted treatment effect	0.76	32220214
10.1080/03007995.2020.1747999	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.44;1.30]	32220214
10.1080/03007995.2020.1747999	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	4	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	4	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	4	NA	Primary outcome: adjusted treatment effect	0.8	32220214
10.1080/03007995.2020.1747999	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;1.38]	32220214
10.1080/03007995.2020.1747999	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	5	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	5	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	5	NA	Primary outcome: adjusted treatment effect	0.84	32220214
10.1080/03007995.2020.1747999	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.49;1.47]	32220214
10.1080/03007995.2020.1747999	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	6	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	6	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	6	NA	Primary outcome: adjusted treatment effect	0.82	32220214
10.1080/03007995.2020.1747999	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.42;1.63]	32220214
10.1080/03007995.2020.1747999	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32220214
10.1080/03007995.2020.1747999	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32220214
10.1080/03007995.2020.1747999	results	7	NA	Number of covariates adjusted for/matched on	NA	32220214
10.1080/03007995.2020.1747999	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32220214
10.1080/03007995.2020.1747999	results	7	NA	Primary outcome: treatment effect contrast	HR	32220214
10.1080/03007995.2020.1747999	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32220214
10.1080/03007995.2020.1747999	results	7	NA	Primary outcome: adjusted treatment effect	0.42	32220214
10.1080/03007995.2020.1747999	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.88]	32220214
10.1080/03007995.2020.1747999	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01665144	NA
10.1080/03007995.2020.1747999	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2020.1747999	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01416181	NA
10.1080/03007995.2020.1747999	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2020.1747999	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	nordic spms study	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2020.1747999	study_information	NA	4	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	panitch et al. (2004) (north american study)	NA
10.1080/03007995.2020.1747999	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	5	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	cohen et al. (2002) (impact)	NA
10.1080/03007995.2020.1747999	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	6	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	6	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	spectrims study group (2001) li et al. (2001)	NA
10.1080/03007995.2020.1747999	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2020.1747999	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	7	Patient-level data used	No	NA
10.1080/03007995.2020.1747999	study_information	NA	7	Clinical Trial	Yes	NA
10.1080/03007995.2020.1747999	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	european study group (1998) kappos et al. (2001)	NA
10.1080/03007995.2020.1747999	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2020.1747999	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of first author affiliations	the netherlands	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of last author affiliations	the netherlands	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of first author affiliations	the netherlands	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of last author affiliations	the netherlands	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1896489	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 1	bosutinib	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 2	nilotinib	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Anchored comparison?	No	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response at 24 months	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2021.1896489	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 1	bosutinib	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 2	dasatinib	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Anchored comparison?	No	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response by 24 months	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2021.1896489	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes	NA
10.1080/03007995.2021.1896489	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	282	NA
10.1080/03007995.2021.1896489	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	248	NA
10.1080/03007995.2021.1896489	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	190	NA
10.1080/03007995.2021.1896489	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/03007995.2021.1896489	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2021.1896489	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1080/03007995.2021.1896489	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	NA
10.1080/03007995.2021.1896489	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2021.1896489	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1080/03007995.2021.1896489	results	1	NA	Primary outcome: adjusted treatment effect	1.01	NA
10.1080/03007995.2021.1896489	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.70;1.45]	NA
10.1080/03007995.2021.1896489	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	259	NA
10.1080/03007995.2021.1896489	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	244	NA
10.1080/03007995.2021.1896489	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	118	NA
10.1080/03007995.2021.1896489	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/03007995.2021.1896489	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2021.1896489	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.1080/03007995.2021.1896489	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1080/03007995.2021.1896489	results	2	NA	Primary outcome: treatment effect contrast	OR	NA
10.1080/03007995.2021.1896489	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	NA
10.1080/03007995.2021.1896489	results	2	NA	Primary outcome: adjusted treatment effect	0.81	NA
10.1080/03007995.2021.1896489	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.54;1.22]	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02130557	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02130557	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2021.1896489	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1896489	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy type 1	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1947216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 1	onasemnogene abeparvovec	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 2	nusinersen	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 2	3	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Anchored comparison?	No	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	event-free survival	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Primary outcome: variable type	Time-to-event	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	34236007
10.1080/03007995.2021.1947216	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34236007
10.1080/03007995.2021.1947216	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	81	34236007
10.1080/03007995.2021.1947216	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	34	34236007
10.1080/03007995.2021.1947216	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	34236007
10.1080/03007995.2021.1947216	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34236007
10.1080/03007995.2021.1947216	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34236007
10.1080/03007995.2021.1947216	results	1	NA	Number of covariates adjusted for/matched on	2	34236007
10.1080/03007995.2021.1947216	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	34236007
10.1080/03007995.2021.1947216	results	1	NA	Primary outcome: treatment effect contrast	HR	34236007
10.1080/03007995.2021.1947216	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34236007
10.1080/03007995.2021.1947216	results	1	NA	Primary outcome: adjusted treatment effect	NA	34236007
10.1080/03007995.2021.1947216	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.07;0.54]	34236007
10.1080/03007995.2021.1947216	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1947216	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1947216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02122952	NA
10.1080/03007995.2021.1947216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/03007995.2021.1947216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1080/03007995.2021.1947216	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2021.1947216	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/03007995.2021.1947216	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1947216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277	NA
10.1080/03007995.2021.1947216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/03007995.2021.1947216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1947216	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2021.1947216	study_information	NA	3	Patient-level data used	No	NA
10.1080/03007995.2021.1947216	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/03007995.2021.1947216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02594124	NA
10.1080/03007995.2021.1947216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1947216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1947216	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory multiple myeloma	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1953456	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 1	ciltacabtagene autoleucel	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 1	1	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 2	idecabtagene vicleucel	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 2	2	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Anchored comparison?	No	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34256668
10.1080/03007995.2021.1953456	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34256668
10.1080/03007995.2021.1953456	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	124	34256668
10.1080/03007995.2021.1953456	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34256668
10.1080/03007995.2021.1953456	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	52	34256668
10.1080/03007995.2021.1953456	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34256668
10.1080/03007995.2021.1953456	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34256668
10.1080/03007995.2021.1953456	results	1	NA	Number of covariates adjusted for/matched on	4	34256668
10.1080/03007995.2021.1953456	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	34256668
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: treatment effect contrast	OR	34256668
10.1080/03007995.2021.1953456	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34256668
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: unadjusted treatment effect	16.52	34256668
10.1080/03007995.2021.1953456	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0002	34256668
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: adjusted treatment effect	94.93	34256668
10.1080/03007995.2021.1953456	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	34256668
10.1080/03007995.2021.1953456	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1953456	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1953456	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03548207	NA
10.1080/03007995.2021.1953456	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1953456	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1080/03007995.2021.1953456	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2021.1953456	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2021.1953456	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1953456	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748	NA
10.1080/03007995.2021.1953456	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1953456	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/03007995.2021.1953456	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Medical Condition of Interest Name	paroxysmal nocturnal hemoglobinuria	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Medical Condition of Interest Name	paroxysmal nocturnal hemoglobinuria	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2021.1971182	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 1	pegcetacoplan	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 2	ravulizumab	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Anchored comparison?	Yes	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportion of patients with transfusion avoidance	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/03007995.2021.1971182	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/03007995.2021.1971182	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	97	NA
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	98	NA
10.1080/03007995.2021.1971182	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	36	NA
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	32	NA
10.1080/03007995.2021.1971182	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/03007995.2021.1971182	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/03007995.2021.1971182	results	1	NA	Number of covariates adjusted for/matched on	5	NA
10.1080/03007995.2021.1971182	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	NA
10.1080/03007995.2021.1971182	results	1	NA	Primary outcome: treatment effect contrast	NA	NA
10.1080/03007995.2021.1971182	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/03007995.2021.1971182	results	1	NA	Primary outcome: adjusted treatment effect	0.714	NA
10.1080/03007995.2021.1971182	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	NA
10.1080/03007995.2021.1971182	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24	NA
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	12	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03500549	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03500549	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1971182	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03056040	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2021.1971182	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03056040	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2021.1971182	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Medical Condition of Interest Name	uncontrolled hypertension	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/03007995.2022.2030112	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 1	NA	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 1	1	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 2	NA	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 2	2	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Anchored comparison?	Yes	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35042448
10.1080/03007995.2022.2030112	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35042448
10.1080/03007995.2022.2030112	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	261	35042448
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	255	35042448
10.1080/03007995.2022.2030112	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	178	35042448
10.1080/03007995.2022.2030112	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	178	35042448
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	179	35042448
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	179	35042448
10.1080/03007995.2022.2030112	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35042448
10.1080/03007995.2022.2030112	results	1	NA	Number of covariates adjusted for/matched on	7	35042448
10.1080/03007995.2022.2030112	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)	35042448
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: treatment effect contrast	Means difference	35042448
10.1080/03007995.2022.2030112	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35042448
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: unadjusted treatment effect	-0.3	35042448
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: adjusted treatment effect	-1.6	35042448
10.1080/03007995.2022.2030112	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35042448
10.1080/03007995.2022.2030112	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	35042448
10.1080/03007995.2022.2030112	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/03007995.2022.2030112	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/03007995.2022.2030112	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2019-000751-13	NA
10.1080/03007995.2022.2030112	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	poland	NA
10.1080/03007995.2022.2030112	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2022.2030112	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/03007995.2022.2030112	study_information	NA	2	Patient-level data used	No	NA
10.1080/03007995.2022.2030112	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/03007995.2022.2030112	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00558428	NA
10.1080/03007995.2022.2030112	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/03007995.2022.2030112	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/03007995.2022.2030112	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/09546634.2020.1747592	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 2	guselkumab	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 2	5	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 2	tildrakizumab 100mg	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 2	6;7	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 2	tildrakizumab 200mg	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 2	6;7	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 1	NA	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 2	tildrakizumab 100mg	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 2	6;7	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 1	NA	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 2	tildrakizumab 200mg	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 2	6;7	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 2	risankizumab	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 2	NA	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 1	ixekizumab	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 1	4	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 2	risankizumab	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 2	8;9	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Anchored comparison?	Yes	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75% improvement responders	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Primary outcome: variable type	NA	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32299269
10.1080/09546634.2020.1747592	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32299269
10.1080/09546634.2020.1747592	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	1	NA	Number of covariates adjusted for/matched on	8	32299269
10.1080/09546634.2020.1747592	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	32299269
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: unadjusted treatment effect	8.3	32299269
10.1080/09546634.2020.1747592	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: adjusted treatment effect	8	32299269
10.1080/09546634.2020.1747592	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	2	NA	Number of covariates adjusted for/matched on	5	32299269
10.1080/09546634.2020.1747592	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	32299269
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: unadjusted treatment effect	27.7	32299269
10.1080/09546634.2020.1747592	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: adjusted treatment effect	27	32299269
10.1080/09546634.2020.1747592	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	3	NA	Number of covariates adjusted for/matched on	5	32299269
10.1080/09546634.2020.1747592	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	32299269
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: unadjusted treatment effect	26.4	32299269
10.1080/09546634.2020.1747592	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: adjusted treatment effect	25.7	32299269
10.1080/09546634.2020.1747592	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	4	NA	Number of covariates adjusted for/matched on	5	32299269
10.1080/09546634.2020.1747592	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32299269
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: unadjusted treatment effect	28.1	32299269
10.1080/09546634.2020.1747592	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: adjusted treatment effect	25.7	32299269
10.1080/09546634.2020.1747592	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	5	NA	Number of covariates adjusted for/matched on	5	32299269
10.1080/09546634.2020.1747592	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	32299269
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: unadjusted treatment effect	NA	32299269
10.1080/09546634.2020.1747592	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: adjusted treatment effect	NA	32299269
10.1080/09546634.2020.1747592	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	6	NA	Number of covariates adjusted for/matched on	NA	32299269
10.1080/09546634.2020.1747592	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32299269
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: unadjusted treatment effect	5.5	32299269
10.1080/09546634.2020.1747592	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32299269
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: adjusted treatment effect	5.5	32299269
10.1080/09546634.2020.1747592	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.1;11.0]	32299269
10.1080/09546634.2020.1747592	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32299269
10.1080/09546634.2020.1747592	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32299269
10.1080/09546634.2020.1747592	results	7	NA	Number of covariates adjusted for/matched on	NA	32299269
10.1080/09546634.2020.1747592	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	NA	32299269
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: treatment effect contrast	NA	32299269
10.1080/09546634.2020.1747592	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32299269
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: unadjusted treatment effect	0.8	32299269
10.1080/09546634.2020.1747592	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-10.9;12.6]	32299269
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: adjusted treatment effect	7.8	32299269
10.1080/09546634.2020.1747592	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-6.7;22.3]	32299269
10.1080/09546634.2020.1747592	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512	NA
10.1080/09546634.2020.1747592	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/09546634.2020.1747592	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245	NA
10.1080/09546634.2020.1747592	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/09546634.2020.1747592	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	3	Patient-level data used	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177	NA
10.1080/09546634.2020.1747592	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/09546634.2020.1747592	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	4	Patient-level data used	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806	NA
10.1080/09546634.2020.1747592	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/09546634.2020.1747592	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	5	Patient-level data used	No	NA
10.1080/09546634.2020.1747592	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02207244	NA
10.1080/09546634.2020.1747592	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/09546634.2020.1747592	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	6	Patient-level data used	No	NA
10.1080/09546634.2020.1747592	study_information	NA	6	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722331	NA
10.1080/09546634.2020.1747592	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	7	Patient-level data used	No	NA
10.1080/09546634.2020.1747592	study_information	NA	7	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01729754	NA
10.1080/09546634.2020.1747592	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	8	Patient-level data used	No	NA
10.1080/09546634.2020.1747592	study_information	NA	8	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684370	NA
10.1080/09546634.2020.1747592	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/09546634.2020.1747592	study_information	NA	9	Patient-level data used	No	NA
10.1080/09546634.2020.1747592	study_information	NA	9	Clinical Trial	Yes	NA
10.1080/09546634.2020.1747592	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684357	NA
10.1080/09546634.2020.1747592	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/09546634.2020.1747592	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory multiple myeloma	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Countries of last author affiliations	greece	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2019.1648806	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/10428194.2019.1648806	methodology	1	NA	Treatment name 1	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Study 'number(s)' for treatment 1	1	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Treatment name 2	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Study 'number(s)' for treatment 2	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Anchored comparison?	No	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Primary outcome: variable type	Time-to-event	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31640435
10.1080/10428194.2019.1648806	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Treatment name 1	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Study 'number(s)' for treatment 1	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Treatment name 2	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Study 'number(s)' for treatment 2	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Type of population-adjusted indirect comparisons performed	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Anchored comparison?	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Form of the indirect comparison	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Primary outcome: variable type	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	31640435
10.1080/10428194.2019.1648806	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31640435
10.1080/10428194.2019.1648806	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31640435
10.1080/10428194.2019.1648806	results	1	NA	Number of covariates adjusted for/matched on	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Primary outcome: treatment effect contrast	HR	31640435
10.1080/10428194.2019.1648806	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Primary outcome: adjusted treatment effect	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	Primary outcome: unadjusted treatment effect	NA	31640435
10.1080/10428194.2019.1648806	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Number of covariates adjusted for/matched on	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Primary outcome: treatment effect contrast	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	Primary outcome: adjusted treatment effect	NA	31640435
10.1080/10428194.2019.1648806	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	31640435
10.1080/10428194.2019.1648806	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2019.1648806	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2019.1648806	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01568866	NA
10.1080/10428194.2019.1648806	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1648806	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1648806	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1648806	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2019.1648806	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2019.1648806	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02136134	NA
10.1080/10428194.2019.1648806	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1648806	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1648806	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Medical Condition of Interest Name	transplant ineligible multiple myeloma	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of first author affiliations	spain	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2019.1675881	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 1	NA	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 1	1	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 2	NA	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Anchored comparison?	No	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Primary outcome: variable type	Time-to-event	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31686561
10.1080/10428194.2019.1675881	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31686561
10.1080/10428194.2019.1675881	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	547	31686561
10.1080/10428194.2019.1675881	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	344	31686561
10.1080/10428194.2019.1675881	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	114	31686561
10.1080/10428194.2019.1675881	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	31686561
10.1080/10428194.2019.1675881	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31686561
10.1080/10428194.2019.1675881	results	1	NA	Number of covariates adjusted for/matched on	8	31686561
10.1080/10428194.2019.1675881	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	31686561
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: treatment effect contrast	HR	31686561
10.1080/10428194.2019.1675881	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	31686561
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: unadjusted treatment effect	0.911	31686561
10.1080/10428194.2019.1675881	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.326	31686561
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: adjusted treatment effect	0.991	31686561
10.1080/10428194.2019.1675881	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.935	31686561
10.1080/10428194.2019.1675881	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2019.1675881	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2019.1675881	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00111319	NA
10.1080/10428194.2019.1675881	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/10428194.2019.1675881	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1675881	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1675881	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2019.1675881	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2019.1675881	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479	NA
10.1080/10428194.2019.1675881	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1675881	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1675881	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1675881	study_information	NA	3	Patient-level data used	No	NA
10.1080/10428194.2019.1675881	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/10428194.2019.1675881	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01063179	NA
10.1080/10428194.2019.1675881	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.1080/10428194.2019.1675881	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1675881	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of first author affiliations	greece	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of first author affiliations	greece	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2019.1682571	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	NA	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 2	lenalidomidedexamethasone continuous	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Anchored comparison?	No	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 2	lenalidomidedexamethasone 18 months (rd18)	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Anchored comparison?	No	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 2	melphalanprednisonethalidomide	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Anchored comparison?	No	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2019.1682571	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	535	NA
10.1080/10428194.2019.1682571	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	350	NA
10.1080/10428194.2019.1682571	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	248	NA
10.1080/10428194.2019.1682571	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/10428194.2019.1682571	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2019.1682571	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/10428194.2019.1682571	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2019.1682571	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: unadjusted treatment effect	0.88	NA
10.1080/10428194.2019.1682571	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.51	NA
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: adjusted treatment effect	0.68	NA
10.1080/10428194.2019.1682571	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.086	NA
10.1080/10428194.2019.1682571	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	541	NA
10.1080/10428194.2019.1682571	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	350	NA
10.1080/10428194.2019.1682571	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	246	NA
10.1080/10428194.2019.1682571	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/10428194.2019.1682571	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2019.1682571	results	2	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/10428194.2019.1682571	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2019.1682571	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: unadjusted treatment effect	0.78	NA
10.1080/10428194.2019.1682571	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.16	NA
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: adjusted treatment effect	0.6	NA
10.1080/10428194.2019.1682571	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02	NA
10.1080/10428194.2019.1682571	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	547	NA
10.1080/10428194.2019.1682571	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	350	NA
10.1080/10428194.2019.1682571	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	248	NA
10.1080/10428194.2019.1682571	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/10428194.2019.1682571	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2019.1682571	results	3	NA	Number of covariates adjusted for/matched on	7	NA
10.1080/10428194.2019.1682571	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2019.1682571	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: unadjusted treatment effect	0.68	NA
10.1080/10428194.2019.1682571	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.024	NA
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: adjusted treatment effect	0.53	NA
10.1080/10428194.2019.1682571	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.003	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1682571	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00689936	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2019.1682571	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00689936	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2019.1682571	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory multiple myeloma	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of first author affiliations	spain	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2021.1913143	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 1	idecabtagene vicleucel	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 1	1	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 2	selinexor + dexamethasone	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 2	2	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Anchored comparison?	No	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33896344
10.1080/10428194.2021.1913143	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 1	NA	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 1	1	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 2	belantamab mafodotin	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 2	3	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Anchored comparison?	No	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33896344
10.1080/10428194.2021.1913143	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33896344
10.1080/10428194.2021.1913143	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	122	33896344
10.1080/10428194.2021.1913143	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	128	33896344
10.1080/10428194.2021.1913143	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56	33896344
10.1080/10428194.2021.1913143	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33896344
10.1080/10428194.2021.1913143	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33896344
10.1080/10428194.2021.1913143	results	1	NA	Number of covariates adjusted for/matched on	NA	33896344
10.1080/10428194.2021.1913143	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	33896344
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: treatment effect contrast	OR	33896344
10.1080/10428194.2021.1913143	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33896344
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: unadjusted treatment effect	7.78	33896344
10.1080/10428194.2021.1913143	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[4.43;13.65]	33896344
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: adjusted treatment effect	7.74	33896344
10.1080/10428194.2021.1913143	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[3.83;15.62]	33896344
10.1080/10428194.2021.1913143	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	97	33896344
10.1080/10428194.2021.1913143	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	128	33896344
10.1080/10428194.2021.1913143	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	45	33896344
10.1080/10428194.2021.1913143	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33896344
10.1080/10428194.2021.1913143	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33896344
10.1080/10428194.2021.1913143	results	2	NA	Number of covariates adjusted for/matched on	6	33896344
10.1080/10428194.2021.1913143	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	33896344
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: treatment effect contrast	OR	33896344
10.1080/10428194.2021.1913143	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33896344
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: unadjusted treatment effect	6.17	33896344
10.1080/10428194.2021.1913143	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33896344
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: adjusted treatment effect	5.12	33896344
10.1080/10428194.2021.1913143	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.35;11.13]	33896344
10.1080/10428194.2021.1913143	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2021.1913143	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913143	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748	NA
10.1080/10428194.2021.1913143	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913143	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/10428194.2021.1913143	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/10428194.2021.1913143	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2021.1913143	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913143	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815	NA
10.1080/10428194.2021.1913143	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913143	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/10428194.2021.1913143	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/10428194.2021.1913143	study_information	NA	3	Patient-level data used	No	NA
10.1080/10428194.2021.1913143	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913143	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678	NA
10.1080/10428194.2021.1913143	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913143	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/10428194.2021.1913143	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2021.1913144	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 1	acalabrutinib + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 2	ibrutinib	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 1	acalabrutinib	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 2	ibrutinib	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 1	acalabrutinib + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 2	ibrutinib + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 2	3	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 1	acalabrutinib	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 2	ibrutinib + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 2	3	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 1	acalabrutinib + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 2	venetoclax + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 2	4	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 1	acalabrutinib	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 2	venetoclax + obinutuzumab	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 2	4	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Anchored comparison?	No	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Primary outcome: variable type	Time-to-event	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/10428194.2021.1913144	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/10428194.2021.1913144	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	136	NA
10.1080/10428194.2021.1913144	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	126	NA
10.1080/10428194.2021.1913144	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	59	NA
10.1080/10428194.2021.1913144	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	1	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	1	NA	Primary outcome: adjusted treatment effect	0.61	NA
10.1080/10428194.2021.1913144	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3	NA
10.1080/10428194.2021.1913144	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	136	NA
10.1080/10428194.2021.1913144	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	136	NA
10.1080/10428194.2021.1913144	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	79	NA
10.1080/10428194.2021.1913144	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	2	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	2	NA	Primary outcome: adjusted treatment effect	0.92	NA
10.1080/10428194.2021.1913144	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.83	NA
10.1080/10428194.2021.1913144	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	113	NA
10.1080/10428194.2021.1913144	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	113	NA
10.1080/10428194.2021.1913144	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	97	NA
10.1080/10428194.2021.1913144	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	3	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	3	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	3	NA	Primary outcome: adjusted treatment effect	0.55	NA
10.1080/10428194.2021.1913144	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.11	NA
10.1080/10428194.2021.1913144	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	113	NA
10.1080/10428194.2021.1913144	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	114	NA
10.1080/10428194.2021.1913144	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	97	NA
10.1080/10428194.2021.1913144	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	4	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	4	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	4	NA	Primary outcome: adjusted treatment effect	0.53	NA
10.1080/10428194.2021.1913144	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.08	NA
10.1080/10428194.2021.1913144	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	216	NA
10.1080/10428194.2021.1913144	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	83	NA
10.1080/10428194.2021.1913144	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43	NA
10.1080/10428194.2021.1913144	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	5	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	5	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	5	NA	Primary outcome: adjusted treatment effect	0.78	NA
10.1080/10428194.2021.1913144	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.57	NA
10.1080/10428194.2021.1913144	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	216	NA
10.1080/10428194.2021.1913144	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	96	NA
10.1080/10428194.2021.1913144	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	51	NA
10.1080/10428194.2021.1913144	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/10428194.2021.1913144	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/10428194.2021.1913144	results	6	NA	Number of covariates adjusted for/matched on	12	NA
10.1080/10428194.2021.1913144	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1080/10428194.2021.1913144	results	6	NA	Primary outcome: treatment effect contrast	HR	NA
10.1080/10428194.2021.1913144	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/10428194.2021.1913144	results	6	NA	Primary outcome: adjusted treatment effect	1.24	NA
10.1080/10428194.2021.1913144	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.59	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02475681	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02475681	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02264574	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02264574	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02242942	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Patient-level data used	No	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/10428194.2021.1913144	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02242942	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2021.1913144	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b-cell lymphomas	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of last author affiliations	netherlands	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2021.2010069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 1	tisagenlecleucel	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 1	1	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 2	lisocabtagene	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 2	2	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Anchored comparison?	No	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34978255
10.1080/10428194.2021.2010069	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34978255
10.1080/10428194.2021.2010069	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	256	34978255
10.1080/10428194.2021.2010069	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	106	34978255
10.1080/10428194.2021.2010069	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	29	34978255
10.1080/10428194.2021.2010069	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34978255
10.1080/10428194.2021.2010069	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34978255
10.1080/10428194.2021.2010069	results	1	NA	Number of covariates adjusted for/matched on	NA	34978255
10.1080/10428194.2021.2010069	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	34978255
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	34978255
10.1080/10428194.2021.2010069	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34978255
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: unadjusted treatment effect	NA	34978255
10.1080/10428194.2021.2010069	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.01	34978255
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: adjusted treatment effect	NA	34978255
10.1080/10428194.2021.2010069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.07	34978255
10.1080/10428194.2021.2010069	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2021.2010069	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2021.2010069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248	NA
10.1080/10428194.2021.2010069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2021.2010069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/10428194.2021.2010069	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/10428194.2021.2010069	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2021.2010069	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2021.2010069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044	NA
10.1080/10428194.2021.2010069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/10428194.2021.2010069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.1080/10428194.2021.2010069	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/10428194.2022.2047962	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 1	NA	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 1	1	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 2	NA	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 2	2	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Anchored comparison?	No	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Primary outcome: variable type	Time-to-event	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35289710
10.1080/10428194.2022.2047962	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35289710
10.1080/10428194.2022.2047962	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	251	35289710
10.1080/10428194.2022.2047962	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	198	35289710
10.1080/10428194.2022.2047962	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	82	35289710
10.1080/10428194.2022.2047962	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	35289710
10.1080/10428194.2022.2047962	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35289710
10.1080/10428194.2022.2047962	results	1	NA	Number of covariates adjusted for/matched on	10	35289710
10.1080/10428194.2022.2047962	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35289710
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: treatment effect contrast	HR	35289710
10.1080/10428194.2022.2047962	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	35289710
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: unadjusted treatment effect	0.54	35289710
10.1080/10428194.2022.2047962	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35289710
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: adjusted treatment effect	0.64	35289710
10.1080/10428194.2022.2047962	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;0.90]	35289710
10.1080/10428194.2022.2047962	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/10428194.2022.2047962	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/10428194.2022.2047962	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03158688	NA
10.1080/10428194.2022.2047962	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2022.2047962	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2022.2047962	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/10428194.2022.2047962	study_information	NA	2	Patient-level data used	No	NA
10.1080/10428194.2022.2047962	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/10428194.2022.2047962	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02136134	NA
10.1080/10428194.2022.2047962	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/10428194.2022.2047962	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/10428194.2022.2047962	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Medical Condition of Interest Name	(ALK)-positive metastatic non-small cell lung cancer	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/13696998.2018.1443111	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 1	NA	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 1	1	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 2	crizotinib	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 2	2	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Primary outcome: variable type	Time-to-event	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29458286
10.1080/13696998.2018.1443111	methodology	1	NA	Anchored comparison?	NA	29458286
10.1080/13696998.2018.1443111	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29458286
10.1080/13696998.2018.1443111	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No	29458286
10.1080/13696998.2018.1443111	results	1	NA	Primary outcome: treatment effect contrast	NA	29458286
10.1080/13696998.2018.1443111	results	1	NA	Primary outcome: adjusted treatment effect	0.64	29458286
10.1080/13696998.2018.1443111	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.47;0.87]	29458286
10.1080/13696998.2018.1443111	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	29458286
10.1080/13696998.2018.1443111	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/13696998.2018.1443111	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/13696998.2018.1443111	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099	NA
10.1080/13696998.2018.1443111	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/13696998.2018.1443111	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2018.1443111	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2018.1443111	study_information	NA	2	Patient-level data used	No	NA
10.1080/13696998.2018.1443111	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/13696998.2018.1443111	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140	NA
10.1080/13696998.2018.1443111	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/13696998.2018.1443111	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2018.1443111	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/13696998.2020.1722139	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 1	calcipotriene 0.005%/betamethasone dipropionate 0.064% foam	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 2	halobetasol 0.01%/tazarotene 0.045%	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 2	4;5	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Anchored comparison?	Yes	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	physicians global assessment treatment success	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/13696998.2020.1722139	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/13696998.2020.1722139	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	276	NA
10.1080/13696998.2020.1722139	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	142	NA
10.1080/13696998.2020.1722139	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	649	NA
10.1080/13696998.2020.1722139	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	199	NA
10.1080/13696998.2020.1722139	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/13696998.2020.1722139	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/13696998.2020.1722139	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.1080/13696998.2020.1722139	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	NA
10.1080/13696998.2020.1722139	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	NA
10.1080/13696998.2020.1722139	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/13696998.2020.1722139	results	1	NA	Primary outcome: adjusted treatment effect	20.7	NA
10.1080/13696998.2020.1722139	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Patient-level data used	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/13696998.2020.1722139	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Patient-level data used	No	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462070	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Patient-level data used	No	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462070	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Patient-level data used	No	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462122	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Patient-level data used	No	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Clinical Trial	Yes	NA
10.1080/13696998.2020.1722139	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462122	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/13696998.2020.1722139	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Medical Condition of Interest Name	amyloidosis with polyneuropathy	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/14656566.2020.1811850	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 1	patisiran	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 2	inotersen	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Anchored comparison?	Yes	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7)	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1080/14656566.2020.1811850	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1080/14656566.2020.1811850	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	112	NA
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	60	NA
10.1080/14656566.2020.1811850	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	148	NA
10.1080/14656566.2020.1811850	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	90	NA
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	77	NA
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	47	NA
10.1080/14656566.2020.1811850	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1080/14656566.2020.1811850	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/14656566.2020.1811850	results	1	NA	Number of covariates adjusted for/matched on	9	NA
10.1080/14656566.2020.1811850	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	NA
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1080/14656566.2020.1811850	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: unadjusted treatment effect	-16.2	NA
10.1080/14656566.2020.1811850	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.001	NA
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: adjusted treatment effect	-12.3	NA
10.1080/14656566.2020.1811850	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.007	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01960348	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01960348	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14656566.2020.1811850	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Patient-level data used	No	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01737398	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Patient-level data used	No	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/14656566.2020.1811850	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01737398	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Phase of the clinical trial (clinical trial only)	XXXX	NA
10.1080/14656566.2020.1811850	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Medical Condition of Interest Name	pneumococcal disease	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/14760584.2021.1994858	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 1	15-valent pneumococcal conjugate vaccine	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 2	20-valent pneumococcal conjugate vaccine	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 2	4	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Anchored comparison?	Yes	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	30 days post-vaccination serotype-specific opa (opsonophagocytic activity)	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	NA
10.1080/14760584.2021.1994858	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes	NA
10.1080/14760584.2021.1994858	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1507	NA
10.1080/14760584.2021.1994858	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	1490	NA
10.1080/14760584.2021.1994858	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	2196	NA
10.1080/14760584.2021.1994858	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	843	NA
10.1080/14760584.2021.1994858	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1080/14760584.2021.1994858	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1080/14760584.2021.1994858	results	1	NA	Number of covariates adjusted for/matched on	2	NA
10.1080/14760584.2021.1994858	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex	NA
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: treatment effect contrast	Means Ratio	NA
10.1080/14760584.2021.1994858	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: unadjusted treatment effect	0.89	NA
10.1080/14760584.2021.1994858	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	NA
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: adjusted treatment effect	0.91	NA
10.1080/14760584.2021.1994858	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950622	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950622	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03480763	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03480763	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950856	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Patient-level data used	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950856	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Patient-level data used	No	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03760146	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Patient-level data used	No	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Clinical Trial	Yes	NA
10.1080/14760584.2021.1994858	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03760146	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1080/14760584.2021.1994858	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory classical hodgkins lymphoma	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1080/17474086.2018.1475226	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 1	pembrolizumab	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 1	1	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 2	st + ard of care	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 2	2	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Type of population-adjusted indirect comparisons performed	NA	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Anchored comparison?	No	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Primary outcome: variable type	Time-to-event	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29764245
10.1080/17474086.2018.1475226	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29764245
10.1080/17474086.2018.1475226	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	83	29764245
10.1080/17474086.2018.1475226	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	175	29764245
10.1080/17474086.2018.1475226	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	29764245
10.1080/17474086.2018.1475226	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29764245
10.1080/17474086.2018.1475226	results	1	NA	Number of covariates adjusted for/matched on	7	29764245
10.1080/17474086.2018.1475226	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	29764245
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: treatment effect contrast	HR	29764245
10.1080/17474086.2018.1475226	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	29764245
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: unadjusted treatment effect	5	29764245
10.1080/17474086.2018.1475226	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[3.56;7.01]	29764245
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: adjusted treatment effect	6.35	29764245
10.1080/17474086.2018.1475226	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[4.04;9.98]	29764245
10.1080/17474086.2018.1475226	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	29764245
10.1080/17474086.2018.1475226	study_information	NA	1	Patient-level data used	Yes	NA
10.1080/17474086.2018.1475226	study_information	NA	1	Clinical Trial	Yes	NA
10.1080/17474086.2018.1475226	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02453594	NA
10.1080/17474086.2018.1475226	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1080/17474086.2018.1475226	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1080/17474086.2018.1475226	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.1080/17474086.2018.1475226	study_information	NA	2	Patient-level data used	No	NA
10.1080/17474086.2018.1475226	study_information	NA	2	Clinical Trial	No	NA
10.1080/17474086.2018.1475226	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	cheah et al., 2016	NA
10.1080/17474086.2018.1475226	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1093/europace/euy160	general_information	NA	NA	Medical Condition of Interest Name	non-valvular atrial fibrillation	NA
10.1093/europace/euy160	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1093/europace/euy160	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1093/europace/euy160	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1093/europace/euy160	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1093/europace/euy160	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1093/europace/euy160	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1093/europace/euy160	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1093/europace/euy160	methodology	1	NA	Treatment name 1	rivaroxaban	30052894
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 1	1	30052894
10.1093/europace/euy160	methodology	1	NA	Treatment name 2	rivaroxaban	30052894
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 2	2	30052894
10.1093/europace/euy160	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30052894
10.1093/europace/euy160	methodology	1	NA	Anchored comparison?	No	30052894
10.1093/europace/euy160	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30052894
10.1093/europace/euy160	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30052894
10.1093/europace/euy160	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30052894
10.1093/europace/euy160	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	30052894
10.1093/europace/euy160	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	30052894
10.1093/europace/euy160	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	30052894
10.1093/europace/euy160	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30052894
10.1093/europace/euy160	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30052894
10.1093/europace/euy160	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30052894
10.1093/europace/euy160	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	7061	30052894
10.1093/europace/euy160	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	4020	30052894
10.1093/europace/euy160	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	2492	30052894
10.1093/europace/euy160	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30052894
10.1093/europace/euy160	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30052894
10.1093/europace/euy160	results	1	NA	Number of covariates adjusted for/matched on	2	30052894
10.1093/europace/euy160	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30052894
10.1093/europace/euy160	results	1	NA	Primary outcome: treatment effect contrast	RR	30052894
10.1093/europace/euy160	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30052894
10.1093/europace/euy160	results	1	NA	Primary outcome: adjusted treatment effect	0.86	30052894
10.1093/europace/euy160	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;1.12]	30052894
10.1093/europace/euy160	study_information	NA	1	Patient-level data used	Yes	NA
10.1093/europace/euy160	study_information	NA	1	Clinical Trial	No	NA
10.1093/europace/euy160	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01606995	NA
10.1093/europace/euy160	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1093/europace/euy160	study_information	NA	2	Patient-level data used	No	NA
10.1093/europace/euy160	study_information	NA	2	Clinical Trial	Yes	NA
10.1093/europace/euy160	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00403767	NA
10.1093/europace/euy160	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1093/europace/euy160	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1093/europace/euy160	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1093/jnci/djab071	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer	NA
10.1093/jnci/djab071	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1093/jnci/djab071	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1093/jnci/djab071	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1093/jnci/djab071	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1093/jnci/djab071	general_information	NA	NA	Mentioned sources of funding	Public grants, Pharmaceutical Industry	NA
10.1093/jnci/djab071	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1093/jnci/djab071	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1093/jnci/djab071	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer	NA
10.1093/jnci/djab071	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1093/jnci/djab071	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1093/jnci/djab071	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.1093/jnci/djab071	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1093/jnci/djab071	general_information	NA	NA	Mentioned sources of funding	XXXX	NA
10.1093/jnci/djab071	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1093/jnci/djab071	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1093/jnci/djab071	methodology	1	NA	Treatment name 1	abiraterone acetate	NA
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1093/jnci/djab071	methodology	1	NA	Treatment name 2	placebo	NA
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1093/jnci/djab071	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1093/jnci/djab071	methodology	1	NA	Anchored comparison?	No	NA
10.1093/jnci/djab071	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1093/jnci/djab071	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1093/jnci/djab071	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	metastasis-free survival	NA
10.1093/jnci/djab071	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1093/jnci/djab071	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1093/jnci/djab071	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1093/jnci/djab071	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1093/jnci/djab071	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.1093/jnci/djab071	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1093/jnci/djab071	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1207	NA
10.1093/jnci/djab071	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	131	NA
10.1093/jnci/djab071	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	81	NA
10.1093/jnci/djab071	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	NA
10.1093/jnci/djab071	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1093/jnci/djab071	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.1093/jnci/djab071	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.1093/jnci/djab071	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1093/jnci/djab071	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1093/jnci/djab071	results	1	NA	Primary outcome: adjusted treatment effect	0.22	NA
10.1093/jnci/djab071	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.12;0.41]	NA
10.1093/jnci/djab071	study_information	NA	1	Patient-level data used	Yes	NA
10.1093/jnci/djab071	study_information	NA	1	Clinical Trial	Yes	NA
10.1093/jnci/djab071	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01314118	NA
10.1093/jnci/djab071	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1093/jnci/djab071	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1093/jnci/djab071	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1093/jnci/djab071	study_information	NA	1	Patient-level data used	Yes	NA
10.1093/jnci/djab071	study_information	NA	1	Clinical Trial	Yes	NA
10.1093/jnci/djab071	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01314118	NA
10.1093/jnci/djab071	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1093/jnci/djab071	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1093/jnci/djab071	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1093/jnci/djab071	study_information	NA	2	Patient-level data used	No	NA
10.1093/jnci/djab071	study_information	NA	2	Clinical Trial	Yes	NA
10.1093/jnci/djab071	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1093/jnci/djab071	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1093/jnci/djab071	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1093/jnci/djab071	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1093/jnci/djab071	study_information	NA	2	Patient-level data used	No	NA
10.1093/jnci/djab071	study_information	NA	2	Clinical Trial	Yes	NA
10.1093/jnci/djab071	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1093/jnci/djab071	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1093/jnci/djab071	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1093/jnci/djab071	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Medical Condition of Interest Name	lumbar disc degeneration	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company	NA
10.1097/brs.0000000000002647	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company	NA
10.1097/brs.0000000000002647	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	XXXX	NA
10.1097/brs.0000000000002647	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 1	total disc replacement	NA
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 2	fusion	NA
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1097/brs.0000000000002647	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1097/brs.0000000000002647	methodology	1	NA	Anchored comparison?	No	NA
10.1097/brs.0000000000002647	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1097/brs.0000000000002647	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1097/brs.0000000000002647	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	5-year change in radiographic adjacent-level degeneration	NA
10.1097/brs.0000000000002647	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1097/brs.0000000000002647	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1097/brs.0000000000002647	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1097/brs.0000000000002647	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1097/brs.0000000000002647	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1097/brs.0000000000002647	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1097/brs.0000000000002647	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	43	NA
10.1097/brs.0000000000002647	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	175	NA
10.1097/brs.0000000000002647	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	139	NA
10.1097/brs.0000000000002647	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1097/brs.0000000000002647	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1097/brs.0000000000002647	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1097/brs.0000000000002647	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	NA
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1097/brs.0000000000002647	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: unadjusted treatment effect	0.28	NA
10.1097/brs.0000000000002647	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.12;0.63]	NA
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: adjusted treatment effect	0.32	NA
10.1097/brs.0000000000002647	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.76]	NA
10.1097/brs.0000000000002647	study_information	NA	1	Patient-level data used	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	1	Clinical Trial	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00589797	NA
10.1097/brs.0000000000002647	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1097/brs.0000000000002647	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/brs.0000000000002647	study_information	NA	1	Patient-level data used	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	1	Clinical Trial	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00589797	NA
10.1097/brs.0000000000002647	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1097/brs.0000000000002647	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/brs.0000000000002647	study_information	NA	2	Patient-level data used	No	NA
10.1097/brs.0000000000002647	study_information	NA	2	Clinical Trial	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00295009	NA
10.1097/brs.0000000000002647	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1097/brs.0000000000002647	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/brs.0000000000002647	study_information	NA	2	Patient-level data used	No	NA
10.1097/brs.0000000000002647	study_information	NA	2	Clinical Trial	Yes	NA
10.1097/brs.0000000000002647	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00295009	NA
10.1097/brs.0000000000002647	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1097/brs.0000000000002647	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1097/ju.0000000000001767	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1097/ju.0000000000001767	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	XXXX	NA
10.1097/ju.0000000000001767	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 1	darolutamide	NA
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 2	apalutamide	NA
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1097/ju.0000000000001767	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1097/ju.0000000000001767	methodology	1	NA	Anchored comparison?	Yes	NA
10.1097/ju.0000000000001767	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1097/ju.0000000000001767	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1097/ju.0000000000001767	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Risk of fall	NA
10.1097/ju.0000000000001767	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1097/ju.0000000000001767	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1097/ju.0000000000001767	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1097/ju.0000000000001767	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1097/ju.0000000000001767	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1097/ju.0000000000001767	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 1	darolutamide	NA
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 2	enzalutamide	NA
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1097/ju.0000000000001767	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1097/ju.0000000000001767	methodology	2	NA	Anchored comparison?	Yes	NA
10.1097/ju.0000000000001767	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1097/ju.0000000000001767	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1097/ju.0000000000001767	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Risk of fall	NA
10.1097/ju.0000000000001767	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1097/ju.0000000000001767	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1097/ju.0000000000001767	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1097/ju.0000000000001767	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1097/ju.0000000000001767	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1097/ju.0000000000001767	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1097/ju.0000000000001767	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	806	NA
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	401	NA
10.1097/ju.0000000000001767	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	943	NA
10.1097/ju.0000000000001767	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	604	NA
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	553	NA
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	391	NA
10.1097/ju.0000000000001767	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1097/ju.0000000000001767	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1097/ju.0000000000001767	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.1097/ju.0000000000001767	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.1097/ju.0000000000001767	results	1	NA	Primary outcome: treatment effect contrast	Risk difference	NA
10.1097/ju.0000000000001767	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1097/ju.0000000000001767	results	1	NA	Primary outcome: adjusted treatment effect	-6.3	NA
10.1097/ju.0000000000001767	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.043	NA
10.1097/ju.0000000000001767	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	933	NA
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468	NA
10.1097/ju.0000000000001767	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	943	NA
10.1097/ju.0000000000001767	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	580	NA
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	553	NA
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	395	NA
10.1097/ju.0000000000001767	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1097/ju.0000000000001767	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1097/ju.0000000000001767	results	2	NA	Number of covariates adjusted for/matched on	8	NA
10.1097/ju.0000000000001767	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1097/ju.0000000000001767	results	2	NA	Primary outcome: treatment effect contrast	Risk difference	NA
10.1097/ju.0000000000001767	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1097/ju.0000000000001767	results	2	NA	Primary outcome: adjusted treatment effect	-6.3	NA
10.1097/ju.0000000000001767	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004	NA
10.1097/ju.0000000000001767	study_information	NA	1	Patient-level data used	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	1	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614	NA
10.1097/ju.0000000000001767	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	study_information	NA	1	Patient-level data used	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	1	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614	NA
10.1097/ju.0000000000001767	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	study_information	NA	2	Patient-level data used	No	NA
10.1097/ju.0000000000001767	study_information	NA	2	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1097/ju.0000000000001767	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	study_information	NA	2	Patient-level data used	No	NA
10.1097/ju.0000000000001767	study_information	NA	2	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204	NA
10.1097/ju.0000000000001767	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	study_information	NA	3	Patient-level data used	No	NA
10.1097/ju.0000000000001767	study_information	NA	3	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924	NA
10.1097/ju.0000000000001767	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1097/ju.0000000000001767	study_information	NA	3	Patient-level data used	No	NA
10.1097/ju.0000000000001767	study_information	NA	3	Clinical Trial	Yes	NA
10.1097/ju.0000000000001767	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924	NA
10.1097/ju.0000000000001767	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1097/ju.0000000000001767	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1097/ju.0000000000001767	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis	NA
10.1111/bjd.16140	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1111/bjd.16140	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.1111/bjd.16140	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1111/bjd.16140	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/bjd.16140	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/bjd.16140	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/bjd.16140	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1111/bjd.16140	methodology	1	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	29171861
10.1111/bjd.16140	methodology	1	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	1	NA	Study 'number(s)' for treatment 2	5;6;7;8	29171861
10.1111/bjd.16140	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	1	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	29171861
10.1111/bjd.16140	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	29171861
10.1111/bjd.16140	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	methodology	2	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3	29171861
10.1111/bjd.16140	methodology	2	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	2	NA	Study 'number(s)' for treatment 2	5;6;7;8	29171861
10.1111/bjd.16140	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	2	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	29171861
10.1111/bjd.16140	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29171861
10.1111/bjd.16140	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	methodology	3	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 1	2;3	29171861
10.1111/bjd.16140	methodology	3	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 2	5	29171861
10.1111/bjd.16140	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	3	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	29171861
10.1111/bjd.16140	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29171861
10.1111/bjd.16140	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	methodology	4	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	4	NA	Study 'number(s)' for treatment 1	2;3	29171861
10.1111/bjd.16140	methodology	4	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	4	NA	Study 'number(s)' for treatment 2	5	29171861
10.1111/bjd.16140	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	4	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	29171861
10.1111/bjd.16140	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29171861
10.1111/bjd.16140	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	methodology	5	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 1	4	29171861
10.1111/bjd.16140	methodology	5	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 2	9	29171861
10.1111/bjd.16140	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	5	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29171861
10.1111/bjd.16140	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29171861
10.1111/bjd.16140	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	methodology	6	NA	Treatment name 1	ixekizumab	29171861
10.1111/bjd.16140	methodology	6	NA	Study 'number(s)' for treatment 1	4	29171861
10.1111/bjd.16140	methodology	6	NA	Treatment name 2	secukinumab	29171861
10.1111/bjd.16140	methodology	6	NA	Study 'number(s)' for treatment 2	NA	29171861
10.1111/bjd.16140	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	29171861
10.1111/bjd.16140	methodology	6	NA	Anchored comparison?	Yes	29171861
10.1111/bjd.16140	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29171861
10.1111/bjd.16140	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	29171861
10.1111/bjd.16140	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	29171861
10.1111/bjd.16140	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)	29171861
10.1111/bjd.16140	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29171861
10.1111/bjd.16140	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	29171861
10.1111/bjd.16140	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	29171861
10.1111/bjd.16140	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29171861
10.1111/bjd.16140	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29171861
10.1111/bjd.16140	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1956	29171861
10.1111/bjd.16140	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	1666	29171861
10.1111/bjd.16140	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	1	NA	Number of covariates adjusted for/matched on	6	29171861
10.1111/bjd.16140	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	1	NA	Primary outcome: treatment effect contrast	Risk difference	29171861
10.1111/bjd.16140	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	2	NA	Number of covariates adjusted for/matched on	6	29171861
10.1111/bjd.16140	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	2	NA	Primary outcome: treatment effect contrast	Risk difference	29171861
10.1111/bjd.16140	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	29171861
10.1111/bjd.16140	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	1465	29171861
10.1111/bjd.16140	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	989	29171861
10.1111/bjd.16140	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	3	NA	Number of covariates adjusted for/matched on	7	29171861
10.1111/bjd.16140	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	3	NA	Primary outcome: treatment effect contrast	Risk difference	29171861
10.1111/bjd.16140	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	4	NA	Number of covariates adjusted for/matched on	7	29171861
10.1111/bjd.16140	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	4	NA	Primary outcome: treatment effect contrast	Risk difference	29171861
10.1111/bjd.16140	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	29171861
10.1111/bjd.16140	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	259	29171861
10.1111/bjd.16140	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	122	29171861
10.1111/bjd.16140	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	5	NA	Number of covariates adjusted for/matched on	8	29171861
10.1111/bjd.16140	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	5	NA	Primary outcome: treatment effect contrast	NA	29171861
10.1111/bjd.16140	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29171861
10.1111/bjd.16140	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29171861
10.1111/bjd.16140	results	6	NA	Number of covariates adjusted for/matched on	8	29171861
10.1111/bjd.16140	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	29171861
10.1111/bjd.16140	results	6	NA	Primary outcome: treatment effect contrast	Risk difference	29171861
10.1111/bjd.16140	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29171861
10.1111/bjd.16140	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	29171861
10.1111/bjd.16140	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	29171861
10.1111/bjd.16140	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	29171861
10.1111/bjd.16140	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	29171861
10.1111/bjd.16140	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/bjd.16140	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512	NA
10.1111/bjd.16140	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	2	Patient-level data used	Yes	NA
10.1111/bjd.16140	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245	NA
10.1111/bjd.16140	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	3	Patient-level data used	Yes	NA
10.1111/bjd.16140	study_information	NA	3	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177	NA
10.1111/bjd.16140	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	4	Patient-level data used	Yes	NA
10.1111/bjd.16140	study_information	NA	4	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806	NA
10.1111/bjd.16140	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	5	Patient-level data used	No	NA
10.1111/bjd.16140	study_information	NA	5	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358578	NA
10.1111/bjd.16140	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	6	Patient-level data used	No	NA
10.1111/bjd.16140	study_information	NA	6	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01365455	NA
10.1111/bjd.16140	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	7	Patient-level data used	No	NA
10.1111/bjd.16140	study_information	NA	7	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01555125	NA
10.1111/bjd.16140	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	8	Patient-level data used	No	NA
10.1111/bjd.16140	study_information	NA	8	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01636687	NA
10.1111/bjd.16140	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/bjd.16140	study_information	NA	9	Patient-level data used	No	NA
10.1111/bjd.16140	study_information	NA	9	Clinical Trial	Yes	NA
10.1111/bjd.16140	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02074982	NA
10.1111/bjd.16140	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/bjd.16140	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/bjd.16140	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	general_information	NA	NA	Medical Condition of Interest Name	asthma	NA
10.1111/cea.13561	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1111/cea.13561	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1111/cea.13561	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/cea.13561	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/cea.13561	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/cea.13561	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/cea.13561	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1111/cea.13561	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1111/cea.13561	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1111/cea.13561	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1111/cea.13561	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/cea.13561	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/cea.13561	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/cea.13561	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/cea.13561	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1111/cea.13561	methodology	1	NA	Treatment name 1	benralizumab	NA
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1111/cea.13561	methodology	1	NA	Treatment name 2	mepolizumab	NA
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1111/cea.13561	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1111/cea.13561	methodology	1	NA	Anchored comparison?	Yes	NA
10.1111/cea.13561	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1111/cea.13561	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1111/cea.13561	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	ocs (oral corticosteroids) dosage reduction from baseline to week 24	NA
10.1111/cea.13561	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1111/cea.13561	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1111/cea.13561	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1111/cea.13561	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1111/cea.13561	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1111/cea.13561	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1111/cea.13561	methodology	2	NA	Treatment name 1	benralizumab	NA
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1111/cea.13561	methodology	2	NA	Treatment name 2	dupilumab	NA
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1111/cea.13561	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1111/cea.13561	methodology	2	NA	Anchored comparison?	Yes	NA
10.1111/cea.13561	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1111/cea.13561	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1111/cea.13561	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	ocs (oral corticosteroids) dosage reduction from baseline to week 24	NA
10.1111/cea.13561	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1111/cea.13561	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	NA
10.1111/cea.13561	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1111/cea.13561	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1111/cea.13561	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1111/cea.13561	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1111/cea.13561	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1111/cea.13561	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1111/cea.13561	results	1	NA	Number of covariates adjusted for/matched on	5	NA
10.1111/cea.13561	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	NA
10.1111/cea.13561	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1111/cea.13561	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1111/cea.13561	results	1	NA	Primary outcome: unadjusted treatment effect	20.1	NA
10.1111/cea.13561	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.1584	NA
10.1111/cea.13561	results	1	NA	Primary outcome: adjusted treatment effect	6.08	NA
10.1111/cea.13561	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.67	NA
10.1111/cea.13561	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1111/cea.13561	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1111/cea.13561	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.1111/cea.13561	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	NA
10.1111/cea.13561	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1111/cea.13561	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1111/cea.13561	results	2	NA	Primary outcome: unadjusted treatment effect	8.1	NA
10.1111/cea.13561	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.46	NA
10.1111/cea.13561	results	2	NA	Primary outcome: adjusted treatment effect	-0.71	NA
10.1111/cea.13561	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.94	NA
10.1111/cea.13561	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/cea.13561	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02075255	NA
10.1111/cea.13561	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/cea.13561	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02075255	NA
10.1111/cea.13561	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	study_information	NA	2	Patient-level data used	No	NA
10.1111/cea.13561	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691508	NA
10.1111/cea.13561	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	study_information	NA	2	Patient-level data used	No	NA
10.1111/cea.13561	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691508	NA
10.1111/cea.13561	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	study_information	NA	3	Patient-level data used	No	NA
10.1111/cea.13561	study_information	NA	3	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02528214	NA
10.1111/cea.13561	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/cea.13561	study_information	NA	3	Patient-level data used	No	NA
10.1111/cea.13561	study_information	NA	3	Clinical Trial	Yes	NA
10.1111/cea.13561	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02528214	NA
10.1111/cea.13561	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/cea.13561	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/cea.13561	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/dom.14497	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes	NA
10.1111/dom.14497	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1111/dom.14497	general_information	NA	NA	Countries of last author affiliations	denmark	NA
10.1111/dom.14497	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/dom.14497	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/dom.14497	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/dom.14497	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/dom.14497	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1111/dom.14497	methodology	1	NA	Treatment name 1	NA	34286894
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 1	1	34286894
10.1111/dom.14497	methodology	1	NA	Treatment name 2	NA	34286894
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 2	2	34286894
10.1111/dom.14497	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34286894
10.1111/dom.14497	methodology	1	NA	Anchored comparison?	Yes	34286894
10.1111/dom.14497	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34286894
10.1111/dom.14497	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34286894
10.1111/dom.14497	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34286894
10.1111/dom.14497	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34286894
10.1111/dom.14497	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34286894
10.1111/dom.14497	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	34286894
10.1111/dom.14497	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34286894
10.1111/dom.14497	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	34286894
10.1111/dom.14497	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34286894
10.1111/dom.14497	methodology	2	NA	Treatment name 1	NA	34286894
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 1	1	34286894
10.1111/dom.14497	methodology	2	NA	Treatment name 2	NA	34286894
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 2	NA	34286894
10.1111/dom.14497	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34286894
10.1111/dom.14497	methodology	2	NA	Anchored comparison?	Yes	34286894
10.1111/dom.14497	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34286894
10.1111/dom.14497	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34286894
10.1111/dom.14497	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34286894
10.1111/dom.14497	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34286894
10.1111/dom.14497	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34286894
10.1111/dom.14497	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	34286894
10.1111/dom.14497	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34286894
10.1111/dom.14497	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	34286894
10.1111/dom.14497	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34286894
10.1111/dom.14497	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	616	34286894
10.1111/dom.14497	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612	34286894
10.1111/dom.14497	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	300	34286894
10.1111/dom.14497	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	299	34286894
10.1111/dom.14497	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34286894
10.1111/dom.14497	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34286894
10.1111/dom.14497	results	1	NA	Number of covariates adjusted for/matched on	3	34286894
10.1111/dom.14497	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34286894
10.1111/dom.14497	results	1	NA	Primary outcome: treatment effect contrast	Means difference	34286894
10.1111/dom.14497	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34286894
10.1111/dom.14497	results	1	NA	Primary outcome: unadjusted treatment effect	-0.24	34286894
10.1111/dom.14497	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.016	34286894
10.1111/dom.14497	results	1	NA	Primary outcome: adjusted treatment effect	NA	34286894
10.1111/dom.14497	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34286894
10.1111/dom.14497	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	614	34286894
10.1111/dom.14497	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612	34286894
10.1111/dom.14497	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	300	34286894
10.1111/dom.14497	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	299	34286894
10.1111/dom.14497	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34286894
10.1111/dom.14497	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34286894
10.1111/dom.14497	results	2	NA	Number of covariates adjusted for/matched on	3	34286894
10.1111/dom.14497	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	34286894
10.1111/dom.14497	results	2	NA	Primary outcome: treatment effect contrast	Means difference	34286894
10.1111/dom.14497	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34286894
10.1111/dom.14497	results	2	NA	Primary outcome: unadjusted treatment effect	-0.07	34286894
10.1111/dom.14497	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.484	34286894
10.1111/dom.14497	results	2	NA	Primary outcome: adjusted treatment effect	-0.08	34286894
10.1111/dom.14497	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.523	34286894
10.1111/dom.14497	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/dom.14497	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/dom.14497	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02648204	NA
10.1111/dom.14497	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/dom.14497	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/dom.14497	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/dom.14497	study_information	NA	2	Patient-level data used	No	NA
10.1111/dom.14497	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/dom.14497	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102	NA
10.1111/dom.14497	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/dom.14497	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/dom.14497	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/dom.14497	study_information	NA	3	Patient-level data used	xx	NA
10.1111/dom.14497	study_information	NA	3	Clinical Trial	xx	NA
10.1111/dom.14497	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	xx	NA
10.1111/dom.14497	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	xx	NA
10.1111/dom.14497	study_information	NA	3	Phase of the clinical trial (clinical trial only)	xx	NA
10.1111/dom.14497	study_information	NA	3	Number of treatment arms (clinical trial only)	xx	NA
10.1111/head.14128	general_information	NA	NA	Medical Condition of Interest Name	migraine	NA
10.1111/head.14128	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1111/head.14128	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1111/head.14128	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/head.14128	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/head.14128	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/head.14128	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/head.14128	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1111/head.14128	methodology	1	NA	Treatment name 1	rimegepant	34021585
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 1	1	34021585
10.1111/head.14128	methodology	1	NA	Treatment name 2	placebo	34021585
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 2	2;3	34021585
10.1111/head.14128	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34021585
10.1111/head.14128	methodology	1	NA	Anchored comparison?	No	34021585
10.1111/head.14128	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	34021585
10.1111/head.14128	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34021585
10.1111/head.14128	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34021585
10.1111/head.14128	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34021585
10.1111/head.14128	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34021585
10.1111/head.14128	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34021585
10.1111/head.14128	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34021585
10.1111/head.14128	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	34021585
10.1111/head.14128	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34021585
10.1111/head.14128	methodology	2	NA	Treatment name 1	rimegepant	34021585
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 1	1	34021585
10.1111/head.14128	methodology	2	NA	Treatment name 2	galcanezumab	34021585
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 2	NA	34021585
10.1111/head.14128	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34021585
10.1111/head.14128	methodology	2	NA	Anchored comparison?	No	34021585
10.1111/head.14128	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	34021585
10.1111/head.14128	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34021585
10.1111/head.14128	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34021585
10.1111/head.14128	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34021585
10.1111/head.14128	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34021585
10.1111/head.14128	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34021585
10.1111/head.14128	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34021585
10.1111/head.14128	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	34021585
10.1111/head.14128	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34021585
10.1111/head.14128	methodology	3	NA	Treatment name 1	rimegepant	34021585
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 1	1	34021585
10.1111/head.14128	methodology	3	NA	Treatment name 2	placebo	34021585
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 2	4	34021585
10.1111/head.14128	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	34021585
10.1111/head.14128	methodology	3	NA	Anchored comparison?	No	34021585
10.1111/head.14128	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34021585
10.1111/head.14128	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34021585
10.1111/head.14128	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34021585
10.1111/head.14128	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34021585
10.1111/head.14128	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34021585
10.1111/head.14128	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34021585
10.1111/head.14128	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34021585
10.1111/head.14128	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	34021585
10.1111/head.14128	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34021585
10.1111/head.14128	methodology	4	NA	Treatment name 1	rimegepant	34021585
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 1	1	34021585
10.1111/head.14128	methodology	4	NA	Treatment name 2	erenumab	34021585
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 2	4	34021585
10.1111/head.14128	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	34021585
10.1111/head.14128	methodology	4	NA	Anchored comparison?	No	34021585
10.1111/head.14128	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34021585
10.1111/head.14128	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34021585
10.1111/head.14128	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34021585
10.1111/head.14128	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)	34021585
10.1111/head.14128	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34021585
10.1111/head.14128	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34021585
10.1111/head.14128	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34021585
10.1111/head.14128	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	34021585
10.1111/head.14128	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34021585
10.1111/head.14128	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1773	34021585
10.1111/head.14128	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	257	34021585
10.1111/head.14128	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	169	34021585
10.1111/head.14128	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34021585
10.1111/head.14128	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34021585
10.1111/head.14128	results	1	NA	Number of covariates adjusted for/matched on	6	34021585
10.1111/head.14128	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	34021585
10.1111/head.14128	results	1	NA	Primary outcome: treatment effect contrast	Means difference	34021585
10.1111/head.14128	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34021585
10.1111/head.14128	results	1	NA	Primary outcome: unadjusted treatment effect	NA	34021585
10.1111/head.14128	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	34021585
10.1111/head.14128	results	1	NA	Primary outcome: adjusted treatment effect	NA	34021585
10.1111/head.14128	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34021585
10.1111/head.14128	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	257	34021585
10.1111/head.14128	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	169	34021585
10.1111/head.14128	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34021585
10.1111/head.14128	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34021585
10.1111/head.14128	results	2	NA	Number of covariates adjusted for/matched on	6	34021585
10.1111/head.14128	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	34021585
10.1111/head.14128	results	2	NA	Primary outcome: treatment effect contrast	Means difference	34021585
10.1111/head.14128	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34021585
10.1111/head.14128	results	2	NA	Primary outcome: unadjusted treatment effect	NA	34021585
10.1111/head.14128	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	34021585
10.1111/head.14128	results	2	NA	Primary outcome: adjusted treatment effect	NA	34021585
10.1111/head.14128	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34021585
10.1111/head.14128	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34021585
10.1111/head.14128	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	257	34021585
10.1111/head.14128	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	214	34021585
10.1111/head.14128	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34021585
10.1111/head.14128	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34021585
10.1111/head.14128	results	3	NA	Number of covariates adjusted for/matched on	NA	34021585
10.1111/head.14128	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	34021585
10.1111/head.14128	results	3	NA	Primary outcome: treatment effect contrast	Means difference	34021585
10.1111/head.14128	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34021585
10.1111/head.14128	results	3	NA	Primary outcome: unadjusted treatment effect	NA	34021585
10.1111/head.14128	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	34021585
10.1111/head.14128	results	3	NA	Primary outcome: adjusted treatment effect	NA	34021585
10.1111/head.14128	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34021585
10.1111/head.14128	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34021585
10.1111/head.14128	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	257	34021585
10.1111/head.14128	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	214	34021585
10.1111/head.14128	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34021585
10.1111/head.14128	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34021585
10.1111/head.14128	results	4	NA	Number of covariates adjusted for/matched on	NA	34021585
10.1111/head.14128	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	34021585
10.1111/head.14128	results	4	NA	Primary outcome: treatment effect contrast	Means difference	34021585
10.1111/head.14128	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34021585
10.1111/head.14128	results	4	NA	Primary outcome: unadjusted treatment effect	NA	34021585
10.1111/head.14128	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	34021585
10.1111/head.14128	results	4	NA	Primary outcome: adjusted treatment effect	NA	34021585
10.1111/head.14128	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34021585
10.1111/head.14128	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34021585
10.1111/head.14128	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/head.14128	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/head.14128	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03266588	NA
10.1111/head.14128	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1111/head.14128	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1111/head.14128	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1111/head.14128	study_information	NA	2	Patient-level data used	No	NA
10.1111/head.14128	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/head.14128	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614183	NA
10.1111/head.14128	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/head.14128	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/head.14128	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/head.14128	study_information	NA	3	Patient-level data used	No	NA
10.1111/head.14128	study_information	NA	3	Clinical Trial	Yes	NA
10.1111/head.14128	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614196	NA
10.1111/head.14128	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/head.14128	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/head.14128	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/head.14128	study_information	NA	4	Patient-level data used	No	NA
10.1111/head.14128	study_information	NA	4	Clinical Trial	Yes	NA
10.1111/head.14128	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02456740	NA
10.1111/head.14128	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/head.14128	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/head.14128	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of first author affiliations	taiwan	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 1	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 1	1	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 2	pemetrexed + cisplatin	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 2	2	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Anchored comparison?	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Primary outcome: variable type	Time-to-event	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	21585706
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	67	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	72	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	46	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Number of covariates adjusted for/matched on	2	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Primary outcome: treatment effect contrast	NA	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	21585706
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Primary outcome: adjusted treatment effect	NA	21585706
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451906	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Patient-level data used	No	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	yang et al. (2010)	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis	NA
10.1111/jdv.15369	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1111/jdv.15369	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1111/jdv.15369	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1111/jdv.15369	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1111/jdv.15369	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1111/jdv.15369	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1111/jdv.15369	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1111/jdv.15369	methodology	1	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	30472749
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4	30472749
10.1111/jdv.15369	methodology	1	NA	Treatment name 2	apremilast	30472749
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 2	5	30472749
10.1111/jdv.15369	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30472749
10.1111/jdv.15369	methodology	1	NA	Anchored comparison?	No	30472749
10.1111/jdv.15369	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30472749
10.1111/jdv.15369	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	30472749
10.1111/jdv.15369	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30472749
10.1111/jdv.15369	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	30472749
10.1111/jdv.15369	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30472749
10.1111/jdv.15369	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	30472749
10.1111/jdv.15369	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30472749
10.1111/jdv.15369	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30472749
10.1111/jdv.15369	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30472749
10.1111/jdv.15369	methodology	2	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	30472749
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3;4	30472749
10.1111/jdv.15369	methodology	2	NA	Treatment name 2	methotrexate	30472749
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 2	6	30472749
10.1111/jdv.15369	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30472749
10.1111/jdv.15369	methodology	2	NA	Anchored comparison?	No	30472749
10.1111/jdv.15369	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30472749
10.1111/jdv.15369	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	30472749
10.1111/jdv.15369	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30472749
10.1111/jdv.15369	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	30472749
10.1111/jdv.15369	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30472749
10.1111/jdv.15369	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	30472749
10.1111/jdv.15369	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30472749
10.1111/jdv.15369	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30472749
10.1111/jdv.15369	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30472749
10.1111/jdv.15369	methodology	3	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	30472749
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3;4	30472749
10.1111/jdv.15369	methodology	3	NA	Treatment name 2	acitretin	30472749
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 2	7	30472749
10.1111/jdv.15369	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	30472749
10.1111/jdv.15369	methodology	3	NA	Anchored comparison?	No	30472749
10.1111/jdv.15369	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30472749
10.1111/jdv.15369	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	30472749
10.1111/jdv.15369	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30472749
10.1111/jdv.15369	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	30472749
10.1111/jdv.15369	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	30472749
10.1111/jdv.15369	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	30472749
10.1111/jdv.15369	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30472749
10.1111/jdv.15369	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30472749
10.1111/jdv.15369	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30472749
10.1111/jdv.15369	methodology	4	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	30472749
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3;4	30472749
10.1111/jdv.15369	methodology	4	NA	Treatment name 2	fumaric acid esters	30472749
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 2	8	30472749
10.1111/jdv.15369	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	30472749
10.1111/jdv.15369	methodology	4	NA	Anchored comparison?	No	30472749
10.1111/jdv.15369	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30472749
10.1111/jdv.15369	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes	30472749
10.1111/jdv.15369	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30472749
10.1111/jdv.15369	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	30472749
10.1111/jdv.15369	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	30472749
10.1111/jdv.15369	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	30472749
10.1111/jdv.15369	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	30472749
10.1111/jdv.15369	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30472749
10.1111/jdv.15369	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30472749
10.1111/jdv.15369	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	148	30472749
10.1111/jdv.15369	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	748	30472749
10.1111/jdv.15369	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	640	30472749
10.1111/jdv.15369	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	30472749
10.1111/jdv.15369	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30472749
10.1111/jdv.15369	results	1	NA	Number of covariates adjusted for/matched on	3	30472749
10.1111/jdv.15369	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	30472749
10.1111/jdv.15369	results	1	NA	Primary outcome: treatment effect contrast	NA	30472749
10.1111/jdv.15369	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	30472749
10.1111/jdv.15369	results	1	NA	Primary outcome: adjusted treatment effect	NA	30472749
10.1111/jdv.15369	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	30472749
10.1111/jdv.15369	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	218	30472749
10.1111/jdv.15369	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	749	30472749
10.1111/jdv.15369	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	633	30472749
10.1111/jdv.15369	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	30472749
10.1111/jdv.15369	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30472749
10.1111/jdv.15369	results	2	NA	Number of covariates adjusted for/matched on	NA	30472749
10.1111/jdv.15369	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30472749
10.1111/jdv.15369	results	2	NA	Primary outcome: treatment effect contrast	NA	30472749
10.1111/jdv.15369	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	30472749
10.1111/jdv.15369	results	2	NA	Primary outcome: adjusted treatment effect	NA	30472749
10.1111/jdv.15369	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	30472749
10.1111/jdv.15369	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	41	30472749
10.1111/jdv.15369	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	748	30472749
10.1111/jdv.15369	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	102	30472749
10.1111/jdv.15369	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	30472749
10.1111/jdv.15369	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30472749
10.1111/jdv.15369	results	3	NA	Number of covariates adjusted for/matched on	4	30472749
10.1111/jdv.15369	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	30472749
10.1111/jdv.15369	results	3	NA	Primary outcome: treatment effect contrast	NA	30472749
10.1111/jdv.15369	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	30472749
10.1111/jdv.15369	results	3	NA	Primary outcome: adjusted treatment effect	NA	30472749
10.1111/jdv.15369	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	30472749
10.1111/jdv.15369	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	115	30472749
10.1111/jdv.15369	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	749	30472749
10.1111/jdv.15369	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	224	30472749
10.1111/jdv.15369	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	30472749
10.1111/jdv.15369	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30472749
10.1111/jdv.15369	results	4	NA	Number of covariates adjusted for/matched on	2	30472749
10.1111/jdv.15369	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	30472749
10.1111/jdv.15369	results	4	NA	Primary outcome: treatment effect contrast	NA	30472749
10.1111/jdv.15369	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	30472749
10.1111/jdv.15369	results	4	NA	Primary outcome: adjusted treatment effect	NA	30472749
10.1111/jdv.15369	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	30472749
10.1111/jdv.15369	study_information	NA	1	Patient-level data used	Yes	NA
10.1111/jdv.15369	study_information	NA	1	Clinical Trial	Yes	NA
10.1111/jdv.15369	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936	NA
10.1111/jdv.15369	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.1111/jdv.15369	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/jdv.15369	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	study_information	NA	2	Patient-level data used	Yes	NA
10.1111/jdv.15369	study_information	NA	2	Clinical Trial	Yes	NA
10.1111/jdv.15369	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163	NA
10.1111/jdv.15369	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1111/jdv.15369	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1111/jdv.15369	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	study_information	NA	3	Patient-level data used	Yes	NA
10.1111/jdv.15369	study_information	NA	3	Clinical Trial	Yes	NA
10.1111/jdv.15369	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886	NA
10.1111/jdv.15369	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1111/jdv.15369	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.1111/jdv.15369	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	study_information	NA	4	Patient-level data used	Yes	NA
10.1111/jdv.15369	study_information	NA	4	Clinical Trial	Yes	NA
10.1111/jdv.15369	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536938	NA
10.1111/jdv.15369	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1111/jdv.15369	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.1111/jdv.15369	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	study_information	NA	5	Patient-level data used	No	NA
10.1111/jdv.15369	study_information	NA	5	Clinical Trial	Yes	NA
10.1111/jdv.15369	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425826	NA
10.1111/jdv.15369	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1111/jdv.15369	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4	NA
10.1111/jdv.15369	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1111/jdv.15369	study_information	NA	6	Patient-level data used	No	NA
10.1111/jdv.15369	study_information	NA	6	Clinical Trial	No	NA
10.1111/jdv.15369	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	zurita et al., (2017)	NA
10.1111/jdv.15369	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	spain	NA
10.1111/jdv.15369	study_information	NA	7	Patient-level data used	No	NA
10.1111/jdv.15369	study_information	NA	7	Clinical Trial	No	NA
10.1111/jdv.15369	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	chiricozzi et al. (2016)	NA
10.1111/jdv.15369	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.1111/jdv.15369	study_information	NA	8	Patient-level data used	No	NA
10.1111/jdv.15369	study_information	NA	8	Clinical Trial	No	NA
10.1111/jdv.15369	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	inzinger et al. (2013)	NA
10.1111/jdv.15369	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	austria	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Medical Condition of Interest Name	rheumatoid arthritis	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Medical Condition of Interest Name	rheumatoid arthritis	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	XXXX	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 1	baricitinib	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 2	adalimumab	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 2	5	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Anchored comparison?	Yes	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 1	baricitinib	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 2	tocilizumab	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Anchored comparison?	Yes	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1136/rmdopen-2019-001131	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 1	baricitinib	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 1	1	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 2	tofacitinib	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 2	4	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Anchored comparison?	Yes	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1136/rmdopen-2019-001131	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1136/rmdopen-2019-001131	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	274	NA
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	257	NA
10.1136/rmdopen-2019-001131	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	159	NA
10.1136/rmdopen-2019-001131	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	151.5	NA
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210	NA
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	181.4	NA
10.1136/rmdopen-2019-001131	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1136/rmdopen-2019-001131	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1136/rmdopen-2019-001131	results	1	NA	Number of covariates adjusted for/matched on	5	NA
10.1136/rmdopen-2019-001131	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1136/rmdopen-2019-001131	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: unadjusted treatment effect	-12.1	NA
10.1136/rmdopen-2019-001131	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	NA
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: adjusted treatment effect	-12.3	NA
10.1136/rmdopen-2019-001131	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.1136/rmdopen-2019-001131	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	159	NA
10.1136/rmdopen-2019-001131	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210	NA
10.1136/rmdopen-2019-001131	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1136/rmdopen-2019-001131	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1136/rmdopen-2019-001131	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.1136/rmdopen-2019-001131	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1136/rmdopen-2019-001131	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: unadjusted treatment effect	-8.7	NA
10.1136/rmdopen-2019-001131	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<=0.05	NA
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: adjusted treatment effect	-7.3	NA
10.1136/rmdopen-2019-001131	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<=0.05	NA
10.1136/rmdopen-2019-001131	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	292	NA
10.1136/rmdopen-2019-001131	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	287	NA
10.1136/rmdopen-2019-001131	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	373	NA
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	186	NA
10.1136/rmdopen-2019-001131	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	159	NA
10.1136/rmdopen-2019-001131	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	146.5	NA
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210	NA
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	177.8	NA
10.1136/rmdopen-2019-001131	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1136/rmdopen-2019-001131	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1136/rmdopen-2019-001131	results	3	NA	Number of covariates adjusted for/matched on	5	NA
10.1136/rmdopen-2019-001131	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1136/rmdopen-2019-001131	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: unadjusted treatment effect	-7.1	NA
10.1136/rmdopen-2019-001131	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<=0.05	NA
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: adjusted treatment effect	-5.4	NA
10.1136/rmdopen-2019-001131	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	>0.05	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Patient-level data used	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01711359	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Patient-level data used	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01711359	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109408	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109408	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01007435	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01007435	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01039688	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01039688	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195663	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Patient-level data used	No	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Clinical Trial	Yes	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195663	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.1136/rmdopen-2019-001131	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1155/2017/6121760	general_information	NA	NA	Medical Condition of Interest Name	basal cell carcinoma	NA
10.1155/2017/6121760	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1155/2017/6121760	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1155/2017/6121760	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1155/2017/6121760	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1155/2017/6121760	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1155/2017/6121760	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1155/2017/6121760	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1155/2017/6121760	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1155/2017/6121760	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1155/2017/6121760	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1155/2017/6121760	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1155/2017/6121760	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1155/2017/6121760	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1155/2017/6121760	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1155/2017/6121760	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1155/2017/6121760	methodology	1	NA	Treatment name 1	sonidegib	NA
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1155/2017/6121760	methodology	1	NA	Treatment name 2	vismodegib	NA
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1155/2017/6121760	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1155/2017/6121760	methodology	1	NA	Anchored comparison?	No	NA
10.1155/2017/6121760	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1155/2017/6121760	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1155/2017/6121760	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1155/2017/6121760	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1155/2017/6121760	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1155/2017/6121760	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1155/2017/6121760	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1155/2017/6121760	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1155/2017/6121760	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1155/2017/6121760	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	63	NA
10.1155/2017/6121760	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	66	NA
10.1155/2017/6121760	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1155/2017/6121760	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1155/2017/6121760	results	1	NA	Number of covariates adjusted for/matched on	2	NA
10.1155/2017/6121760	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Past treatments for the disease of interest	NA
10.1155/2017/6121760	results	1	NA	Primary outcome: treatment effect contrast	NA	NA
10.1155/2017/6121760	study_information	NA	1	Patient-level data used	Yes	NA
10.1155/2017/6121760	study_information	NA	1	Clinical Trial	Yes	NA
10.1155/2017/6121760	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01327053	NA
10.1155/2017/6121760	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1155/2017/6121760	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1155/2017/6121760	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1155/2017/6121760	study_information	NA	1	Patient-level data used	Yes	NA
10.1155/2017/6121760	study_information	NA	1	Clinical Trial	Yes	NA
10.1155/2017/6121760	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01327053	NA
10.1155/2017/6121760	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1155/2017/6121760	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1155/2017/6121760	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.1155/2017/6121760	study_information	NA	2	Patient-level data used	No	NA
10.1155/2017/6121760	study_information	NA	2	Clinical Trial	Yes	NA
10.1155/2017/6121760	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833417	NA
10.1155/2017/6121760	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1155/2017/6121760	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1155/2017/6121760	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1155/2017/6121760	study_information	NA	2	Patient-level data used	No	NA
10.1155/2017/6121760	study_information	NA	2	Clinical Trial	Yes	NA
10.1155/2017/6121760	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833417	NA
10.1155/2017/6121760	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1155/2017/6121760	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1155/2017/6121760	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1177/1756286420975916	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis	NA
10.1177/1756286420975916	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1177/1756286420975916	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1177/1756286420975916	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1177/1756286420975916	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.1177/1756286420975916	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1177/1756286420975916	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1177/1756286420975916	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1177/1756286420975916	methodology	1	NA	Treatment name 1	peginterferon beta-1a	33488773
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 1	1	33488773
10.1177/1756286420975916	methodology	1	NA	Treatment name 2	glatiramer acetate	33488773
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 2	2	33488773
10.1177/1756286420975916	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33488773
10.1177/1756286420975916	methodology	1	NA	Anchored comparison?	No	33488773
10.1177/1756286420975916	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33488773
10.1177/1756286420975916	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33488773
10.1177/1756286420975916	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33488773
10.1177/1756286420975916	methodology	1	NA	Primary outcome: variable type	NA	33488773
10.1177/1756286420975916	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	33488773
10.1177/1756286420975916	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33488773
10.1177/1756286420975916	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33488773
10.1177/1756286420975916	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33488773
10.1177/1756286420975916	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33488773
10.1177/1756286420975916	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	834	33488773
10.1177/1756286420975916	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	407	33488773
10.1177/1756286420975916	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	276	33488773
10.1177/1756286420975916	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33488773
10.1177/1756286420975916	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33488773
10.1177/1756286420975916	results	1	NA	Number of covariates adjusted for/matched on	5	33488773
10.1177/1756286420975916	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33488773
10.1177/1756286420975916	results	1	NA	Primary outcome: treatment effect contrast	NA	33488773
10.1177/1756286420975916	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	33488773
10.1177/1756286420975916	results	1	NA	Primary outcome: adjusted treatment effect	NA	33488773
10.1177/1756286420975916	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33488773
10.1177/1756286420975916	study_information	NA	1	Patient-level data used	Yes	NA
10.1177/1756286420975916	study_information	NA	1	Clinical Trial	Yes	NA
10.1177/1756286420975916	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00906399	NA
10.1177/1756286420975916	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1177/1756286420975916	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1177/1756286420975916	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1177/1756286420975916	study_information	NA	2	Patient-level data used	No	NA
10.1177/1756286420975916	study_information	NA	2	Clinical Trial	Yes	NA
10.1177/1756286420975916	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01067521	NA
10.1177/1756286420975916	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1177/1756286420975916	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1177/1756286420975916	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1177/17588359211049639	general_information	NA	NA	Medical Condition of Interest Name	advanced ovarian cancer	NA
10.1177/17588359211049639	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.1177/17588359211049639	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1177/17588359211049639	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1177/17588359211049639	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1177/17588359211049639	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1177/17588359211049639	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1177/17588359211049639	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1177/17588359211049639	methodology	1	NA	Treatment name 1	NA	34616492
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 1	1	34616492
10.1177/17588359211049639	methodology	1	NA	Treatment name 2	niraparib	34616492
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 2	2	34616492
10.1177/17588359211049639	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34616492
10.1177/17588359211049639	methodology	1	NA	Anchored comparison?	No	34616492
10.1177/17588359211049639	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34616492
10.1177/17588359211049639	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	34616492
10.1177/17588359211049639	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34616492
10.1177/17588359211049639	methodology	1	NA	Primary outcome: variable type	Time-to-event	34616492
10.1177/17588359211049639	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34616492
10.1177/17588359211049639	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34616492
10.1177/17588359211049639	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34616492
10.1177/17588359211049639	methodology	2	NA	Treatment name 1	NA	34616492
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 1	NA	34616492
10.1177/17588359211049639	methodology	2	NA	Treatment name 2	NA	34616492
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 2	NA	34616492
10.1177/17588359211049639	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34616492
10.1177/17588359211049639	methodology	2	NA	Anchored comparison?	No	34616492
10.1177/17588359211049639	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34616492
10.1177/17588359211049639	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	34616492
10.1177/17588359211049639	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34616492
10.1177/17588359211049639	methodology	2	NA	Primary outcome: variable type	Time-to-event	34616492
10.1177/17588359211049639	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34616492
10.1177/17588359211049639	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34616492
10.1177/17588359211049639	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34616492
10.1177/17588359211049639	methodology	3	NA	Treatment name 1	NA	34616492
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 1	1	34616492
10.1177/17588359211049639	methodology	3	NA	Treatment name 2	NA	34616492
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 2	2	34616492
10.1177/17588359211049639	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	34616492
10.1177/17588359211049639	methodology	3	NA	Anchored comparison?	No	34616492
10.1177/17588359211049639	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34616492
10.1177/17588359211049639	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	34616492
10.1177/17588359211049639	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34616492
10.1177/17588359211049639	methodology	3	NA	Primary outcome: variable type	Time-to-event	34616492
10.1177/17588359211049639	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34616492
10.1177/17588359211049639	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34616492
10.1177/17588359211049639	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34616492
10.1177/17588359211049639	methodology	4	NA	Treatment name 1	NA	34616492
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 1	1	34616492
10.1177/17588359211049639	methodology	4	NA	Treatment name 2	NA	34616492
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 2	2	34616492
10.1177/17588359211049639	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	34616492
10.1177/17588359211049639	methodology	4	NA	Anchored comparison?	No	34616492
10.1177/17588359211049639	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34616492
10.1177/17588359211049639	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes	34616492
10.1177/17588359211049639	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34616492
10.1177/17588359211049639	methodology	4	NA	Primary outcome: variable type	Time-to-event	34616492
10.1177/17588359211049639	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	34616492
10.1177/17588359211049639	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34616492
10.1177/17588359211049639	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34616492
10.1177/17588359211049639	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34616492
10.1177/17588359211049639	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	487	34616492
10.1177/17588359211049639	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	399	34616492
10.1177/17588359211049639	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	358	34616492
10.1177/17588359211049639	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34616492
10.1177/17588359211049639	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34616492
10.1177/17588359211049639	results	1	NA	Number of covariates adjusted for/matched on	8	34616492
10.1177/17588359211049639	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34616492
10.1177/17588359211049639	results	1	NA	Primary outcome: treatment effect contrast	HR	34616492
10.1177/17588359211049639	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34616492
10.1177/17588359211049639	results	1	NA	Primary outcome: adjusted treatment effect	0.57	34616492
10.1177/17588359211049639	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.47;0.69]	34616492
10.1177/17588359211049639	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	487	34616492
10.1177/17588359211049639	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	196	34616492
10.1177/17588359211049639	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	174	34616492
10.1177/17588359211049639	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34616492
10.1177/17588359211049639	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34616492
10.1177/17588359211049639	results	2	NA	Number of covariates adjusted for/matched on	8	34616492
10.1177/17588359211049639	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34616492
10.1177/17588359211049639	results	2	NA	Primary outcome: treatment effect contrast	HR	34616492
10.1177/17588359211049639	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	34616492
10.1177/17588359211049639	results	2	NA	Primary outcome: adjusted treatment effect	1.07	34616492
10.1177/17588359211049639	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.87;1.32]	34616492
10.1177/17588359211049639	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34616492
10.1177/17588359211049639	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34616492
10.1177/17588359211049639	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	34616492
10.1177/17588359211049639	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34616492
10.1177/17588359211049639	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34616492
10.1177/17588359211049639	results	3	NA	Number of covariates adjusted for/matched on	NA	34616492
10.1177/17588359211049639	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34616492
10.1177/17588359211049639	results	3	NA	Primary outcome: treatment effect contrast	HR	34616492
10.1177/17588359211049639	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34616492
10.1177/17588359211049639	results	3	NA	Primary outcome: adjusted treatment effect	NA	34616492
10.1177/17588359211049639	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34616492
10.1177/17588359211049639	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34616492
10.1177/17588359211049639	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34616492
10.1177/17588359211049639	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	34616492
10.1177/17588359211049639	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34616492
10.1177/17588359211049639	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34616492
10.1177/17588359211049639	results	4	NA	Number of covariates adjusted for/matched on	NA	34616492
10.1177/17588359211049639	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34616492
10.1177/17588359211049639	results	4	NA	Primary outcome: treatment effect contrast	HR	34616492
10.1177/17588359211049639	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	34616492
10.1177/17588359211049639	results	4	NA	Primary outcome: adjusted treatment effect	NA	34616492
10.1177/17588359211049639	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	34616492
10.1177/17588359211049639	study_information	NA	1	Patient-level data used	Yes	NA
10.1177/17588359211049639	study_information	NA	1	Clinical Trial	Yes	NA
10.1177/17588359211049639	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477644	NA
10.1177/17588359211049639	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1177/17588359211049639	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1177/17588359211049639	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1177/17588359211049639	study_information	NA	2	Patient-level data used	No	NA
10.1177/17588359211049639	study_information	NA	2	Clinical Trial	Yes	NA
10.1177/17588359211049639	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02655016	NA
10.1177/17588359211049639	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1177/17588359211049639	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1177/17588359211049639	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Medical Condition of Interest Name	severe uncontrolled asthma	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1183/13993003.01393-2018	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1183/13993003.01393-2018	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 1	benralizumab	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 2	mepolizumab	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Anchored comparison?	Yes	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annual rate of clinically significant exacerbations	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	30309978
10.1183/13993003.01393-2018	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30309978
10.1183/13993003.01393-2018	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	538	30309978
10.1183/13993003.01393-2018	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	346	30309978
10.1183/13993003.01393-2018	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30309978
10.1183/13993003.01393-2018	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30309978
10.1183/13993003.01393-2018	results	1	NA	Number of covariates adjusted for/matched on	7	30309978
10.1183/13993003.01393-2018	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	30309978
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: treatment effect contrast	RR	30309978
10.1183/13993003.01393-2018	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30309978
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: unadjusted treatment effect	1.06	30309978
10.1183/13993003.01393-2018	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	30309978
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: adjusted treatment effect	0.94	30309978
10.1183/13993003.01393-2018	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.5207	30309978
10.1183/13993003.01393-2018	study_information	NA	1	Patient-level data used	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	1	Clinical Trial	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928771	NA
10.1183/13993003.01393-2018	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1183/13993003.01393-2018	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1183/13993003.01393-2018	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1183/13993003.01393-2018	study_information	NA	2	Patient-level data used	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	2	Clinical Trial	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01914757	NA
10.1183/13993003.01393-2018	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1183/13993003.01393-2018	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1183/13993003.01393-2018	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1183/13993003.01393-2018	study_information	NA	3	Patient-level data used	No	NA
10.1183/13993003.01393-2018	study_information	NA	3	Clinical Trial	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691521	NA
10.1183/13993003.01393-2018	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1183/13993003.01393-2018	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1183/13993003.01393-2018	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1183/13993003.01393-2018	study_information	NA	4	Patient-level data used	No	NA
10.1183/13993003.01393-2018	study_information	NA	4	Clinical Trial	Yes	NA
10.1183/13993003.01393-2018	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01000506	NA
10.1183/13993003.01393-2018	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1183/13993003.01393-2018	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.1183/13993003.01393-2018	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1185/03007995.2011.576238	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1185/03007995.2011.576238	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1185/03007995.2011.576238	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 1	nilotinib	NA
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 2	dasatinib	NA
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1185/03007995.2011.576238	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1185/03007995.2011.576238	methodology	1	NA	Anchored comparison?	No	NA
10.1185/03007995.2011.576238	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1185/03007995.2011.576238	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1185/03007995.2011.576238	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response by 12 months	NA
10.1185/03007995.2011.576238	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1185/03007995.2011.576238	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1185/03007995.2011.576238	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.1185/03007995.2011.576238	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1185/03007995.2011.576238	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1185/03007995.2011.576238	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1185/03007995.2011.576238	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	259	NA
10.1185/03007995.2011.576238	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	273	NA
10.1185/03007995.2011.576238	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1185/03007995.2011.576238	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1185/03007995.2011.576238	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1185/03007995.2011.576238	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	NA
10.1185/03007995.2011.576238	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: unadjusted treatment effect	9.4	NA
10.1185/03007995.2011.576238	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.03	NA
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: adjusted treatment effect	10.8	NA
10.1185/03007995.2011.576238	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.014	NA
10.1185/03007995.2011.576238	study_information	NA	1	Patient-level data used	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	1	Clinical Trial	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497	NA
10.1185/03007995.2011.576238	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2011.576238	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2011.576238	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2011.576238	study_information	NA	1	Patient-level data used	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	1	Clinical Trial	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497	NA
10.1185/03007995.2011.576238	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2011.576238	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2011.576238	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2011.576238	study_information	NA	2	Patient-level data used	No	NA
10.1185/03007995.2011.576238	study_information	NA	2	Clinical Trial	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247	NA
10.1185/03007995.2011.576238	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2011.576238	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2011.576238	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2011.576238	study_information	NA	2	Patient-level data used	No	NA
10.1185/03007995.2011.576238	study_information	NA	2	Clinical Trial	Yes	NA
10.1185/03007995.2011.576238	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247	NA
10.1185/03007995.2011.576238	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2011.576238	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2011.576238	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia in chronic phase	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1185/03007995.2014.977992	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1185/03007995.2014.977992	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 1	nilotinib	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 1	1	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 2	dasatinib	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 2	2	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Anchored comparison?	Yes	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	25356603
10.1185/03007995.2014.977992	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	25356603
10.1185/03007995.2014.977992	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	259	25356603
10.1185/03007995.2014.977992	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	260	25356603
10.1185/03007995.2014.977992	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	278	25356603
10.1185/03007995.2014.977992	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	282	25356603
10.1185/03007995.2014.977992	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	25356603
10.1185/03007995.2014.977992	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	25356603
10.1185/03007995.2014.977992	results	1	NA	Number of covariates adjusted for/matched on	NA	25356603
10.1185/03007995.2014.977992	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	25356603
10.1185/03007995.2014.977992	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	25356603
10.1185/03007995.2014.977992	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	25356603
10.1185/03007995.2014.977992	results	1	NA	Primary outcome: adjusted treatment effect	NA	25356603
10.1185/03007995.2014.977992	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.045	25356603
10.1185/03007995.2014.977992	study_information	NA	1	Patient-level data used	Yes	NA
10.1185/03007995.2014.977992	study_information	NA	1	Clinical Trial	Yes	NA
10.1185/03007995.2014.977992	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497	NA
10.1185/03007995.2014.977992	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2014.977992	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2014.977992	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2014.977992	study_information	NA	2	Patient-level data used	No	NA
10.1185/03007995.2014.977992	study_information	NA	2	Clinical Trial	Yes	NA
10.1185/03007995.2014.977992	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247	NA
10.1185/03007995.2014.977992	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2014.977992	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2014.977992	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Medical Condition of Interest Name	genotype 4 hepatitis c virus (hcv) infection	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of first author affiliations	belgium	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1185/03007995.2015.1106934	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 1	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 1	1	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 2	2	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Anchored comparison?	No	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26455472
10.1185/03007995.2015.1106934	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 1	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 1	1	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Anchored comparison?	No	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26455472
10.1185/03007995.2015.1106934	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 1	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 1	1	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 2	4	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Anchored comparison?	No	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26455472
10.1185/03007995.2015.1106934	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 1	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 1	1	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 2	5	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Anchored comparison?	No	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26455472
10.1185/03007995.2015.1106934	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 1	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 1	1	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 2	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 2	6	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Anchored comparison?	No	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	Yes	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26455472
10.1185/03007995.2015.1106934	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26455472
10.1185/03007995.2015.1106934	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	30	26455472
10.1185/03007995.2015.1106934	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26455472
10.1185/03007995.2015.1106934	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	29	26455472
10.1185/03007995.2015.1106934	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26455472
10.1185/03007995.2015.1106934	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26455472
10.1185/03007995.2015.1106934	results	1	NA	Number of covariates adjusted for/matched on	5	26455472
10.1185/03007995.2015.1106934	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	26455472
10.1185/03007995.2015.1106934	results	1	NA	Primary outcome: treatment effect contrast	OR	26455472
10.1185/03007995.2015.1106934	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26455472
10.1185/03007995.2015.1106934	results	1	NA	Primary outcome: adjusted treatment effect	3.28	26455472
10.1185/03007995.2015.1106934	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	18	26455472
10.1185/03007995.2015.1106934	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26455472
10.1185/03007995.2015.1106934	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	15	26455472
10.1185/03007995.2015.1106934	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26455472
10.1185/03007995.2015.1106934	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26455472
10.1185/03007995.2015.1106934	results	2	NA	Number of covariates adjusted for/matched on	5	26455472
10.1185/03007995.2015.1106934	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	26455472
10.1185/03007995.2015.1106934	results	2	NA	Primary outcome: treatment effect contrast	OR	26455472
10.1185/03007995.2015.1106934	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26455472
10.1185/03007995.2015.1106934	results	2	NA	Primary outcome: adjusted treatment effect	4.26	26455472
10.1185/03007995.2015.1106934	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	95	26455472
10.1185/03007995.2015.1106934	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26455472
10.1185/03007995.2015.1106934	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	14	26455472
10.1185/03007995.2015.1106934	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26455472
10.1185/03007995.2015.1106934	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26455472
10.1185/03007995.2015.1106934	results	3	NA	Number of covariates adjusted for/matched on	2	26455472
10.1185/03007995.2015.1106934	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	26455472
10.1185/03007995.2015.1106934	results	3	NA	Primary outcome: treatment effect contrast	OR	26455472
10.1185/03007995.2015.1106934	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26455472
10.1185/03007995.2015.1106934	results	3	NA	Primary outcome: adjusted treatment effect	10.02	26455472
10.1185/03007995.2015.1106934	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	40	26455472
10.1185/03007995.2015.1106934	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26455472
10.1185/03007995.2015.1106934	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	26	26455472
10.1185/03007995.2015.1106934	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26455472
10.1185/03007995.2015.1106934	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26455472
10.1185/03007995.2015.1106934	results	4	NA	Number of covariates adjusted for/matched on	2	26455472
10.1185/03007995.2015.1106934	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	26455472
10.1185/03007995.2015.1106934	results	4	NA	Primary outcome: treatment effect contrast	OR	26455472
10.1185/03007995.2015.1106934	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26455472
10.1185/03007995.2015.1106934	results	4	NA	Primary outcome: adjusted treatment effect	6.69	26455472
10.1185/03007995.2015.1106934	results	4	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	26455472
10.1185/03007995.2015.1106934	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	109	26455472
10.1185/03007995.2015.1106934	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26455472
10.1185/03007995.2015.1106934	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	17	26455472
10.1185/03007995.2015.1106934	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26455472
10.1185/03007995.2015.1106934	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26455472
10.1185/03007995.2015.1106934	results	5	NA	Number of covariates adjusted for/matched on	2	26455472
10.1185/03007995.2015.1106934	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	26455472
10.1185/03007995.2015.1106934	results	5	NA	Primary outcome: treatment effect contrast	OR	26455472
10.1185/03007995.2015.1106934	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26455472
10.1185/03007995.2015.1106934	results	5	NA	Primary outcome: adjusted treatment effect	5.43	26455472
10.1185/03007995.2015.1106934	study_information	NA	1	Patient-level data used	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	1	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01567735	NA
10.1185/03007995.2015.1106934	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1185/03007995.2015.1106934	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1185/03007995.2015.1106934	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1185/03007995.2015.1106934	study_information	NA	2	Patient-level data used	No	NA
10.1185/03007995.2015.1106934	study_information	NA	2	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	varghese et al. (2009)	NA
10.1185/03007995.2015.1106934	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	kuwait	NA
10.1185/03007995.2015.1106934	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1185/03007995.2015.1106934	study_information	NA	3	Patient-level data used	No	NA
10.1185/03007995.2015.1106934	study_information	NA	3	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	rumi et al. (2010)	NA
10.1185/03007995.2015.1106934	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.1185/03007995.2015.1106934	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2015.1106934	study_information	NA	4	Patient-level data used	No	NA
10.1185/03007995.2015.1106934	study_information	NA	4	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	el makhzangy et al. (2009)	NA
10.1185/03007995.2015.1106934	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	egypt	NA
10.1185/03007995.2015.1106934	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1185/03007995.2015.1106934	study_information	NA	5	Patient-level data used	No	NA
10.1185/03007995.2015.1106934	study_information	NA	5	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00421434	NA
10.1185/03007995.2015.1106934	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	egypt	NA
10.1185/03007995.2015.1106934	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.1185/03007995.2015.1106934	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.1185/03007995.2015.1106934	study_information	NA	6	Patient-level data used	No	NA
10.1185/03007995.2015.1106934	study_information	NA	6	Clinical Trial	Yes	NA
10.1185/03007995.2015.1106934	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00502099	NA
10.1185/03007995.2015.1106934	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	egypt	NA
10.1185/03007995.2015.1106934	study_information	NA	6	Phase of the clinical trial (clinical trial only)	4	NA
10.1185/03007995.2015.1106934	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumor	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1186/2162-3619-2-32	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/2162-3619-2-32	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 1	everolimus	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 1	1	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 2	NA	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 2	2	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Anchored comparison?	No	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Primary outcome: variable type	Time-to-event	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	24314093
10.1186/2162-3619-2-32	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 1	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 1	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 2	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 2	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Type of population-adjusted indirect comparisons performed	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Anchored comparison?	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Form of the indirect comparison	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Primary outcome: variable type	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	24314093
10.1186/2162-3619-2-32	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 1	everolimus	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 1	1	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 2	sunitinib	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 2	2	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Anchored comparison?	Yes	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Primary outcome: variable type	Time-to-event	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	24314093
10.1186/2162-3619-2-32	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	24314093
10.1186/2162-3619-2-32	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	86	24314093
10.1186/2162-3619-2-32	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	24314093
10.1186/2162-3619-2-32	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	24314093
10.1186/2162-3619-2-32	results	1	NA	Number of covariates adjusted for/matched on	8	24314093
10.1186/2162-3619-2-32	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	24314093
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: treatment effect contrast	HR	24314093
10.1186/2162-3619-2-32	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	24314093
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: unadjusted treatment effect	0.69	24314093
10.1186/2162-3619-2-32	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.087	24314093
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: adjusted treatment effect	0.81	24314093
10.1186/2162-3619-2-32	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.383	24314093
10.1186/2162-3619-2-32	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Number of covariates adjusted for/matched on	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: treatment effect contrast	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: unadjusted treatment effect	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: adjusted treatment effect	NA	24314093
10.1186/2162-3619-2-32	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	24314093
10.1186/2162-3619-2-32	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	86	24314093
10.1186/2162-3619-2-32	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	85	24314093
10.1186/2162-3619-2-32	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	24314093
10.1186/2162-3619-2-32	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	24314093
10.1186/2162-3619-2-32	results	3	NA	Number of covariates adjusted for/matched on	8	24314093
10.1186/2162-3619-2-32	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	24314093
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: treatment effect contrast	HR	24314093
10.1186/2162-3619-2-32	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	24314093
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: unadjusted treatment effect	0.9	24314093
10.1186/2162-3619-2-32	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.695	24314093
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: adjusted treatment effect	0.84	24314093
10.1186/2162-3619-2-32	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.578	24314093
10.1186/2162-3619-2-32	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	24314093
10.1186/2162-3619-2-32	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	24314093
10.1186/2162-3619-2-32	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/2162-3619-2-32	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/2162-3619-2-32	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068	NA
10.1186/2162-3619-2-32	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/2162-3619-2-32	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/2162-3619-2-32	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/2162-3619-2-32	study_information	NA	2	Patient-level data used	No	NA
10.1186/2162-3619-2-32	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/2162-3619-2-32	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597	NA
10.1186/2162-3619-2-32	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/2162-3619-2-32	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/2162-3619-2-32	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Medical Condition of Interest Name	metastatic renal cell carcinoma	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Medical Condition of Interest Name	metastatic renal cell carcinoma	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s12885-018-5157-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 1	axitinib	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 2	cabozantinib	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Anchored comparison?	No	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1186/s12885-018-5157-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 1	axitinib	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 2	everolimus	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Anchored comparison?	No	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1186/s12885-018-5157-0	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1186/s12885-018-5157-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	135	NA
10.1186/s12885-018-5157-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104	NA
10.1186/s12885-018-5157-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1186/s12885-018-5157-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1186/s12885-018-5157-0	results	1	NA	Number of covariates adjusted for/matched on	9	NA
10.1186/s12885-018-5157-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1186/s12885-018-5157-0	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1186/s12885-018-5157-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1186/s12885-018-5157-0	results	1	NA	Primary outcome: adjusted treatment effect	1.15	NA
10.1186/s12885-018-5157-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.423	NA
10.1186/s12885-018-5157-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	194	NA
10.1186/s12885-018-5157-0	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	132	NA
10.1186/s12885-018-5157-0	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61	NA
10.1186/s12885-018-5157-0	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1186/s12885-018-5157-0	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1186/s12885-018-5157-0	results	2	NA	Number of covariates adjusted for/matched on	9	NA
10.1186/s12885-018-5157-0	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	NA
10.1186/s12885-018-5157-0	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1186/s12885-018-5157-0	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1186/s12885-018-5157-0	results	2	NA	Primary outcome: adjusted treatment effect	0.53	NA
10.1186/s12885-018-5157-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.002	NA
10.1186/s12885-018-5157-0	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	194	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s12885-018-5157-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Patient-level data used	No	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01865747	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Patient-level data used	No	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s12885-018-5157-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01865747	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s12885-018-5157-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b cell lymphoma	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of last author affiliations	france	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s13045-021-01144-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 1	1	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 2	axicabtagene ciloleucel	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 2	2	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Anchored comparison?	No	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34493319
10.1186/s13045-021-01144-9	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34493319
10.1186/s13045-021-01144-9	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	101	34493319
10.1186/s13045-021-01144-9	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34493319
10.1186/s13045-021-01144-9	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	42.1	34493319
10.1186/s13045-021-01144-9	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	34493319
10.1186/s13045-021-01144-9	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34493319
10.1186/s13045-021-01144-9	results	1	NA	Number of covariates adjusted for/matched on	10	34493319
10.1186/s13045-021-01144-9	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34493319
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: treatment effect contrast	OR	34493319
10.1186/s13045-021-01144-9	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34493319
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: unadjusted treatment effect	0.92	34493319
10.1186/s13045-021-01144-9	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.753	34493319
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: adjusted treatment effect	1.4	34493319
10.1186/s13045-021-01144-9	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.476	34493319
10.1186/s13045-021-01144-9	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s13045-021-01144-9	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s13045-021-01144-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044	NA
10.1186/s13045-021-01144-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1186/s13045-021-01144-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1186/s13045-021-01144-9	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1186/s13045-021-01144-9	study_information	NA	2	Patient-level data used	No	NA
10.1186/s13045-021-01144-9	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s13045-021-01144-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216	NA
10.1186/s13045-021-01144-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s13045-021-01144-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.1186/s13045-021-01144-9	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory aggressive large b-cell lymphomas	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company, Pharmaceutical Industry	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of first author affiliations	france	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	XXXX	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s40164-022-00268-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 2	tisagenlecleucel	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Anchored comparison?	No	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1186/s40164-022-00268-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1186/s40164-022-00268-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	111	NA
10.1186/s40164-022-00268-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	256	NA
10.1186/s40164-022-00268-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	164	NA
10.1186/s40164-022-00268-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.1186/s40164-022-00268-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1186/s40164-022-00268-z	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.1186/s40164-022-00268-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: treatment effect contrast	OR	NA
10.1186/s40164-022-00268-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: unadjusted treatment effect	2.49	NA
10.1186/s40164-022-00268-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.52;4.07]	NA
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: adjusted treatment effect	2.78	NA
10.1186/s40164-022-00268-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.63;4.74]	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Patient-level data used	No	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Patient-level data used	No	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s40164-022-00268-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.1186/s40164-022-00268-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Medical Condition of Interest Name	huntington disease	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1186/s40734-017-0051-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 1	deutetrabenazine	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 1	1	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 2	tetrabenazine	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 2	2	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Anchored comparison?	Yes	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	28265459
10.1186/s40734-017-0051-5	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	28265459
10.1186/s40734-017-0051-5	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	54	28265459
10.1186/s40734-017-0051-5	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	30	28265459
10.1186/s40734-017-0051-5	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	45	28265459
10.1186/s40734-017-0051-5	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	28265459
10.1186/s40734-017-0051-5	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	28265459
10.1186/s40734-017-0051-5	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	28265459
10.1186/s40734-017-0051-5	results	1	NA	Number of covariates adjusted for/matched on	3	28265459
10.1186/s40734-017-0051-5	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	28265459
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: treatment effect contrast	Risk difference	28265459
10.1186/s40734-017-0051-5	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	28265459
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: unadjusted treatment effect	NA	28265459
10.1186/s40734-017-0051-5	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	28265459
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: adjusted treatment effect	NA	28265459
10.1186/s40734-017-0051-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	28265459
10.1186/s40734-017-0051-5	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	28265459
10.1186/s40734-017-0051-5	study_information	NA	1	Patient-level data used	Yes	NA
10.1186/s40734-017-0051-5	study_information	NA	1	Clinical Trial	Yes	NA
10.1186/s40734-017-0051-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01795859	NA
10.1186/s40734-017-0051-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1186/s40734-017-0051-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s40734-017-0051-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s40734-017-0051-5	study_information	NA	2	Patient-level data used	No	NA
10.1186/s40734-017-0051-5	study_information	NA	2	Clinical Trial	Yes	NA
10.1186/s40734-017-0051-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00219804	NA
10.1186/s40734-017-0051-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.1186/s40734-017-0051-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1186/s40734-017-0051-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.1210/clinem/dgab905	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes	NA
10.1210/clinem/dgab905	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1210/clinem/dgab905	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1210/clinem/dgab905	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.1210/clinem/dgab905	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1210/clinem/dgab905	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1210/clinem/dgab905	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1210/clinem/dgab905	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1210/clinem/dgab905	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes	NA
10.1210/clinem/dgab905	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.1210/clinem/dgab905	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.1210/clinem/dgab905	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	XXXX	NA
10.1210/clinem/dgab905	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	XXXX	NA
10.1210/clinem/dgab905	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1210/clinem/dgab905	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1210/clinem/dgab905	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 1	semaglutide 2.0 mg	NA
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 2	dulaglutide 3.0 mg	NA
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.1210/clinem/dgab905	methodology	1	NA	Type of population-adjusted indirect comparisons performed	Multilevel network meta-regression	NA
10.1210/clinem/dgab905	methodology	1	NA	Anchored comparison?	Yes	NA
10.1210/clinem/dgab905	methodology	1	NA	Form of the indirect comparison	Larger network (ie involving more than 2 studies)	NA
10.1210/clinem/dgab905	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1210/clinem/dgab905	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c	NA
10.1210/clinem/dgab905	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1210/clinem/dgab905	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1210/clinem/dgab905	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1210/clinem/dgab905	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1210/clinem/dgab905	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1210/clinem/dgab905	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 1	semaglutide 2.0 mg	NA
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 2	dulaglutide 4.5 mg	NA
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.1210/clinem/dgab905	methodology	2	NA	Type of population-adjusted indirect comparisons performed	Multilevel network meta-regression	NA
10.1210/clinem/dgab905	methodology	2	NA	Anchored comparison?	Yes	NA
10.1210/clinem/dgab905	methodology	2	NA	Form of the indirect comparison	Larger network (ie involving more than 2 studies)	NA
10.1210/clinem/dgab905	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.1210/clinem/dgab905	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c	NA
10.1210/clinem/dgab905	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.1210/clinem/dgab905	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1210/clinem/dgab905	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	NA
10.1210/clinem/dgab905	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.1210/clinem/dgab905	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1210/clinem/dgab905	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.1210/clinem/dgab905	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	616	NA
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612	NA
10.1210/clinem/dgab905	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	480	NA
10.1210/clinem/dgab905	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480	NA
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	481	NA
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	481	NA
10.1210/clinem/dgab905	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1210/clinem/dgab905	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.1210/clinem/dgab905	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1210/clinem/dgab905	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1210/clinem/dgab905	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1210/clinem/dgab905	results	1	NA	Primary outcome: unadjusted treatment effect	-0.47	NA
10.1210/clinem/dgab905	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.69;-0.23]	NA
10.1210/clinem/dgab905	results	1	NA	Primary outcome: adjusted treatment effect	-0.44	NA
10.1210/clinem/dgab905	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.68;-0.19]	NA
10.1210/clinem/dgab905	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	614	NA
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612	NA
10.1210/clinem/dgab905	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	480	NA
10.1210/clinem/dgab905	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480	NA
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	481	NA
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	481	NA
10.1210/clinem/dgab905	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1210/clinem/dgab905	results	2	NA	Number of covariates adjusted for/matched on	3	NA
10.1210/clinem/dgab905	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1210/clinem/dgab905	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.1210/clinem/dgab905	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1210/clinem/dgab905	results	2	NA	Primary outcome: unadjusted treatment effect	-0.31	NA
10.1210/clinem/dgab905	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.53;-0.08]	NA
10.1210/clinem/dgab905	results	2	NA	Primary outcome: adjusted treatment effect	-0.28	NA
10.1210/clinem/dgab905	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.52;-0.03]	NA
10.1210/clinem/dgab905	study_information	NA	1	Patient-level data used	Yes	NA
10.1210/clinem/dgab905	study_information	NA	1	Clinical Trial	Yes	NA
10.1210/clinem/dgab905	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03989232	NA
10.1210/clinem/dgab905	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1210/clinem/dgab905	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1210/clinem/dgab905	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1210/clinem/dgab905	study_information	NA	1	Patient-level data used	Yes	NA
10.1210/clinem/dgab905	study_information	NA	1	Clinical Trial	XXXX	NA
10.1210/clinem/dgab905	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03989232	NA
10.1210/clinem/dgab905	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1210/clinem/dgab905	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.1210/clinem/dgab905	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.1210/clinem/dgab905	study_information	NA	3	Patient-level data used	No	NA
10.1210/clinem/dgab905	study_information	NA	3	Clinical Trial	Yes	NA
10.1210/clinem/dgab905	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102	NA
10.1210/clinem/dgab905	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1210/clinem/dgab905	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1210/clinem/dgab905	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1210/clinem/dgab905	study_information	NA	3	Patient-level data used	XXXX	NA
10.1210/clinem/dgab905	study_information	NA	3	Clinical Trial	Yes	NA
10.1210/clinem/dgab905	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102	NA
10.1210/clinem/dgab905	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1210/clinem/dgab905	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1210/clinem/dgab905	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of first author affiliations	belgium	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of last author affiliations	spain	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of first author affiliations	belgium	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of last author affiliations	spain	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 1	daratumumab	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 2	pomalidomide + low-dose dexamethasone	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Anchored comparison?	No	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1634/theoncologist.2017-0103	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 1	daratumumab	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 2	pomalidomide + low-dose dexamethasone	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 2	4	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Anchored comparison?	No	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.1634/theoncologist.2017-0103	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.1634/theoncologist.2017-0103	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	302	NA
10.1634/theoncologist.2017-0103	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	136	NA
10.1634/theoncologist.2017-0103	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55	NA
10.1634/theoncologist.2017-0103	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1634/theoncologist.2017-0103	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1634/theoncologist.2017-0103	results	1	NA	Number of covariates adjusted for/matched on	10	NA
10.1634/theoncologist.2017-0103	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.1634/theoncologist.2017-0103	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: unadjusted treatment effect	0.61	NA
10.1634/theoncologist.2017-0103	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0005	NA
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: adjusted treatment effect	0.56	NA
10.1634/theoncologist.2017-0103	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0041	NA
10.1634/theoncologist.2017-0103	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	682	NA
10.1634/theoncologist.2017-0103	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	148	NA
10.1634/theoncologist.2017-0103	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	95	NA
10.1634/theoncologist.2017-0103	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.1634/theoncologist.2017-0103	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.1634/theoncologist.2017-0103	results	2	NA	Number of covariates adjusted for/matched on	7	NA
10.1634/theoncologist.2017-0103	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.1634/theoncologist.2017-0103	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: unadjusted treatment effect	0.55	NA
10.1634/theoncologist.2017-0103	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001	NA
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: adjusted treatment effect	0.51	NA
10.1634/theoncologist.2017-0103	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Patient-level data used	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00574288	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Patient-level data used	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00574288	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.1634/theoncologist.2017-0103	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Patient-level data used	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Patient-level data used	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.1634/theoncologist.2017-0103	study_information	NA	2	Number of treatment arms (clinical trial only)	XXXX	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Patient-level data used	No	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01311687	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Patient-level data used	No	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01311687	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.1634/theoncologist.2017-0103	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Patient-level data used	No	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01712789	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Patient-level data used	No	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Clinical Trial	Yes	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01712789	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.1634/theoncologist.2017-0103	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2147/ceor.s203482	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia	NA
10.2147/ceor.s203482	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/ceor.s203482	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.2147/ceor.s203482	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/ceor.s203482	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/ceor.s203482	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/ceor.s203482	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/ceor.s203482	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/ceor.s203482	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia	NA
10.2147/ceor.s203482	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/ceor.s203482	general_information	NA	NA	Countries of last author affiliations	XXXX	NA
10.2147/ceor.s203482	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/ceor.s203482	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/ceor.s203482	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/ceor.s203482	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/ceor.s203482	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/ceor.s203482	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine	NA
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.2147/ceor.s203482	methodology	1	NA	Treatment name 2	azacitidine	NA
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.2147/ceor.s203482	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.2147/ceor.s203482	methodology	1	NA	Anchored comparison?	Yes	NA
10.2147/ceor.s203482	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2147/ceor.s203482	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2147/ceor.s203482	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2147/ceor.s203482	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.2147/ceor.s203482	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.2147/ceor.s203482	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2147/ceor.s203482	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.2147/ceor.s203482	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/ceor.s203482	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/ceor.s203482	methodology	2	NA	Treatment name 1	glasdegib + low-dose cytarabine	NA
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.2147/ceor.s203482	methodology	2	NA	Treatment name 2	decitabine	NA
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.2147/ceor.s203482	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	NA
10.2147/ceor.s203482	methodology	2	NA	Anchored comparison?	Yes	NA
10.2147/ceor.s203482	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2147/ceor.s203482	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2147/ceor.s203482	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2147/ceor.s203482	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.2147/ceor.s203482	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	NA
10.2147/ceor.s203482	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2147/ceor.s203482	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.2147/ceor.s203482	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/ceor.s203482	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/ceor.s203482	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	241	NA
10.2147/ceor.s203482	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	158	NA
10.2147/ceor.s203482	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	78	NA
10.2147/ceor.s203482	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78	NA
10.2147/ceor.s203482	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38	NA
10.2147/ceor.s203482	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38	NA
10.2147/ceor.s203482	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/ceor.s203482	results	1	NA	Number of covariates adjusted for/matched on	3	NA
10.2147/ceor.s203482	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	NA
10.2147/ceor.s203482	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.2147/ceor.s203482	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/ceor.s203482	results	1	NA	Primary outcome: unadjusted treatment effect	0.514	NA
10.2147/ceor.s203482	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.310;0.852]	NA
10.2147/ceor.s203482	results	1	NA	Primary outcome: adjusted treatment effect	0.424	NA
10.2147/ceor.s203482	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.228;0.789]	NA
10.2147/ceor.s203482	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	242	NA
10.2147/ceor.s203482	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	215	NA
10.2147/ceor.s203482	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	78	NA
10.2147/ceor.s203482	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78	NA
10.2147/ceor.s203482	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38	NA
10.2147/ceor.s203482	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38	NA
10.2147/ceor.s203482	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/ceor.s203482	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.2147/ceor.s203482	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	NA
10.2147/ceor.s203482	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.2147/ceor.s203482	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/ceor.s203482	results	2	NA	Primary outcome: unadjusted treatment effect	0.565	NA
10.2147/ceor.s203482	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.351;0.909]	NA
10.2147/ceor.s203482	results	2	NA	Primary outcome: adjusted treatment effect	0.505	NA
10.2147/ceor.s203482	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.269;0.949]	NA
10.2147/ceor.s203482	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	NA
10.2147/ceor.s203482	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/ceor.s203482	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038	NA
10.2147/ceor.s203482	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.2147/ceor.s203482	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ceor.s203482	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/ceor.s203482	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038	NA
10.2147/ceor.s203482	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.2147/ceor.s203482	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ceor.s203482	study_information	NA	2	Patient-level data used	No	NA
10.2147/ceor.s203482	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01074047	NA
10.2147/ceor.s203482	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ceor.s203482	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ceor.s203482	study_information	NA	2	Patient-level data used	No	NA
10.2147/ceor.s203482	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01074047	NA
10.2147/ceor.s203482	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ceor.s203482	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ceor.s203482	study_information	NA	3	Patient-level data used	No	NA
10.2147/ceor.s203482	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00260832	NA
10.2147/ceor.s203482	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ceor.s203482	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ceor.s203482	study_information	NA	3	Patient-level data used	No	NA
10.2147/ceor.s203482	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/ceor.s203482	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00260832	NA
10.2147/ceor.s203482	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ceor.s203482	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ceor.s203482	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/cmar.s163478	general_information	NA	NA	Medical Condition of Interest Name	hr+, her2? advanced breast cancer	NA
10.2147/cmar.s163478	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/cmar.s163478	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2147/cmar.s163478	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/cmar.s163478	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/cmar.s163478	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/cmar.s163478	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/cmar.s163478	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/cmar.s163478	methodology	1	NA	Treatment name 1	NA	29861642
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 1	NA	29861642
10.2147/cmar.s163478	methodology	1	NA	Treatment name 2	NA	29861642
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 2	2	29861642
10.2147/cmar.s163478	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	29861642
10.2147/cmar.s163478	methodology	1	NA	Anchored comparison?	Yes	29861642
10.2147/cmar.s163478	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	29861642
10.2147/cmar.s163478	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	29861642
10.2147/cmar.s163478	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	29861642
10.2147/cmar.s163478	methodology	1	NA	Primary outcome: variable type	Time-to-event	29861642
10.2147/cmar.s163478	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	29861642
10.2147/cmar.s163478	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	29861642
10.2147/cmar.s163478	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	29861642
10.2147/cmar.s163478	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	29861642
10.2147/cmar.s163478	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	29861642
10.2147/cmar.s163478	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	444	29861642
10.2147/cmar.s163478	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	222	29861642
10.2147/cmar.s163478	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	29861642
10.2147/cmar.s163478	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	29861642
10.2147/cmar.s163478	results	1	NA	Number of covariates adjusted for/matched on	9	29861642
10.2147/cmar.s163478	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	29861642
10.2147/cmar.s163478	results	1	NA	Primary outcome: treatment effect contrast	HR	29861642
10.2147/cmar.s163478	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	29861642
10.2147/cmar.s163478	results	1	NA	Primary outcome: unadjusted treatment effect	0.959	29861642
10.2147/cmar.s163478	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.681;1.350]	29861642
10.2147/cmar.s163478	results	1	NA	Primary outcome: adjusted treatment effect	0.904	29861642
10.2147/cmar.s163478	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.644;1.268]	29861642
10.2147/cmar.s163478	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	29861642
10.2147/cmar.s163478	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	29861642
10.2147/cmar.s163478	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	29861642
10.2147/cmar.s163478	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	29861642
10.2147/cmar.s163478	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/cmar.s163478	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/cmar.s163478	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01958021	NA
10.2147/cmar.s163478	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/cmar.s163478	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/cmar.s163478	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/cmar.s163478	study_information	NA	2	Patient-level data used	No	NA
10.2147/cmar.s163478	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/cmar.s163478	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01740427	NA
10.2147/cmar.s163478	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/cmar.s163478	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/cmar.s163478	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/cmar.s325043	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2? advanced breast cancer	NA
10.2147/cmar.s325043	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.2147/cmar.s325043	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2147/cmar.s325043	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/cmar.s325043	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/cmar.s325043	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/cmar.s325043	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/cmar.s325043	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/cmar.s325043	methodology	1	NA	Treatment name 1	ribociclib + fulvestrant	34754238
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 1	1	34754238
10.2147/cmar.s325043	methodology	1	NA	Treatment name 2	palbociclib + letrozole	34754238
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 2	2	34754238
10.2147/cmar.s325043	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34754238
10.2147/cmar.s325043	methodology	1	NA	Anchored comparison?	No	34754238
10.2147/cmar.s325043	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34754238
10.2147/cmar.s325043	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34754238
10.2147/cmar.s325043	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34754238
10.2147/cmar.s325043	methodology	1	NA	Primary outcome: variable type	Time-to-event	34754238
10.2147/cmar.s325043	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34754238
10.2147/cmar.s325043	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34754238
10.2147/cmar.s325043	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34754238
10.2147/cmar.s325043	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34754238
10.2147/cmar.s325043	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34754238
10.2147/cmar.s325043	methodology	2	NA	Treatment name 1	placebo + fulvestrant	34754238
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 1	1	34754238
10.2147/cmar.s325043	methodology	2	NA	Treatment name 2	letrozole	34754238
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 2	2	34754238
10.2147/cmar.s325043	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	34754238
10.2147/cmar.s325043	methodology	2	NA	Anchored comparison?	No	34754238
10.2147/cmar.s325043	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34754238
10.2147/cmar.s325043	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34754238
10.2147/cmar.s325043	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	34754238
10.2147/cmar.s325043	methodology	2	NA	Primary outcome: variable type	Time-to-event	34754238
10.2147/cmar.s325043	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	34754238
10.2147/cmar.s325043	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34754238
10.2147/cmar.s325043	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34754238
10.2147/cmar.s325043	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34754238
10.2147/cmar.s325043	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34754238
10.2147/cmar.s325043	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84	34754238
10.2147/cmar.s325043	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	329	34754238
10.2147/cmar.s325043	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	221	34754238
10.2147/cmar.s325043	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34754238
10.2147/cmar.s325043	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34754238
10.2147/cmar.s325043	results	1	NA	Number of covariates adjusted for/matched on	7	34754238
10.2147/cmar.s325043	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34754238
10.2147/cmar.s325043	results	1	NA	Primary outcome: treatment effect contrast	HR	34754238
10.2147/cmar.s325043	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34754238
10.2147/cmar.s325043	results	1	NA	Primary outcome: unadjusted treatment effect	0.83	34754238
10.2147/cmar.s325043	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.2838	34754238
10.2147/cmar.s325043	results	1	NA	Primary outcome: adjusted treatment effect	0.77	34754238
10.2147/cmar.s325043	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.1553	34754238
10.2147/cmar.s325043	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	81	34754238
10.2147/cmar.s325043	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	178	34754238
10.2147/cmar.s325043	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	117	34754238
10.2147/cmar.s325043	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34754238
10.2147/cmar.s325043	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34754238
10.2147/cmar.s325043	results	2	NA	Number of covariates adjusted for/matched on	7	34754238
10.2147/cmar.s325043	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	34754238
10.2147/cmar.s325043	results	2	NA	Primary outcome: treatment effect contrast	HR	34754238
10.2147/cmar.s325043	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34754238
10.2147/cmar.s325043	results	2	NA	Primary outcome: unadjusted treatment effect	0.66	34754238
10.2147/cmar.s325043	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0094	34754238
10.2147/cmar.s325043	results	2	NA	Primary outcome: adjusted treatment effect	0.58	34754238
10.2147/cmar.s325043	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0019	34754238
10.2147/cmar.s325043	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/cmar.s325043	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/cmar.s325043	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615	NA
10.2147/cmar.s325043	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/cmar.s325043	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/cmar.s325043	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/cmar.s325043	study_information	NA	2	Patient-level data used	No	NA
10.2147/cmar.s325043	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/cmar.s325043	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00721409	NA
10.2147/cmar.s325043	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/cmar.s325043	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.2147/cmar.s325043	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s104074	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a	NA
10.2147/jbm.s104074	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/jbm.s104074	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2147/jbm.s104074	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s104074	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s104074	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s104074	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s104074	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/jbm.s104074	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a	NA
10.2147/jbm.s104074	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/jbm.s104074	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2147/jbm.s104074	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s104074	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s104074	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s104074	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s104074	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/jbm.s104074	methodology	1	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	NA
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2147/jbm.s104074	methodology	1	NA	Treatment name 2	rahf-pfm	NA
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 2	4	NA
10.2147/jbm.s104074	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s104074	methodology	1	NA	Anchored comparison?	No	NA
10.2147/jbm.s104074	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2147/jbm.s104074	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2147/jbm.s104074	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	square root transformed abr : annualized bleed rates at 1 year (all bleed)	NA
10.2147/jbm.s104074	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s104074	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s104074	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s104074	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s104074	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/jbm.s104074	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s104074	methodology	2	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	NA
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2147/jbm.s104074	methodology	2	NA	Treatment name 2	rahf-pfm	NA
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 2	3	NA
10.2147/jbm.s104074	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s104074	methodology	2	NA	Anchored comparison?	No	NA
10.2147/jbm.s104074	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2147/jbm.s104074	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2147/jbm.s104074	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleed rates for all bleeds (1-year)	NA
10.2147/jbm.s104074	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s104074	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s104074	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s104074	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s104074	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/jbm.s104074	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s104074	methodology	3	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	NA
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2147/jbm.s104074	methodology	3	NA	Treatment name 2	turoctocog alfa	NA
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 2	5	NA
10.2147/jbm.s104074	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s104074	methodology	3	NA	Anchored comparison?	No	NA
10.2147/jbm.s104074	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2147/jbm.s104074	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2147/jbm.s104074	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleed rates for all bleeds (1-year)	NA
10.2147/jbm.s104074	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s104074	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s104074	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s104074	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s104074	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/jbm.s104074	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s104074	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	66	NA
10.2147/jbm.s104074	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	121	NA
10.2147/jbm.s104074	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s104074	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s104074	results	1	NA	Number of covariates adjusted for/matched on	2	NA
10.2147/jbm.s104074	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity	NA
10.2147/jbm.s104074	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2147/jbm.s104074	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s104074	results	1	NA	Primary outcome: unadjusted treatment effect	0.1	NA
10.2147/jbm.s104074	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.3;0.4]	NA
10.2147/jbm.s104074	results	1	NA	Primary outcome: adjusted treatment effect	0.1	NA
10.2147/jbm.s104074	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.3;0.4]	NA
10.2147/jbm.s104074	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	107	NA
10.2147/jbm.s104074	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	121	NA
10.2147/jbm.s104074	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s104074	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s104074	results	2	NA	Number of covariates adjusted for/matched on	2	NA
10.2147/jbm.s104074	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity	NA
10.2147/jbm.s104074	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2147/jbm.s104074	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s104074	results	2	NA	Primary outcome: unadjusted treatment effect	-1.9	NA
10.2147/jbm.s104074	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.5;-0.4] p<0.05	NA
10.2147/jbm.s104074	results	2	NA	Primary outcome: adjusted treatment effect	-1.5	NA
10.2147/jbm.s104074	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.7;-0.7] p=0.18	NA
10.2147/jbm.s104074	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	150	NA
10.2147/jbm.s104074	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	121	NA
10.2147/jbm.s104074	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s104074	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s104074	results	3	NA	Number of covariates adjusted for/matched on	3	NA
10.2147/jbm.s104074	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)	NA
10.2147/jbm.s104074	results	3	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2147/jbm.s104074	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s104074	results	3	NA	Primary outcome: unadjusted treatment effect	-2.1	NA
10.2147/jbm.s104074	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.3;-1.0] p<0.01	NA
10.2147/jbm.s104074	results	3	NA	Primary outcome: adjusted treatment effect	-2.2	NA
10.2147/jbm.s104074	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.4;-1.0] p<0.05	NA
10.2147/jbm.s104074	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s104074	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01029340	NA
10.2147/jbm.s104074	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s104074	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s104074	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01029340	NA
10.2147/jbm.s104074	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s104074	study_information	NA	2	Patient-level data used	Yes	NA
10.2147/jbm.s104074	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01233258	NA
10.2147/jbm.s104074	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s104074	study_information	NA	2	Patient-level data used	Yes	NA
10.2147/jbm.s104074	study_information	NA	2	Clinical Trial	XXXX	NA
10.2147/jbm.s104074	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01233258	NA
10.2147/jbm.s104074	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	2	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/jbm.s104074	study_information	NA	3	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)	NA
10.2147/jbm.s104074	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	3	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)	NA
10.2147/jbm.s104074	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.2147/jbm.s104074	study_information	NA	4	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	4	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386	NA
10.2147/jbm.s104074	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4	NA
10.2147/jbm.s104074	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s104074	study_information	NA	4	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	4	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386	NA
10.2147/jbm.s104074	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4	NA
10.2147/jbm.s104074	study_information	NA	4	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/jbm.s104074	study_information	NA	5	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	5	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00840086	NA
10.2147/jbm.s104074	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s104074	study_information	NA	5	Patient-level data used	No	NA
10.2147/jbm.s104074	study_information	NA	5	Clinical Trial	Yes	NA
10.2147/jbm.s104074	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00840086	NA
10.2147/jbm.s104074	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s104074	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s104074	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s206806	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a	NA
10.2147/jbm.s206806	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/jbm.s206806	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.2147/jbm.s206806	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s206806	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s206806	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s206806	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s206806	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/jbm.s206806	methodology	1	NA	Treatment name 1	bay 94-9027	31417326
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 1	1	31417326
10.2147/jbm.s206806	methodology	1	NA	Treatment name 2	rfviiifc	31417326
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 2	2	31417326
10.2147/jbm.s206806	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31417326
10.2147/jbm.s206806	methodology	1	NA	Anchored comparison?	No	31417326
10.2147/jbm.s206806	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31417326
10.2147/jbm.s206806	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31417326
10.2147/jbm.s206806	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31417326
10.2147/jbm.s206806	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	31417326
10.2147/jbm.s206806	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	31417326
10.2147/jbm.s206806	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31417326
10.2147/jbm.s206806	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31417326
10.2147/jbm.s206806	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31417326
10.2147/jbm.s206806	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31417326
10.2147/jbm.s206806	methodology	2	NA	Treatment name 1	bay 94-9027	31417326
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 1	1	31417326
10.2147/jbm.s206806	methodology	2	NA	Treatment name 2	bax 855	31417326
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 2	NA	31417326
10.2147/jbm.s206806	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	31417326
10.2147/jbm.s206806	methodology	2	NA	Anchored comparison?	No	31417326
10.2147/jbm.s206806	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31417326
10.2147/jbm.s206806	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31417326
10.2147/jbm.s206806	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate	31417326
10.2147/jbm.s206806	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	31417326
10.2147/jbm.s206806	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	31417326
10.2147/jbm.s206806	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31417326
10.2147/jbm.s206806	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31417326
10.2147/jbm.s206806	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31417326
10.2147/jbm.s206806	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31417326
10.2147/jbm.s206806	methodology	3	NA	Treatment name 1	bay 94-9027	31417326
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 1	1	31417326
10.2147/jbm.s206806	methodology	3	NA	Treatment name 2	NA	31417326
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 2	4	31417326
10.2147/jbm.s206806	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	31417326
10.2147/jbm.s206806	methodology	3	NA	Anchored comparison?	No	31417326
10.2147/jbm.s206806	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31417326
10.2147/jbm.s206806	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31417326
10.2147/jbm.s206806	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate	31417326
10.2147/jbm.s206806	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	31417326
10.2147/jbm.s206806	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	31417326
10.2147/jbm.s206806	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31417326
10.2147/jbm.s206806	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31417326
10.2147/jbm.s206806	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31417326
10.2147/jbm.s206806	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31417326
10.2147/jbm.s206806	methodology	4	NA	Treatment name 1	bay 94-9027	31417326
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 1	1	31417326
10.2147/jbm.s206806	methodology	4	NA	Treatment name 2	NA	31417326
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 2	5	31417326
10.2147/jbm.s206806	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	31417326
10.2147/jbm.s206806	methodology	4	NA	Anchored comparison?	No	31417326
10.2147/jbm.s206806	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31417326
10.2147/jbm.s206806	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31417326
10.2147/jbm.s206806	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate	31417326
10.2147/jbm.s206806	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)	31417326
10.2147/jbm.s206806	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	31417326
10.2147/jbm.s206806	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31417326
10.2147/jbm.s206806	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31417326
10.2147/jbm.s206806	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31417326
10.2147/jbm.s206806	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31417326
10.2147/jbm.s206806	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	140	31417326
10.2147/jbm.s206806	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	103	31417326
10.2147/jbm.s206806	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	44.6	31417326
10.2147/jbm.s206806	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31417326
10.2147/jbm.s206806	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	1	NA	Primary outcome: treatment effect contrast	Means difference	31417326
10.2147/jbm.s206806	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31417326
10.2147/jbm.s206806	results	1	NA	Primary outcome: unadjusted treatment effect	0.17	31417326
10.2147/jbm.s206806	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.35;1.70]	31417326
10.2147/jbm.s206806	results	1	NA	Primary outcome: adjusted treatment effect	-0.12	31417326
10.2147/jbm.s206806	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-1.62;1.37]	31417326
10.2147/jbm.s206806	results	1	NA	Number of covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31417326
10.2147/jbm.s206806	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	101	31417326
10.2147/jbm.s206806	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	104	31417326
10.2147/jbm.s206806	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78.3	31417326
10.2147/jbm.s206806	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31417326
10.2147/jbm.s206806	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	2	NA	Primary outcome: treatment effect contrast	Means difference	31417326
10.2147/jbm.s206806	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31417326
10.2147/jbm.s206806	results	2	NA	Primary outcome: unadjusted treatment effect	0.35	31417326
10.2147/jbm.s206806	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.00;1.70]	31417326
10.2147/jbm.s206806	results	2	NA	Primary outcome: adjusted treatment effect	0.25	31417326
10.2147/jbm.s206806	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-1.19;1.70]	31417326
10.2147/jbm.s206806	results	2	NA	Number of covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31417326
10.2147/jbm.s206806	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31417326
10.2147/jbm.s206806	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	104	31417326
10.2147/jbm.s206806	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	31417326
10.2147/jbm.s206806	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31417326
10.2147/jbm.s206806	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	3	NA	Primary outcome: treatment effect contrast	Means difference	31417326
10.2147/jbm.s206806	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31417326
10.2147/jbm.s206806	results	3	NA	Primary outcome: unadjusted treatment effect	-2.25	31417326
10.2147/jbm.s206806	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	31417326
10.2147/jbm.s206806	results	3	NA	Primary outcome: adjusted treatment effect	-2.02	31417326
10.2147/jbm.s206806	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-4.35;0.30]	31417326
10.2147/jbm.s206806	results	3	NA	Number of covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31417326
10.2147/jbm.s206806	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31417326
10.2147/jbm.s206806	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	104	31417326
10.2147/jbm.s206806	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55.33	31417326
10.2147/jbm.s206806	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31417326
10.2147/jbm.s206806	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	4	NA	Primary outcome: treatment effect contrast	Means difference	31417326
10.2147/jbm.s206806	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31417326
10.2147/jbm.s206806	results	4	NA	Primary outcome: unadjusted treatment effect	0.03	31417326
10.2147/jbm.s206806	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.32;0.37]	31417326
10.2147/jbm.s206806	results	4	NA	Primary outcome: adjusted treatment effect	0.07	31417326
10.2147/jbm.s206806	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.32;0.46]	31417326
10.2147/jbm.s206806	results	4	NA	Number of covariates adjusted for/matched on	NA	31417326
10.2147/jbm.s206806	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31417326
10.2147/jbm.s206806	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s206806	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s206806	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293	NA
10.2147/jbm.s206806	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s206806	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s206806	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s206806	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s206806	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s206806	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128	NA
10.2147/jbm.s206806	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s206806	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s206806	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s206806	study_information	NA	3	Patient-level data used	No	NA
10.2147/jbm.s206806	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/jbm.s206806	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01736475	NA
10.2147/jbm.s206806	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s206806	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s206806	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s206806	study_information	NA	4	Patient-level data used	No	NA
10.2147/jbm.s206806	study_information	NA	4	Clinical Trial	Yes	NA
10.2147/jbm.s206806	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)	NA
10.2147/jbm.s206806	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s206806	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.2147/jbm.s206806	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s206806	study_information	NA	4	Phase of the clinical trial (clinical trial only)	NA	NA
10.2147/jbm.s206806	study_information	NA	5	Patient-level data used	No	NA
10.2147/jbm.s206806	study_information	NA	5	Clinical Trial	Yes	NA
10.2147/jbm.s206806	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386	NA
10.2147/jbm.s206806	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s206806	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4	NA
10.2147/jbm.s206806	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s288283	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a without inhibitors	NA
10.2147/jbm.s288283	general_information	NA	NA	Countries of first author affiliations	germany	NA
10.2147/jbm.s288283	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2147/jbm.s288283	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s288283	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s288283	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s288283	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s288283	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/jbm.s288283	methodology	1	NA	Treatment name 1	rfviiifc	33664606
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 1	1	33664606
10.2147/jbm.s288283	methodology	1	NA	Treatment name 2	NA	33664606
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 2	2	33664606
10.2147/jbm.s288283	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33664606
10.2147/jbm.s288283	methodology	1	NA	Anchored comparison?	No	33664606
10.2147/jbm.s288283	methodology	1	NA	Form of the indirect comparison	NA	33664606
10.2147/jbm.s288283	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33664606
10.2147/jbm.s288283	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33664606
10.2147/jbm.s288283	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33664606
10.2147/jbm.s288283	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	33664606
10.2147/jbm.s288283	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33664606
10.2147/jbm.s288283	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33664606
10.2147/jbm.s288283	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	33664606
10.2147/jbm.s288283	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33664606
10.2147/jbm.s288283	methodology	2	NA	Treatment name 1	rfviiifc	33664606
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 1	1	33664606
10.2147/jbm.s288283	methodology	2	NA	Treatment name 2	NA	33664606
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 2	2	33664606
10.2147/jbm.s288283	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33664606
10.2147/jbm.s288283	methodology	2	NA	Anchored comparison?	No	33664606
10.2147/jbm.s288283	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33664606
10.2147/jbm.s288283	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33664606
10.2147/jbm.s288283	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33664606
10.2147/jbm.s288283	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33664606
10.2147/jbm.s288283	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	33664606
10.2147/jbm.s288283	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33664606
10.2147/jbm.s288283	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33664606
10.2147/jbm.s288283	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	33664606
10.2147/jbm.s288283	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33664606
10.2147/jbm.s288283	methodology	3	NA	Treatment name 1	rfviiifc	33664606
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 1	1	33664606
10.2147/jbm.s288283	methodology	3	NA	Treatment name 2	NA	33664606
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 2	NA	33664606
10.2147/jbm.s288283	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	33664606
10.2147/jbm.s288283	methodology	3	NA	Anchored comparison?	No	33664606
10.2147/jbm.s288283	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33664606
10.2147/jbm.s288283	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33664606
10.2147/jbm.s288283	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33664606
10.2147/jbm.s288283	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	33664606
10.2147/jbm.s288283	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	33664606
10.2147/jbm.s288283	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	33664606
10.2147/jbm.s288283	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33664606
10.2147/jbm.s288283	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	33664606
10.2147/jbm.s288283	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33664606
10.2147/jbm.s288283	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	99	33664606
10.2147/jbm.s288283	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33664606
10.2147/jbm.s288283	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	94	33664606
10.2147/jbm.s288283	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33664606
10.2147/jbm.s288283	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33664606
10.2147/jbm.s288283	results	1	NA	Number of covariates adjusted for/matched on	5	33664606
10.2147/jbm.s288283	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33664606
10.2147/jbm.s288283	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	33664606
10.2147/jbm.s288283	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33664606
10.2147/jbm.s288283	results	1	NA	Primary outcome: adjusted treatment effect	0.93	33664606
10.2147/jbm.s288283	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.63;1.39]	33664606
10.2147/jbm.s288283	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	35	33664606
10.2147/jbm.s288283	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33664606
10.2147/jbm.s288283	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	19	33664606
10.2147/jbm.s288283	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33664606
10.2147/jbm.s288283	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33664606
10.2147/jbm.s288283	results	2	NA	Number of covariates adjusted for/matched on	5	33664606
10.2147/jbm.s288283	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33664606
10.2147/jbm.s288283	results	2	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	33664606
10.2147/jbm.s288283	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33664606
10.2147/jbm.s288283	results	2	NA	Primary outcome: adjusted treatment effect	0.57	33664606
10.2147/jbm.s288283	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.28;1.17]	33664606
10.2147/jbm.s288283	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	41	33664606
10.2147/jbm.s288283	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	117	33664606
10.2147/jbm.s288283	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36	33664606
10.2147/jbm.s288283	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33664606
10.2147/jbm.s288283	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33664606
10.2147/jbm.s288283	results	3	NA	Number of covariates adjusted for/matched on	5	33664606
10.2147/jbm.s288283	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33664606
10.2147/jbm.s288283	results	3	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	33664606
10.2147/jbm.s288283	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33664606
10.2147/jbm.s288283	results	3	NA	Primary outcome: adjusted treatment effect	0.61	33664606
10.2147/jbm.s288283	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.37;1.02]	33664606
10.2147/jbm.s288283	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s288283	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s288283	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128	NA
10.2147/jbm.s288283	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s288283	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s288283	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s288283	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s288283	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s288283	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02847637	NA
10.2147/jbm.s288283	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s288283	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s288283	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s288283	study_information	NA	3	Patient-level data used	No	NA
10.2147/jbm.s288283	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/jbm.s288283	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03020160	NA
10.2147/jbm.s288283	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s288283	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s288283	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s312885	general_information	NA	NA	Medical Condition of Interest Name	hemophilia b	NA
10.2147/jbm.s312885	general_information	NA	NA	Countries of first author affiliations	sweden	NA
10.2147/jbm.s312885	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.2147/jbm.s312885	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s312885	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s312885	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s312885	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s312885	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/jbm.s312885	general_information	NA	NA	Medical Condition of Interest Name	hemophilia b	NA
10.2147/jbm.s312885	general_information	NA	NA	Countries of first author affiliations	sweden	NA
10.2147/jbm.s312885	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.2147/jbm.s312885	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s312885	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s312885	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s312885	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s312885	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/jbm.s312885	methodology	1	NA	Treatment name 1	prior prophylaxis rfixfc	NA
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.2147/jbm.s312885	methodology	1	NA	Treatment name 2	prior prophylaxis rix-fp	NA
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.2147/jbm.s312885	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s312885	methodology	1	NA	Anchored comparison?	No	NA
10.2147/jbm.s312885	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2147/jbm.s312885	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2147/jbm.s312885	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)	NA
10.2147/jbm.s312885	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s312885	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s312885	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s312885	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s312885	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.2147/jbm.s312885	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s312885	methodology	2	NA	Treatment name 1	prior episodic treatment rfixfc	NA
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 1	1	NA
10.2147/jbm.s312885	methodology	2	NA	Treatment name 2	prior episodic treatment rix-fp	NA
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 2	2	NA
10.2147/jbm.s312885	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s312885	methodology	2	NA	Anchored comparison?	No	NA
10.2147/jbm.s312885	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2147/jbm.s312885	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2147/jbm.s312885	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)	NA
10.2147/jbm.s312885	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s312885	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s312885	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s312885	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s312885	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.2147/jbm.s312885	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s312885	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	40	NA
10.2147/jbm.s312885	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	45	NA
10.2147/jbm.s312885	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	26	NA
10.2147/jbm.s312885	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s312885	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s312885	results	1	NA	Number of covariates adjusted for/matched on	4	NA
10.2147/jbm.s312885	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	NA
10.2147/jbm.s312885	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	NA
10.2147/jbm.s312885	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s312885	results	1	NA	Primary outcome: adjusted treatment effect	1.18	NA
10.2147/jbm.s312885	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;2.10]	NA
10.2147/jbm.s312885	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	19	NA
10.2147/jbm.s312885	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	42	NA
10.2147/jbm.s312885	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	10	NA
10.2147/jbm.s312885	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s312885	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s312885	results	2	NA	Number of covariates adjusted for/matched on	4	NA
10.2147/jbm.s312885	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)	NA
10.2147/jbm.s312885	results	2	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	NA
10.2147/jbm.s312885	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s312885	results	2	NA	Primary outcome: adjusted treatment effect	1.01	NA
10.2147/jbm.s312885	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.40;2.57]	NA
10.2147/jbm.s312885	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s312885	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s312885	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01027364	NA
10.2147/jbm.s312885	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s312885	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s312885	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s312885	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s312885	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s312885	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01027364	NA
10.2147/jbm.s312885	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s312885	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s312885	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/jbm.s312885	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s312885	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s312885	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01496274	NA
10.2147/jbm.s312885	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s312885	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s312885	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s312885	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s312885	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s312885	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01496274	NA
10.2147/jbm.s312885	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s312885	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s312885	study_information	NA	2	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/jbm.s321288	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a	NA
10.2147/jbm.s321288	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/jbm.s321288	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.2147/jbm.s321288	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s321288	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s321288	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s321288	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s321288	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/jbm.s321288	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.2147/jbm.s321288	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2147/jbm.s321288	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.2147/jbm.s321288	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2147/jbm.s321288	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2147/jbm.s321288	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/jbm.s321288	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/jbm.s321288	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2147/jbm.s321288	methodology	1	NA	Treatment name 1	damoctocog alfa pegol (bay 94-9027)	NA
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.2147/jbm.s321288	methodology	1	NA	Treatment name 2	turoctocog alfa pegol (n8-gp)	NA
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.2147/jbm.s321288	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/jbm.s321288	methodology	1	NA	Anchored comparison?	No	NA
10.2147/jbm.s321288	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2147/jbm.s321288	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2147/jbm.s321288	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rate	NA
10.2147/jbm.s321288	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2147/jbm.s321288	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/jbm.s321288	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/jbm.s321288	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/jbm.s321288	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/jbm.s321288	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/jbm.s321288	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	175	NA
10.2147/jbm.s321288	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	102	NA
10.2147/jbm.s321288	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61.94	NA
10.2147/jbm.s321288	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2147/jbm.s321288	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/jbm.s321288	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.2147/jbm.s321288	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	NA
10.2147/jbm.s321288	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio	NA
10.2147/jbm.s321288	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/jbm.s321288	results	1	NA	Primary outcome: unadjusted treatment effect	1.1	NA
10.2147/jbm.s321288	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.4492	NA
10.2147/jbm.s321288	results	1	NA	Primary outcome: adjusted treatment effect	1.11	NA
10.2147/jbm.s321288	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.449	NA
10.2147/jbm.s321288	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s321288	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s321288	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293	NA
10.2147/jbm.s321288	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s321288	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s321288	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/jbm.s321288	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/jbm.s321288	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/jbm.s321288	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293	NA
10.2147/jbm.s321288	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s321288	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2147/jbm.s321288	study_information	NA	1	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/jbm.s321288	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s321288	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s321288	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01480180	NA
10.2147/jbm.s321288	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s321288	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s321288	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2147/jbm.s321288	study_information	NA	2	Patient-level data used	No	NA
10.2147/jbm.s321288	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/jbm.s321288	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01480180	NA
10.2147/jbm.s321288	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/jbm.s321288	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/jbm.s321288	study_information	NA	2	Number of treatment arms (clinical trial only)	XXXX	NA
10.2147/ptt.s326121	general_information	NA	NA	Medical Condition of Interest Name	NA	NA
10.2147/ptt.s326121	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.2147/ptt.s326121	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.2147/ptt.s326121	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.2147/ptt.s326121	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.2147/ptt.s326121	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/ptt.s326121	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/ptt.s326121	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/ptt.s326121	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.2147/ptt.s326121	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.2147/ptt.s326121	general_information	NA	NA	Countries of last author affiliations	germany	NA
10.2147/ptt.s326121	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.2147/ptt.s326121	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	XXXX	NA
10.2147/ptt.s326121	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2147/ptt.s326121	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2147/ptt.s326121	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2147/ptt.s326121	methodology	1	NA	Treatment name 1	brodalumab	NA
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2147/ptt.s326121	methodology	1	NA	Treatment name 2	guselkumab	NA
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.2147/ptt.s326121	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2147/ptt.s326121	methodology	1	NA	Anchored comparison?	No	NA
10.2147/ptt.s326121	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2147/ptt.s326121	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2147/ptt.s326121	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12	NA
10.2147/ptt.s326121	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.2147/ptt.s326121	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2147/ptt.s326121	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2147/ptt.s326121	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2147/ptt.s326121	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2147/ptt.s326121	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2147/ptt.s326121	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	135	NA
10.2147/ptt.s326121	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	121	NA
10.2147/ptt.s326121	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	90	NA
10.2147/ptt.s326121	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported	NA
10.2147/ptt.s326121	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2147/ptt.s326121	results	1	NA	Number of covariates adjusted for/matched on	11	NA
10.2147/ptt.s326121	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.2147/ptt.s326121	results	1	NA	Primary outcome: treatment effect contrast	Risk difference	NA
10.2147/ptt.s326121	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2147/ptt.s326121	results	1	NA	Primary outcome: adjusted treatment effect	14.6	NA
10.2147/ptt.s326121	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.002	NA
10.2147/ptt.s326121	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/ptt.s326121	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708603	NA
10.2147/ptt.s326121	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ptt.s326121	study_information	NA	1	Patient-level data used	Yes	NA
10.2147/ptt.s326121	study_information	NA	1	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708603	NA
10.2147/ptt.s326121	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ptt.s326121	study_information	NA	2	Patient-level data used	Yes	NA
10.2147/ptt.s326121	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708629	NA
10.2147/ptt.s326121	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ptt.s326121	study_information	NA	2	Patient-level data used	Yes	NA
10.2147/ptt.s326121	study_information	NA	2	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708629	NA
10.2147/ptt.s326121	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ptt.s326121	study_information	NA	3	Patient-level data used	No	NA
10.2147/ptt.s326121	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02203032	NA
10.2147/ptt.s326121	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2147/ptt.s326121	study_information	NA	3	Patient-level data used	No	NA
10.2147/ptt.s326121	study_information	NA	3	Clinical Trial	Yes	NA
10.2147/ptt.s326121	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02203032	NA
10.2147/ptt.s326121	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2147/ptt.s326121	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2147/ptt.s326121	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes mellitus	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes mellitus	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2165/11592490-000000000-00000	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 1	vildagliptin 50 mg twice daily	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 2	sitagliptin 50 mg once daily	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Anchored comparison?	Yes	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.2165/11592490-000000000-00000	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 1	vildagliptin 50 mg twice daily	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 1	2	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 2	sitagliptin 50 mg once daily	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 2	4	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Anchored comparison?	Yes	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.2165/11592490-000000000-00000	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 1	vildagliptin 50 mg twice daily	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 1	2	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 2	sitagliptin 100 mg once daily	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 2	4;5	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Anchored comparison?	Yes	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	NA
10.2165/11592490-000000000-00000	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2165/11592490-000000000-00000	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	163	NA
10.2165/11592490-000000000-00000	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	156	NA
10.2165/11592490-000000000-00000	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2165/11592490-000000000-00000	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2165/11592490-000000000-00000	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.2165/11592490-000000000-00000	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	NA
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2165/11592490-000000000-00000	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: unadjusted treatment effect	-0.17	NA
10.2165/11592490-000000000-00000	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.024	NA
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: adjusted treatment effect	-0.2	NA
10.2165/11592490-000000000-00000	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.009	NA
10.2165/11592490-000000000-00000	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	188	NA
10.2165/11592490-000000000-00000	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	192	NA
10.2165/11592490-000000000-00000	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	72	NA
10.2165/11592490-000000000-00000	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	73	NA
10.2165/11592490-000000000-00000	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	76	NA
10.2165/11592490-000000000-00000	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	72	NA
10.2165/11592490-000000000-00000	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2165/11592490-000000000-00000	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2165/11592490-000000000-00000	results	2	NA	Number of covariates adjusted for/matched on	6	NA
10.2165/11592490-000000000-00000	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	NA
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2165/11592490-000000000-00000	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: unadjusted treatment effect	-0.2	NA
10.2165/11592490-000000000-00000	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.133	NA
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: adjusted treatment effect	-0.56	NA
10.2165/11592490-000000000-00000	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.2165/11592490-000000000-00000	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	NA
10.2165/11592490-000000000-00000	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	149	NA
10.2165/11592490-000000000-00000	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	76	NA
10.2165/11592490-000000000-00000	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	72	NA
10.2165/11592490-000000000-00000	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2165/11592490-000000000-00000	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2165/11592490-000000000-00000	results	3	NA	Number of covariates adjusted for/matched on	6	NA
10.2165/11592490-000000000-00000	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	NA
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: treatment effect contrast	Means difference	NA
10.2165/11592490-000000000-00000	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: unadjusted treatment effect	-0.19	NA
10.2165/11592490-000000000-00000	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.113	NA
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: adjusted treatment effect	-0.35	NA
10.2165/11592490-000000000-00000	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.013	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Patient-level data used	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00368134	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Patient-level data used	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00368134	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Patient-level data used	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00351832	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Patient-level data used	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Clinical Trial	XXXX	NA
10.2165/11592490-000000000-00000	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00351832	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00411554	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Clinical Trial	XXXX	NA
10.2165/11592490-000000000-00000	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00411554	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2165/11592490-000000000-00000	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00127192	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00127192	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.2165/11592490-000000000-00000	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00371007	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Patient-level data used	No	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Clinical Trial	Yes	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.2165/11592490-000000000-00000	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2165/11592490-000000000-00000	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NA	NA
10.2217/cer-2016-0085	general_information	NA	NA	Medical Condition of Interest Name	relapsingremitting multiple sclerosis	NA
10.2217/cer-2016-0085	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.2217/cer-2016-0085	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2016-0085	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.2217/cer-2016-0085	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2016-0085	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2016-0085	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2016-0085	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2016-0085	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.2217/cer-2016-0085	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.2217/cer-2016-0085	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2016-0085	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry	NA
10.2217/cer-2016-0085	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2016-0085	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2016-0085	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2016-0085	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 1	delayed-release dimethyl fumarate	NA
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 2	glatiramer acetate	NA
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 2	3	NA
10.2217/cer-2016-0085	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2016-0085	methodology	1	NA	Anchored comparison?	Yes	NA
10.2217/cer-2016-0085	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2016-0085	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2016-0085	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate at 2 years	NA
10.2217/cer-2016-0085	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2217/cer-2016-0085	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2016-0085	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2217/cer-2016-0085	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2217/cer-2016-0085	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2016-0085	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 1	delayed-release dimethyl fumarate	NA
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 2	glatiramer acetate	NA
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 2	4	NA
10.2217/cer-2016-0085	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2016-0085	methodology	2	NA	Anchored comparison?	Yes	NA
10.2217/cer-2016-0085	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2016-0085	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2016-0085	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate at 2 years	NA
10.2217/cer-2016-0085	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)	NA
10.2217/cer-2016-0085	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2016-0085	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2217/cer-2016-0085	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2217/cer-2016-0085	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2016-0085	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 1	delayed-release dimethyl fumarate	NA
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 1	1;2	NA
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 2	glatiramer acetate	NA
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 2	5	NA
10.2217/cer-2016-0085	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2016-0085	methodology	3	NA	Anchored comparison?	No	NA
10.2217/cer-2016-0085	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2016-0085	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2016-0085	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	12-week confirmed disability progression	NA
10.2217/cer-2016-0085	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	NA
10.2217/cer-2016-0085	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2016-0085	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	NA
10.2217/cer-2016-0085	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2217/cer-2016-0085	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2016-0085	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2016-0085	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2016-0085	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2016-0085	results	1	NA	Number of covariates adjusted for/matched on	7	NA
10.2217/cer-2016-0085	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest	NA
10.2217/cer-2016-0085	results	1	NA	Primary outcome: treatment effect contrast	Rate ratio	NA
10.2217/cer-2016-0085	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2016-0085	results	1	NA	Primary outcome: unadjusted treatment effect	NA	NA
10.2217/cer-2016-0085	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	NA
10.2217/cer-2016-0085	results	1	NA	Primary outcome: adjusted treatment effect	NA	NA
10.2217/cer-2016-0085	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	NA
10.2217/cer-2016-0085	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2016-0085	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2016-0085	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.2217/cer-2016-0085	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	NA
10.2217/cer-2016-0085	results	2	NA	Primary outcome: treatment effect contrast	Rate ratio	NA
10.2217/cer-2016-0085	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2016-0085	results	2	NA	Primary outcome: unadjusted treatment effect	NA	NA
10.2217/cer-2016-0085	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	NA
10.2217/cer-2016-0085	results	2	NA	Primary outcome: adjusted treatment effect	NA	NA
10.2217/cer-2016-0085	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	NA
10.2217/cer-2016-0085	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2016-0085	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2016-0085	results	3	NA	Number of covariates adjusted for/matched on	7	NA
10.2217/cer-2016-0085	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest	NA
10.2217/cer-2016-0085	results	3	NA	Primary outcome: treatment effect contrast	RR	NA
10.2217/cer-2016-0085	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2016-0085	results	3	NA	Primary outcome: unadjusted treatment effect	0.73	NA
10.2217/cer-2016-0085	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.015	NA
10.2217/cer-2016-0085	results	3	NA	Primary outcome: adjusted treatment effect	0.51	NA
10.2217/cer-2016-0085	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	NA
10.2217/cer-2016-0085	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2016-0085	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.2217/cer-2016-0085	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2016-0085	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212	NA
10.2217/cer-2016-0085	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2016-0085	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.2217/cer-2016-0085	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2016-0085	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451	NA
10.2217/cer-2016-0085	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00004814	NA
10.2217/cer-2016-0085	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer-2016-0085	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00004814	NA
10.2217/cer-2016-0085	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	XXXX	NA
10.2217/cer-2016-0085	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	eur/can study	NA
10.2217/cer-2016-0085	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	eur/can study	NA
10.2217/cer-2016-0085	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	4	Phase of the clinical trial (clinical trial only)	XXXX	NA
10.2217/cer-2016-0085	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00099502	NA
10.2217/cer-2016-0085	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2016-0085	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2016-0085	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2016-0085	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00099502	NA
10.2217/cer-2016-0085	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2016-0085	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2016-0085	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0020	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumors	NA
10.2217/cer-2018-0020	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.2217/cer-2018-0020	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.2217/cer-2018-0020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2018-0020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2018-0020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2018-0020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2018-0020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 1	sunitinib	30168349
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 1	1	30168349
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 2	everolimus	30168349
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 2	2	30168349
10.2217/cer-2018-0020	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30168349
10.2217/cer-2018-0020	methodology	1	NA	Anchored comparison?	Yes	30168349
10.2217/cer-2018-0020	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30168349
10.2217/cer-2018-0020	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	30168349
10.2217/cer-2018-0020	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	30168349
10.2217/cer-2018-0020	methodology	1	NA	Primary outcome: variable type	Time-to-event	30168349
10.2217/cer-2018-0020	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	30168349
10.2217/cer-2018-0020	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	30168349
10.2217/cer-2018-0020	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	30168349
10.2217/cer-2018-0020	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30168349
10.2217/cer-2018-0020	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30168349
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 1	sunitinib	30168349
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 1	1	30168349
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 2	everolimus	30168349
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 2	2	30168349
10.2217/cer-2018-0020	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30168349
10.2217/cer-2018-0020	methodology	2	NA	Anchored comparison?	No	30168349
10.2217/cer-2018-0020	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	30168349
10.2217/cer-2018-0020	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	30168349
10.2217/cer-2018-0020	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	30168349
10.2217/cer-2018-0020	methodology	2	NA	Primary outcome: variable type	Time-to-event	30168349
10.2217/cer-2018-0020	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	30168349
10.2217/cer-2018-0020	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	30168349
10.2217/cer-2018-0020	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	30168349
10.2217/cer-2018-0020	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30168349
10.2217/cer-2018-0020	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30168349
10.2217/cer-2018-0020	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	207	30168349
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	203	30168349
10.2217/cer-2018-0020	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	86	30168349
10.2217/cer-2018-0020	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30168349
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	30168349
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	31	30168349
10.2217/cer-2018-0020	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30168349
10.2217/cer-2018-0020	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30168349
10.2217/cer-2018-0020	results	1	NA	Number of covariates adjusted for/matched on	NA	30168349
10.2217/cer-2018-0020	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30168349
10.2217/cer-2018-0020	results	1	NA	Primary outcome: treatment effect contrast	HR	30168349
10.2217/cer-2018-0020	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30168349
10.2217/cer-2018-0020	results	1	NA	Primary outcome: unadjusted treatment effect	1.2	30168349
10.2217/cer-2018-0020	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.72;2.01]	30168349
10.2217/cer-2018-0020	results	1	NA	Primary outcome: adjusted treatment effect	0.85	30168349
10.2217/cer-2018-0020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.39;1.89]	30168349
10.2217/cer-2018-0020	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	207	30168349
10.2217/cer-2018-0020	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	86	30168349
10.2217/cer-2018-0020	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30168349
10.2217/cer-2018-0020	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30168349
10.2217/cer-2018-0020	results	2	NA	Number of covariates adjusted for/matched on	NA	30168349
10.2217/cer-2018-0020	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	30168349
10.2217/cer-2018-0020	results	2	NA	Primary outcome: treatment effect contrast	HR	30168349
10.2217/cer-2018-0020	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30168349
10.2217/cer-2018-0020	results	2	NA	Primary outcome: unadjusted treatment effect	1.03	30168349
10.2217/cer-2018-0020	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.75;1.42]	30168349
10.2217/cer-2018-0020	results	2	NA	Primary outcome: adjusted treatment effect	0.82	30168349
10.2217/cer-2018-0020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.53;1.27]	30168349
10.2217/cer-2018-0020	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	30168349
10.2217/cer-2018-0020	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2018-0020	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2018-0020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597	NA
10.2217/cer-2018-0020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2018-0020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2018-0020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0020	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2018-0020	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2018-0020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068	NA
10.2217/cer-2018-0020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2018-0020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2018-0020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0141	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis	NA
10.2217/cer-2018-0141	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2018-0141	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.2217/cer-2018-0141	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2018-0141	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2018-0141	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2018-0141	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2018-0141	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 1	NA	30806520
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	30806520
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 2	infliximab	30806520
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 2	3	30806520
10.2217/cer-2018-0141	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30806520
10.2217/cer-2018-0141	methodology	1	NA	Anchored comparison?	No	30806520
10.2217/cer-2018-0141	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30806520
10.2217/cer-2018-0141	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30806520
10.2217/cer-2018-0141	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30806520
10.2217/cer-2018-0141	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	30806520
10.2217/cer-2018-0141	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30806520
10.2217/cer-2018-0141	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30806520
10.2217/cer-2018-0141	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30806520
10.2217/cer-2018-0141	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30806520
10.2217/cer-2018-0141	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30806520
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 1	NA	30806520
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	30806520
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 2	infliximab	30806520
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 2	3	30806520
10.2217/cer-2018-0141	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30806520
10.2217/cer-2018-0141	methodology	2	NA	Anchored comparison?	No	30806520
10.2217/cer-2018-0141	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30806520
10.2217/cer-2018-0141	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30806520
10.2217/cer-2018-0141	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30806520
10.2217/cer-2018-0141	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	30806520
10.2217/cer-2018-0141	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30806520
10.2217/cer-2018-0141	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30806520
10.2217/cer-2018-0141	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30806520
10.2217/cer-2018-0141	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30806520
10.2217/cer-2018-0141	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	30806520
10.2217/cer-2018-0141	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	100	30806520
10.2217/cer-2018-0141	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	84	30806520
10.2217/cer-2018-0141	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30806520
10.2217/cer-2018-0141	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	NA	30806520
10.2217/cer-2018-0141	results	1	NA	Number of covariates adjusted for/matched on	11	30806520
10.2217/cer-2018-0141	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	30806520
10.2217/cer-2018-0141	results	1	NA	Primary outcome: treatment effect contrast	OR	30806520
10.2217/cer-2018-0141	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30806520
10.2217/cer-2018-0141	results	1	NA	Primary outcome: adjusted treatment effect	2.31	30806520
10.2217/cer-2018-0141	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.008	30806520
10.2217/cer-2018-0141	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	30806520
10.2217/cer-2018-0141	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	100	30806520
10.2217/cer-2018-0141	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70	30806520
10.2217/cer-2018-0141	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30806520
10.2217/cer-2018-0141	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30806520
10.2217/cer-2018-0141	results	2	NA	Number of covariates adjusted for/matched on	11	30806520
10.2217/cer-2018-0141	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	30806520
10.2217/cer-2018-0141	results	2	NA	Primary outcome: treatment effect contrast	OR	30806520
10.2217/cer-2018-0141	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30806520
10.2217/cer-2018-0141	results	2	NA	Primary outcome: adjusted treatment effect	2.72	30806520
10.2217/cer-2018-0141	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.006	30806520
10.2217/cer-2018-0141	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	30806520
10.2217/cer-2018-0141	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2018-0141	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2018-0141	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634	NA
10.2217/cer-2018-0141	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2018-0141	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2018-0141	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0141	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2018-0141	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2018-0141	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468	NA
10.2217/cer-2018-0141	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2018-0141	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2018-0141	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0141	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2018-0141	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2018-0141	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623	NA
10.2217/cer-2018-0141	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2018-0141	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2018-0141	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.2217/cer-2019-0145	general_information	NA	NA	Medical Condition of Interest Name	advanced gastric or gastroesophageal junction cancer	NA
10.2217/cer-2019-0145	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.2217/cer-2019-0145	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2019-0145	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2019-0145	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2019-0145	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2019-0145	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2019-0145	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 1	nivolumab	31872771
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 1	1	31872771
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 2	NA	31872771
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 2	2	31872771
10.2217/cer-2019-0145	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	31872771
10.2217/cer-2019-0145	methodology	1	NA	Anchored comparison?	No	31872771
10.2217/cer-2019-0145	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	31872771
10.2217/cer-2019-0145	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	31872771
10.2217/cer-2019-0145	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31872771
10.2217/cer-2019-0145	methodology	1	NA	Primary outcome: variable type	Time-to-event	31872771
10.2217/cer-2019-0145	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	31872771
10.2217/cer-2019-0145	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	31872771
10.2217/cer-2019-0145	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31872771
10.2217/cer-2019-0145	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	31872771
10.2217/cer-2019-0145	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31872771
10.2217/cer-2019-0145	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	31872771
10.2217/cer-2019-0145	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	31872771
10.2217/cer-2019-0145	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31872771
10.2217/cer-2019-0145	results	1	NA	Number of covariates adjusted for/matched on	6	31872771
10.2217/cer-2019-0145	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31872771
10.2217/cer-2019-0145	results	1	NA	Primary outcome: treatment effect contrast	HR	31872771
10.2217/cer-2019-0145	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31872771
10.2217/cer-2019-0145	results	1	NA	Primary outcome: adjusted treatment effect	0.5	31872771
10.2217/cer-2019-0145	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.36;0.68]	31872771
10.2217/cer-2019-0145	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	31872771
10.2217/cer-2019-0145	results	1	NA	Primary outcome: unadjusted treatment effect	NA	31872771
10.2217/cer-2019-0145	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	31872771
10.2217/cer-2019-0145	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2019-0145	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2019-0145	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928394	NA
10.2217/cer-2019-0145	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0145	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.2217/cer-2019-0145	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2019-0145	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2019-0145	study_information	NA	2	Clinical Trial	No	NA
10.2217/cer-2019-0145	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	flatiron healths electronic health record database	NA
10.2217/cer-2019-0145	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer-2019-0169	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis	NA
10.2217/cer-2019-0169	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2019-0169	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2019-0169	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2019-0169	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2019-0169	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2019-0169	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2019-0169	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 1	ozanimod	31948278
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	31948278
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 2	fingolimod	31948278
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5	31948278
10.2217/cer-2019-0169	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31948278
10.2217/cer-2019-0169	methodology	1	NA	Anchored comparison?	No	31948278
10.2217/cer-2019-0169	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31948278
10.2217/cer-2019-0169	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31948278
10.2217/cer-2019-0169	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31948278
10.2217/cer-2019-0169	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	31948278
10.2217/cer-2019-0169	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31948278
10.2217/cer-2019-0169	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31948278
10.2217/cer-2019-0169	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31948278
10.2217/cer-2019-0169	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	31948278
10.2217/cer-2019-0169	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31948278
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 1	ozanimod	31948278
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 1	NA	31948278
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 2	fingolimod	31948278
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 2	3	31948278
10.2217/cer-2019-0169	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	31948278
10.2217/cer-2019-0169	methodology	2	NA	Anchored comparison?	Yes	31948278
10.2217/cer-2019-0169	methodology	2	NA	Form of the indirect comparison	NA	31948278
10.2217/cer-2019-0169	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31948278
10.2217/cer-2019-0169	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31948278
10.2217/cer-2019-0169	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	31948278
10.2217/cer-2019-0169	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31948278
10.2217/cer-2019-0169	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31948278
10.2217/cer-2019-0169	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31948278
10.2217/cer-2019-0169	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	31948278
10.2217/cer-2019-0169	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31948278
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 1	ozanimod	31948278
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 1	NA	31948278
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 2	fingolimod	31948278
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 2	4;5	31948278
10.2217/cer-2019-0169	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	31948278
10.2217/cer-2019-0169	methodology	3	NA	Anchored comparison?	No	31948278
10.2217/cer-2019-0169	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31948278
10.2217/cer-2019-0169	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31948278
10.2217/cer-2019-0169	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	31948278
10.2217/cer-2019-0169	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	31948278
10.2217/cer-2019-0169	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	31948278
10.2217/cer-2019-0169	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	31948278
10.2217/cer-2019-0169	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	31948278
10.2217/cer-2019-0169	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes	31948278
10.2217/cer-2019-0169	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31948278
10.2217/cer-2019-0169	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1212	31948278
10.2217/cer-2019-0169	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1773	31948278
10.2217/cer-2019-0169	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	597	31948278
10.2217/cer-2019-0169	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31948278
10.2217/cer-2019-0169	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31948278
10.2217/cer-2019-0169	results	1	NA	Number of covariates adjusted for/matched on	11	31948278
10.2217/cer-2019-0169	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	31948278
10.2217/cer-2019-0169	results	1	NA	Primary outcome: treatment effect contrast	Risk difference	31948278
10.2217/cer-2019-0169	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31948278
10.2217/cer-2019-0169	results	1	NA	Primary outcome: adjusted treatment effect	-1.4	31948278
10.2217/cer-2019-0169	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31948278
10.2217/cer-2019-0169	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	429	31948278
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	431	31948278
10.2217/cer-2019-0169	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	882	31948278
10.2217/cer-2019-0169	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	31948278
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	885	31948278
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	317	31948278
10.2217/cer-2019-0169	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31948278
10.2217/cer-2019-0169	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31948278
10.2217/cer-2019-0169	results	2	NA	Number of covariates adjusted for/matched on	9	31948278
10.2217/cer-2019-0169	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	31948278
10.2217/cer-2019-0169	results	2	NA	Primary outcome: treatment effect contrast	Risk difference	31948278
10.2217/cer-2019-0169	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31948278
10.2217/cer-2019-0169	results	2	NA	Primary outcome: adjusted treatment effect	-9.9	31948278
10.2217/cer-2019-0169	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.05	31948278
10.2217/cer-2019-0169	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	783	31948278
10.2217/cer-2019-0169	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	434	31948278
10.2217/cer-2019-0169	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	158	31948278
10.2217/cer-2019-0169	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31948278
10.2217/cer-2019-0169	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31948278
10.2217/cer-2019-0169	results	3	NA	Number of covariates adjusted for/matched on	8	31948278
10.2217/cer-2019-0169	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	31948278
10.2217/cer-2019-0169	results	3	NA	Primary outcome: treatment effect contrast	Risk difference	31948278
10.2217/cer-2019-0169	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31948278
10.2217/cer-2019-0169	results	3	NA	Primary outcome: adjusted treatment effect	-22.7	31948278
10.2217/cer-2019-0169	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31948278
10.2217/cer-2019-0169	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2019-0169	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2019-0169	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734	NA
10.2217/cer-2019-0169	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0169	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2019-0169	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2019-0169	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2019-0169	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2019-0169	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058	NA
10.2217/cer-2019-0169	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0169	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2019-0169	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2019-0169	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2019-0169	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2019-0169	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00340834	NA
10.2217/cer-2019-0169	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0169	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2019-0169	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2019-0169	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2019-0169	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2019-0169	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978	NA
10.2217/cer-2019-0169	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0169	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2019-0169	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2019-0169	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2019-0169	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2019-0169	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134	NA
10.2217/cer-2019-0169	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2019-0169	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2019-0169	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0063	general_information	NA	NA	Medical Condition of Interest Name	non-small cell lung cancer	NA
10.2217/cer-2020-0063	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.2217/cer-2020-0063	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.2217/cer-2020-0063	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0063	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0063	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0063	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0063	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2020-0063	general_information	NA	NA	Medical Condition of Interest Name	XXXX	NA
10.2217/cer-2020-0063	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.2217/cer-2020-0063	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.2217/cer-2020-0063	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0063	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0063	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0063	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0063	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 1	entrectinib	NA
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	NA
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 2	crizotinib	NA
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 2	4	NA
10.2217/cer-2020-0063	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2020-0063	methodology	1	NA	Anchored comparison?	No	NA
10.2217/cer-2020-0063	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2020-0063	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2020-0063	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2217/cer-2020-0063	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.2217/cer-2020-0063	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2020-0063	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2020-0063	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 1	entrectinib	NA
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3	NA
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 2	pemetrexed + platinum followed by pemetrexed maintenance	NA
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 2	5	NA
10.2217/cer-2020-0063	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2020-0063	methodology	2	NA	Anchored comparison?	No	NA
10.2217/cer-2020-0063	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2020-0063	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2020-0063	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2217/cer-2020-0063	methodology	2	NA	Primary outcome: variable type	Time-to-event	NA
10.2217/cer-2020-0063	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2020-0063	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2020-0063	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 1	entrectinib	NA
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3	NA
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 2	pemetrexed/docetaxel	NA
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 2	6	NA
10.2217/cer-2020-0063	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2020-0063	methodology	3	NA	Anchored comparison?	No	NA
10.2217/cer-2020-0063	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	NA
10.2217/cer-2020-0063	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2020-0063	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2217/cer-2020-0063	methodology	3	NA	Primary outcome: variable type	Time-to-event	NA
10.2217/cer-2020-0063	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	NA
10.2217/cer-2020-0063	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0063	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2020-0063	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2020-0063	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	53	NA
10.2217/cer-2020-0063	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	53	NA
10.2217/cer-2020-0063	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	34.18	NA
10.2217/cer-2020-0063	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2020-0063	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2020-0063	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.2217/cer-2020-0063	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.2217/cer-2020-0063	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.2217/cer-2020-0063	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2020-0063	results	1	NA	Primary outcome: adjusted treatment effect	0.471	NA
10.2217/cer-2020-0063	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.112;1.034]	NA
10.2217/cer-2020-0063	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	187	NA
10.2217/cer-2020-0063	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	53	NA
10.2217/cer-2020-0063	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	47.5	NA
10.2217/cer-2020-0063	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2020-0063	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2020-0063	results	2	NA	Number of covariates adjusted for/matched on	5	NA
10.2217/cer-2020-0063	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.2217/cer-2020-0063	results	2	NA	Primary outcome: treatment effect contrast	HR	NA
10.2217/cer-2020-0063	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2020-0063	results	2	NA	Primary outcome: adjusted treatment effect	0.478	NA
10.2217/cer-2020-0063	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.167;0.918]	NA
10.2217/cer-2020-0063	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	174	NA
10.2217/cer-2020-0063	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	53	NA
10.2217/cer-2020-0063	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36.09	NA
10.2217/cer-2020-0063	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2020-0063	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2020-0063	results	3	NA	Number of covariates adjusted for/matched on	5	NA
10.2217/cer-2020-0063	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)	NA
10.2217/cer-2020-0063	results	3	NA	Primary outcome: treatment effect contrast	HR	NA
10.2217/cer-2020-0063	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2020-0063	results	3	NA	Primary outcome: adjusted treatment effect	0.434	NA
10.2217/cer-2020-0063	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.157;0.755]	NA
10.2217/cer-2020-0063	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88	NA
10.2217/cer-2020-0063	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/cer-2020-0063	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88	NA
10.2217/cer-2020-0063	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/cer-2020-0063	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810	NA
10.2217/cer-2020-0063	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810	NA
10.2217/cer-2020-0063	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	3	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267	NA
10.2217/cer-2020-0063	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0063	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	3	Patient-level data used	Yes	NA
10.2217/cer-2020-0063	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267	NA
10.2217/cer-2020-0063	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0063	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2020-0063	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.2217/cer-2020-0063	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2020-0063	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.2217/cer-2020-0063	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0063	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2020-0063	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099	NA
10.2217/cer-2020-0063	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0063	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0063	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2020-0063	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099	NA
10.2217/cer-2020-0063	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0063	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0063	study_information	NA	6	Patient-level data used	No	NA
10.2217/cer-2020-0063	study_information	NA	6	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893	NA
10.2217/cer-2020-0063	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0063	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0063	study_information	NA	6	Patient-level data used	XXXX	NA
10.2217/cer-2020-0063	study_information	NA	6	Clinical Trial	Yes	NA
10.2217/cer-2020-0063	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893	NA
10.2217/cer-2020-0063	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0063	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0063	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0069	general_information	NA	NA	Medical Condition of Interest Name	pediatric relapsed/refractory acute lymphoblastic leukemia	NA
10.2217/cer-2020-0069	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2020-0069	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2020-0069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 1	tisagenlecleucel	32602756
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 1	1	32602756
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 2	blinatumomab	32602756
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 2	2	32602756
10.2217/cer-2020-0069	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	32602756
10.2217/cer-2020-0069	methodology	1	NA	Anchored comparison?	No	32602756
10.2217/cer-2020-0069	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32602756
10.2217/cer-2020-0069	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32602756
10.2217/cer-2020-0069	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32602756
10.2217/cer-2020-0069	methodology	1	NA	Primary outcome: variable type	Time-to-event	32602756
10.2217/cer-2020-0069	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32602756
10.2217/cer-2020-0069	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32602756
10.2217/cer-2020-0069	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32602756
10.2217/cer-2020-0069	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32602756
10.2217/cer-2020-0069	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32602756
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 1	tisagenlecleucel	32602756
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 1	1	32602756
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 2	NA	32602756
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 2	3	32602756
10.2217/cer-2020-0069	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	32602756
10.2217/cer-2020-0069	methodology	2	NA	Anchored comparison?	No	32602756
10.2217/cer-2020-0069	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32602756
10.2217/cer-2020-0069	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32602756
10.2217/cer-2020-0069	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32602756
10.2217/cer-2020-0069	methodology	2	NA	Primary outcome: variable type	Time-to-event	32602756
10.2217/cer-2020-0069	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32602756
10.2217/cer-2020-0069	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32602756
10.2217/cer-2020-0069	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32602756
10.2217/cer-2020-0069	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32602756
10.2217/cer-2020-0069	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32602756
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 1	tisagenlecleucel	32602756
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 1	1	32602756
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 2	NA	32602756
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 2	4;5;6	32602756
10.2217/cer-2020-0069	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	32602756
10.2217/cer-2020-0069	methodology	3	NA	Anchored comparison?	No	32602756
10.2217/cer-2020-0069	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	32602756
10.2217/cer-2020-0069	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32602756
10.2217/cer-2020-0069	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32602756
10.2217/cer-2020-0069	methodology	3	NA	Primary outcome: variable type	Time-to-event	32602756
10.2217/cer-2020-0069	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32602756
10.2217/cer-2020-0069	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32602756
10.2217/cer-2020-0069	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32602756
10.2217/cer-2020-0069	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32602756
10.2217/cer-2020-0069	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32602756
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 1	tisagenlecleucel	32602756
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 1	1	32602756
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 2	NA	32602756
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 2	7	32602756
10.2217/cer-2020-0069	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	32602756
10.2217/cer-2020-0069	methodology	4	NA	Anchored comparison?	No	32602756
10.2217/cer-2020-0069	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32602756
10.2217/cer-2020-0069	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32602756
10.2217/cer-2020-0069	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32602756
10.2217/cer-2020-0069	methodology	4	NA	Primary outcome: variable type	Time-to-event	32602756
10.2217/cer-2020-0069	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32602756
10.2217/cer-2020-0069	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32602756
10.2217/cer-2020-0069	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32602756
10.2217/cer-2020-0069	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32602756
10.2217/cer-2020-0069	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32602756
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 1	tisagenlecleucel	32602756
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 1	1	32602756
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 2	NA	32602756
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 2	8	32602756
10.2217/cer-2020-0069	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	32602756
10.2217/cer-2020-0069	methodology	5	NA	Anchored comparison?	No	32602756
10.2217/cer-2020-0069	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	32602756
10.2217/cer-2020-0069	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	32602756
10.2217/cer-2020-0069	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	32602756
10.2217/cer-2020-0069	methodology	5	NA	Primary outcome: variable type	Time-to-event	32602756
10.2217/cer-2020-0069	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	32602756
10.2217/cer-2020-0069	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	32602756
10.2217/cer-2020-0069	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	32602756
10.2217/cer-2020-0069	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	32602756
10.2217/cer-2020-0069	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	32602756
10.2217/cer-2020-0069	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	70	32602756
10.2217/cer-2020-0069	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	79	32602756
10.2217/cer-2020-0069	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32602756
10.2217/cer-2020-0069	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32602756
10.2217/cer-2020-0069	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32602756
10.2217/cer-2020-0069	results	1	NA	Number of covariates adjusted for/matched on	9	32602756
10.2217/cer-2020-0069	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	32602756
10.2217/cer-2020-0069	results	1	NA	Primary outcome: treatment effect contrast	HR	32602756
10.2217/cer-2020-0069	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32602756
10.2217/cer-2020-0069	results	1	NA	Primary outcome: unadjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32602756
10.2217/cer-2020-0069	results	1	NA	Primary outcome: adjusted treatment effect	0.32	32602756
10.2217/cer-2020-0069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0015	32602756
10.2217/cer-2020-0069	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	61	32602756
10.2217/cer-2020-0069	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	79	32602756
10.2217/cer-2020-0069	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32602756
10.2217/cer-2020-0069	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32602756
10.2217/cer-2020-0069	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32602756
10.2217/cer-2020-0069	results	2	NA	Number of covariates adjusted for/matched on	5	32602756
10.2217/cer-2020-0069	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Race/ethnicity, Past treatments for the disease of interest	32602756
10.2217/cer-2020-0069	results	2	NA	Primary outcome: treatment effect contrast	HR	32602756
10.2217/cer-2020-0069	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32602756
10.2217/cer-2020-0069	results	2	NA	Primary outcome: unadjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32602756
10.2217/cer-2020-0069	results	2	NA	Primary outcome: adjusted treatment effect	0.24	32602756
10.2217/cer-2020-0069	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	32602756
10.2217/cer-2020-0069	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	74	32602756
10.2217/cer-2020-0069	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	79	32602756
10.2217/cer-2020-0069	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32602756
10.2217/cer-2020-0069	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32602756
10.2217/cer-2020-0069	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32602756
10.2217/cer-2020-0069	results	3	NA	Number of covariates adjusted for/matched on	2	32602756
10.2217/cer-2020-0069	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Past treatments for the disease of interest	32602756
10.2217/cer-2020-0069	results	3	NA	Primary outcome: treatment effect contrast	HR	32602756
10.2217/cer-2020-0069	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32602756
10.2217/cer-2020-0069	results	3	NA	Primary outcome: unadjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32602756
10.2217/cer-2020-0069	results	3	NA	Primary outcome: adjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	32602756
10.2217/cer-2020-0069	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	51	32602756
10.2217/cer-2020-0069	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	32602756
10.2217/cer-2020-0069	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32602756
10.2217/cer-2020-0069	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32602756
10.2217/cer-2020-0069	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32602756
10.2217/cer-2020-0069	results	4	NA	Number of covariates adjusted for/matched on	3	32602756
10.2217/cer-2020-0069	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Past treatments for the disease of interest	32602756
10.2217/cer-2020-0069	results	4	NA	Primary outcome: treatment effect contrast	HR	32602756
10.2217/cer-2020-0069	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32602756
10.2217/cer-2020-0069	results	4	NA	Primary outcome: unadjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32602756
10.2217/cer-2020-0069	results	4	NA	Primary outcome: adjusted treatment effect	0.15	32602756
10.2217/cer-2020-0069	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	32602756
10.2217/cer-2020-0069	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	242	32602756
10.2217/cer-2020-0069	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	79	32602756
10.2217/cer-2020-0069	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	32602756
10.2217/cer-2020-0069	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	32602756
10.2217/cer-2020-0069	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	32602756
10.2217/cer-2020-0069	results	5	NA	Number of covariates adjusted for/matched on	NA	32602756
10.2217/cer-2020-0069	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	32602756
10.2217/cer-2020-0069	results	5	NA	Primary outcome: treatment effect contrast	HR	32602756
10.2217/cer-2020-0069	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	32602756
10.2217/cer-2020-0069	results	5	NA	Primary outcome: unadjusted treatment effect	NA	32602756
10.2217/cer-2020-0069	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	32602756
10.2217/cer-2020-0069	results	5	NA	Primary outcome: adjusted treatment effect	0.27	32602756
10.2217/cer-2020-0069	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001	32602756
10.2217/cer-2020-0069	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0069	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435849	NA
10.2217/cer-2020-0069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0069	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01471782	NA
10.2217/cer-2020-0069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.2217/cer-2020-0069	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2020-0069	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jeha et al. (2006)	NA
10.2217/cer-2020-0069	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0069	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer-2020-0069	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2020-0069	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00315705	NA
10.2217/cer-2020-0069	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer-2020-0069	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.2217/cer-2020-0069	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2020-0069	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	locatelli et al. (2017)	NA
10.2217/cer-2020-0069	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0069	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/cer-2020-0069	study_information	NA	6	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	6	Clinical Trial	No	NA
10.2217/cer-2020-0069	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	miano et al. (2012)	NA
10.2217/cer-2020-0069	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/cer-2020-0069	study_information	NA	6	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2020-0069	study_information	NA	7	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	7	Clinical Trial	No	NA
10.2217/cer-2020-0069	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	von stackelbeg et al. (2010)	NA
10.2217/cer-2020-0069	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	germany	NA
10.2217/cer-2020-0069	study_information	NA	8	Patient-level data used	No	NA
10.2217/cer-2020-0069	study_information	NA	8	Clinical Trial	No	NA
10.2217/cer-2020-0069	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	all-sct-bfm 2003 & all-sct-bfm	NA
10.2217/cer-2020-0069	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0236	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma	NA
10.2217/cer-2020-0236	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2020-0236	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2020-0236	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0236	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0236	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0236	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0236	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2020-0236	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma	NA
10.2217/cer-2020-0236	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2020-0236	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2020-0236	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0236	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0236	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0236	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0236	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab	NA
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 1	1	NA
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 2	placebo	NA
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 2	2	NA
10.2217/cer-2020-0236	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	NA
10.2217/cer-2020-0236	methodology	1	NA	Anchored comparison?	No	NA
10.2217/cer-2020-0236	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	NA
10.2217/cer-2020-0236	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	NA
10.2217/cer-2020-0236	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	NA
10.2217/cer-2020-0236	methodology	1	NA	Primary outcome: variable type	Time-to-event	NA
10.2217/cer-2020-0236	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset	NA
10.2217/cer-2020-0236	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	NA
10.2217/cer-2020-0236	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	NA
10.2217/cer-2020-0236	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	NA
10.2217/cer-2020-0236	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	NA
10.2217/cer-2020-0236	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	237	NA
10.2217/cer-2020-0236	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	50	NA
10.2217/cer-2020-0236	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	NA
10.2217/cer-2020-0236	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	NA
10.2217/cer-2020-0236	results	1	NA	Number of covariates adjusted for/matched on	6	NA
10.2217/cer-2020-0236	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	NA
10.2217/cer-2020-0236	results	1	NA	Primary outcome: treatment effect contrast	HR	NA
10.2217/cer-2020-0236	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	NA
10.2217/cer-2020-0236	results	1	NA	Primary outcome: adjusted treatment effect	0.35	NA
10.2217/cer-2020-0236	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.21;0.58]	NA
10.2217/cer-2020-0236	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0236	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0236	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01658878	NA
10.2217/cer-2020-0236	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0236	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.2217/cer-2020-0236	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0236	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0236	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0236	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01658878	NA
10.2217/cer-2020-0236	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0236	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.2217/cer-2020-0236	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0236	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2020-0236	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0236	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.2217/cer-2020-0236	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0236	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0236	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0236	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2020-0236	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0236	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426	NA
10.2217/cer-2020-0236	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0236	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0236	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0272	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer	NA
10.2217/cer-2020-0272	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2020-0272	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.2217/cer-2020-0272	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0272	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0272	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0272	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0272	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 1	NA	33626934
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 1	1	33626934
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant	33626934
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 2	2	33626934
10.2217/cer-2020-0272	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33626934
10.2217/cer-2020-0272	methodology	1	NA	Anchored comparison?	Yes	33626934
10.2217/cer-2020-0272	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33626934
10.2217/cer-2020-0272	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	33626934
10.2217/cer-2020-0272	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33626934
10.2217/cer-2020-0272	methodology	1	NA	Primary outcome: variable type	Time-to-event	33626934
10.2217/cer-2020-0272	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33626934
10.2217/cer-2020-0272	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	33626934
10.2217/cer-2020-0272	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33626934
10.2217/cer-2020-0272	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33626934
10.2217/cer-2020-0272	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33626934
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 1	palbociclib + fulvestrant	33626934
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 1	1	33626934
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 2	ribociclib + fulvestrant	33626934
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 2	3	33626934
10.2217/cer-2020-0272	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33626934
10.2217/cer-2020-0272	methodology	2	NA	Anchored comparison?	Yes	33626934
10.2217/cer-2020-0272	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33626934
10.2217/cer-2020-0272	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	33626934
10.2217/cer-2020-0272	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33626934
10.2217/cer-2020-0272	methodology	2	NA	Primary outcome: variable type	Time-to-event	33626934
10.2217/cer-2020-0272	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33626934
10.2217/cer-2020-0272	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No	33626934
10.2217/cer-2020-0272	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33626934
10.2217/cer-2020-0272	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33626934
10.2217/cer-2020-0272	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33626934
10.2217/cer-2020-0272	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	183	33626934
10.2217/cer-2020-0272	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	97	33626934
10.2217/cer-2020-0272	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33626934
10.2217/cer-2020-0272	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33626934
10.2217/cer-2020-0272	results	1	NA	Number of covariates adjusted for/matched on	12	33626934
10.2217/cer-2020-0272	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33626934
10.2217/cer-2020-0272	results	1	NA	Primary outcome: treatment effect contrast	HR	33626934
10.2217/cer-2020-0272	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33626934
10.2217/cer-2020-0272	results	1	NA	Primary outcome: unadjusted treatment effect	NA	33626934
10.2217/cer-2020-0272	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33626934
10.2217/cer-2020-0272	results	1	NA	Primary outcome: adjusted treatment effect	NA	33626934
10.2217/cer-2020-0272	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33626934
10.2217/cer-2020-0272	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	142	33626934
10.2217/cer-2020-0272	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	75	33626934
10.2217/cer-2020-0272	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33626934
10.2217/cer-2020-0272	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33626934
10.2217/cer-2020-0272	results	2	NA	Number of covariates adjusted for/matched on	NA	33626934
10.2217/cer-2020-0272	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33626934
10.2217/cer-2020-0272	results	2	NA	Primary outcome: treatment effect contrast	HR	33626934
10.2217/cer-2020-0272	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33626934
10.2217/cer-2020-0272	results	2	NA	Primary outcome: unadjusted treatment effect	1.09	33626934
10.2217/cer-2020-0272	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.70;1.69]	33626934
10.2217/cer-2020-0272	results	2	NA	Primary outcome: adjusted treatment effect	0.89	33626934
10.2217/cer-2020-0272	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.48;1.63]	33626934
10.2217/cer-2020-0272	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0272	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0272	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135	NA
10.2217/cer-2020-0272	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0272	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0272	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0272	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2020-0272	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0272	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703	NA
10.2217/cer-2020-0272	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0272	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0272	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0272	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2020-0272	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2020-0272	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615	NA
10.2217/cer-2020-0272	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0272	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0272	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0280	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia	NA
10.2217/cer-2020-0280	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.2217/cer-2020-0280	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2020-0280	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2020-0280	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2020-0280	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2020-0280	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2020-0280	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 1	NA	33733815
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 1	1	33733815
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 2	venetoclax + low-dose cytarabine	33733815
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 2	2	33733815
10.2217/cer-2020-0280	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	33733815
10.2217/cer-2020-0280	methodology	1	NA	Anchored comparison?	Yes	33733815
10.2217/cer-2020-0280	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33733815
10.2217/cer-2020-0280	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33733815
10.2217/cer-2020-0280	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33733815
10.2217/cer-2020-0280	methodology	1	NA	Primary outcome: variable type	Time-to-event	33733815
10.2217/cer-2020-0280	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33733815
10.2217/cer-2020-0280	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33733815
10.2217/cer-2020-0280	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33733815
10.2217/cer-2020-0280	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	NA	33733815
10.2217/cer-2020-0280	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	33733815
10.2217/cer-2020-0280	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	143	33733815
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	68	33733815
10.2217/cer-2020-0280	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	78	33733815
10.2217/cer-2020-0280	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78	33733815
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38	33733815
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38	33733815
10.2217/cer-2020-0280	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33733815
10.2217/cer-2020-0280	results	1	NA	Number of covariates adjusted for/matched on	6	33733815
10.2217/cer-2020-0280	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)	33733815
10.2217/cer-2020-0280	results	1	NA	Primary outcome: treatment effect contrast	HR	33733815
10.2217/cer-2020-0280	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33733815
10.2217/cer-2020-0280	results	1	NA	Primary outcome: unadjusted treatment effect	0.66	33733815
10.2217/cer-2020-0280	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.38;1.15]	33733815
10.2217/cer-2020-0280	results	1	NA	Primary outcome: adjusted treatment effect	0.56	33733815
10.2217/cer-2020-0280	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.24;1.32]	33733815
10.2217/cer-2020-0280	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2020-0280	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2020-0280	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038	NA
10.2217/cer-2020-0280	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0280	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/cer-2020-0280	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2020-0280	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2020-0280	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2020-0280	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03069352	NA
10.2217/cer-2020-0280	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2020-0280	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2020-0280	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0178	general_information	NA	NA	Medical Condition of Interest Name	parkinson's disease	NA
10.2217/cer-2021-0178	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2021-0178	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer-2021-0178	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2021-0178	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2021-0178	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2021-0178	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2021-0178	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2021-0178	methodology	1	NA	Treatment name 1	apomorphine sublingual film	35068168
10.2217/cer-2021-0178	methodology	1	NA	Study 'number(s)' for treatment 1	1	35068168
10.2217/cer-2021-0178	methodology	1	NA	Treatment name 2	levodopa inhalation powder	35068168
10.2217/cer-2021-0178	methodology	1	NA	Study 'number(s)' for treatment 2	2	35068168
10.2217/cer-2021-0178	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35068168
10.2217/cer-2021-0178	methodology	1	NA	Anchored comparison?	Yes	35068168
10.2217/cer-2021-0178	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35068168
10.2217/cer-2021-0178	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	35068168
10.2217/cer-2021-0178	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35068168
10.2217/cer-2021-0178	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)	35068168
10.2217/cer-2021-0178	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	35068168
10.2217/cer-2021-0178	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	35068168
10.2217/cer-2021-0178	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35068168
10.2217/cer-2021-0178	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35068168
10.2217/cer-2021-0178	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35068168
10.2217/cer-2021-0178	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	114	35068168
10.2217/cer-2021-0178	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	112	35068168
10.2217/cer-2021-0178	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	44	35068168
10.2217/cer-2021-0178	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35068168
10.2217/cer-2021-0178	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35068168
10.2217/cer-2021-0178	results	1	NA	Number of covariates adjusted for/matched on	4	35068168
10.2217/cer-2021-0178	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	35068168
10.2217/cer-2021-0178	results	1	NA	Primary outcome: treatment effect contrast	Means difference	35068168
10.2217/cer-2021-0178	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35068168
10.2217/cer-2021-0178	results	1	NA	Primary outcome: unadjusted treatment effect	0.57	35068168
10.2217/cer-2021-0178	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.818	35068168
10.2217/cer-2021-0178	results	1	NA	Primary outcome: adjusted treatment effect	0.15	35068168
10.2217/cer-2021-0178	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.953	35068168
10.2217/cer-2021-0178	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	35068168
10.2217/cer-2021-0178	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2021-0178	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2021-0178	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02469090	NA
10.2217/cer-2021-0178	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0178	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0178	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0178	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2021-0178	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2021-0178	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0178	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0178	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0178	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02240030	NA
10.2217/cer-2021-0216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy	NA
10.2217/cer-2021-0216	general_information	NA	NA	Countries of first author affiliations	switzerland	NA
10.2217/cer-2021-0216	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.2217/cer-2021-0216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2021-0216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2021-0216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2021-0216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2021-0216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer-2021-0216	methodology	1	NA	Treatment name 1	risdiplam	35040693
10.2217/cer-2021-0216	methodology	1	NA	Study 'number(s)' for treatment 1	1	35040693
10.2217/cer-2021-0216	methodology	1	NA	Treatment name 2	nusinersen	35040693
10.2217/cer-2021-0216	methodology	1	NA	Study 'number(s)' for treatment 2	3	35040693
10.2217/cer-2021-0216	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35040693
10.2217/cer-2021-0216	methodology	1	NA	Anchored comparison?	No	35040693
10.2217/cer-2021-0216	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35040693
10.2217/cer-2021-0216	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35040693
10.2217/cer-2021-0216	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35040693
10.2217/cer-2021-0216	methodology	1	NA	Primary outcome: variable type	Time-to-event	35040693
10.2217/cer-2021-0216	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	35040693
10.2217/cer-2021-0216	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35040693
10.2217/cer-2021-0216	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35040693
10.2217/cer-2021-0216	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	35040693
10.2217/cer-2021-0216	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35040693
10.2217/cer-2021-0216	methodology	2	NA	Treatment name 1	risdiplam	35040693
10.2217/cer-2021-0216	methodology	2	NA	Study 'number(s)' for treatment 1	1	35040693
10.2217/cer-2021-0216	methodology	2	NA	Treatment name 2	NA	35040693
10.2217/cer-2021-0216	methodology	2	NA	Study 'number(s)' for treatment 2	5	35040693
10.2217/cer-2021-0216	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	35040693
10.2217/cer-2021-0216	methodology	2	NA	Anchored comparison?	No	35040693
10.2217/cer-2021-0216	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35040693
10.2217/cer-2021-0216	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35040693
10.2217/cer-2021-0216	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	event-free survival	35040693
10.2217/cer-2021-0216	methodology	2	NA	Primary outcome: variable type	Time-to-event	35040693
10.2217/cer-2021-0216	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	35040693
10.2217/cer-2021-0216	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35040693
10.2217/cer-2021-0216	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	35040693
10.2217/cer-2021-0216	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35040693
10.2217/cer-2021-0216	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35040693
10.2217/cer-2021-0216	methodology	3	NA	Treatment name 1	risdiplam	35040693
10.2217/cer-2021-0216	methodology	3	NA	Study 'number(s)' for treatment 1	2	35040693
10.2217/cer-2021-0216	methodology	3	NA	Treatment name 2	nusinersen	35040693
10.2217/cer-2021-0216	methodology	3	NA	Study 'number(s)' for treatment 2	4	35040693
10.2217/cer-2021-0216	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	35040693
10.2217/cer-2021-0216	methodology	3	NA	Anchored comparison?	Yes	35040693
10.2217/cer-2021-0216	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35040693
10.2217/cer-2021-0216	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35040693
10.2217/cer-2021-0216	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35040693
10.2217/cer-2021-0216	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)	35040693
10.2217/cer-2021-0216	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	35040693
10.2217/cer-2021-0216	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35040693
10.2217/cer-2021-0216	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35040693
10.2217/cer-2021-0216	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	35040693
10.2217/cer-2021-0216	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35040693
10.2217/cer-2021-0216	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	121	35040693
10.2217/cer-2021-0216	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	58	35040693
10.2217/cer-2021-0216	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36.5	35040693
10.2217/cer-2021-0216	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	35040693
10.2217/cer-2021-0216	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35040693
10.2217/cer-2021-0216	results	1	NA	Number of covariates adjusted for/matched on	3	35040693
10.2217/cer-2021-0216	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	35040693
10.2217/cer-2021-0216	results	1	NA	Primary outcome: treatment effect contrast	HR	35040693
10.2217/cer-2021-0216	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35040693
10.2217/cer-2021-0216	results	1	NA	Primary outcome: unadjusted treatment effect	0.24	35040693
10.2217/cer-2021-0216	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.09;0.46]	35040693
10.2217/cer-2021-0216	results	1	NA	Primary outcome: adjusted treatment effect	0.2	35040693
10.2217/cer-2021-0216	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.06;0.42]	35040693
10.2217/cer-2021-0216	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	22	35040693
10.2217/cer-2021-0216	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	58	35040693
10.2217/cer-2021-0216	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	58	35040693
10.2217/cer-2021-0216	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35040693
10.2217/cer-2021-0216	results	2	NA	Number of covariates adjusted for/matched on	2	35040693
10.2217/cer-2021-0216	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	35040693
10.2217/cer-2021-0216	results	2	NA	Primary outcome: treatment effect contrast	HR	35040693
10.2217/cer-2021-0216	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35040693
10.2217/cer-2021-0216	results	2	NA	Primary outcome: unadjusted treatment effect	NA	35040693
10.2217/cer-2021-0216	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.721;2.665]	35040693
10.2217/cer-2021-0216	results	2	NA	Primary outcome: adjusted treatment effect	NA	35040693
10.2217/cer-2021-0216	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35040693
10.2217/cer-2021-0216	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	35040693
10.2217/cer-2021-0216	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	35040693
10.2217/cer-2021-0216	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	43	35040693
10.2217/cer-2021-0216	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	28.3	35040693
10.2217/cer-2021-0216	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	25	35040693
10.2217/cer-2021-0216	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	8.8	35040693
10.2217/cer-2021-0216	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	35040693
10.2217/cer-2021-0216	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35040693
10.2217/cer-2021-0216	results	3	NA	Number of covariates adjusted for/matched on	3	35040693
10.2217/cer-2021-0216	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	35040693
10.2217/cer-2021-0216	results	3	NA	Primary outcome: treatment effect contrast	Means difference	35040693
10.2217/cer-2021-0216	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35040693
10.2217/cer-2021-0216	results	3	NA	Primary outcome: unadjusted treatment effect	-0.6	35040693
10.2217/cer-2021-0216	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-2.24;1.22]	35040693
10.2217/cer-2021-0216	results	3	NA	Primary outcome: adjusted treatment effect	-0.49	35040693
10.2217/cer-2021-0216	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.33;2.53]	35040693
10.2217/cer-2021-0216	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2021-0216	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2021-0216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02913482	NA
10.2217/cer-2021-0216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2217/cer-2021-0216	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2021-0216	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer-2021-0216	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2021-0216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02908685	NA
10.2217/cer-2021-0216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.2217/cer-2021-0216	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0216	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer-2021-0216	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer-2021-0216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02193074	NA
10.2217/cer-2021-0216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0216	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0216	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer-2021-0216	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer-2021-0216	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02292537	NA
10.2217/cer-2021-0216	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0216	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0216	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0216	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer-2021-0216	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer-2021-0216	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277	NA
10.2217/cer-2021-0216	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer-2021-0216	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0216	study_information	NA	5	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer-2021-0221	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer	NA
10.2217/cer-2021-0221	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer-2021-0221	general_information	NA	NA	Countries of last author affiliations	canada	NA
10.2217/cer-2021-0221	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer-2021-0221	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer-2021-0221	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer-2021-0221	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer-2021-0221	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 1	NA	34751591
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 1	1	34751591
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 2	NA	34751591
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 2	2	34751591
10.2217/cer-2021-0221	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34751591
10.2217/cer-2021-0221	methodology	1	NA	Anchored comparison?	Yes	34751591
10.2217/cer-2021-0221	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34751591
10.2217/cer-2021-0221	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34751591
10.2217/cer-2021-0221	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34751591
10.2217/cer-2021-0221	methodology	1	NA	Primary outcome: variable type	NA	34751591
10.2217/cer-2021-0221	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34751591
10.2217/cer-2021-0221	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	34751591
10.2217/cer-2021-0221	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	34751591
10.2217/cer-2021-0221	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34751591
10.2217/cer-2021-0221	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34751591
10.2217/cer-2021-0221	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34751591
10.2217/cer-2021-0221	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	34751591
10.2217/cer-2021-0221	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials	34751591
10.2217/cer-2021-0221	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	34751591
10.2217/cer-2021-0221	results	1	NA	Number of covariates adjusted for/matched on	11	34751591
10.2217/cer-2021-0221	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)	34751591
10.2217/cer-2021-0221	results	1	NA	Primary outcome: treatment effect contrast	Means difference	34751591
10.2217/cer-2021-0221	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	34751591
10.2217/cer-2021-0221	results	1	NA	Primary outcome: unadjusted treatment effect	4.6	34751591
10.2217/cer-2021-0221	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.016	34751591
10.2217/cer-2021-0221	results	1	NA	Primary outcome: adjusted treatment effect	6.95	34751591
10.2217/cer-2021-0221	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004	34751591
10.2217/cer-2021-0221	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	34751591
10.2217/cer-2021-0221	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	34751591
10.2217/cer-2021-0221	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer-2021-0221	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer-2021-0221	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135	NA
10.2217/cer-2021-0221	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0221	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0221	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer-2021-0221	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer-2021-0221	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer-2021-0221	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703	NA
10.2217/cer-2021-0221	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer-2021-0221	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer-2021-0221	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	general_information	NA	NA	Medical Condition of Interest Name	chronic genotype 1b hepatitis c	NA
10.2217/cer.15.33	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer.15.33	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer.15.33	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer.15.33	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer.15.33	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer.15.33	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer.15.33	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer.15.33	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 1	2;3	26159375
10.2217/cer.15.33	methodology	1	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6	26159375
10.2217/cer.15.33	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	1	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	2	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 1	2;3	26159375
10.2217/cer.15.33	methodology	2	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 2	8	26159375
10.2217/cer.15.33	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	2	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	3	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 1	2;3	26159375
10.2217/cer.15.33	methodology	3	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 2	10;11	26159375
10.2217/cer.15.33	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	3	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	4	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 1	2;3	26159375
10.2217/cer.15.33	methodology	4	NA	Treatment name 2	sofosbuvir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 2	13	26159375
10.2217/cer.15.33	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	4	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	5	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 1	2;3	26159375
10.2217/cer.15.33	methodology	5	NA	Treatment name 2	peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 2	4;8;10;11	26159375
10.2217/cer.15.33	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	5	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	5	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	6	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3	26159375
10.2217/cer.15.33	methodology	6	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 2	7	26159375
10.2217/cer.15.33	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	6	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	6	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	7	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 1	1;2;3	26159375
10.2217/cer.15.33	methodology	7	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 2	9	26159375
10.2217/cer.15.33	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	7	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	7	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	7	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	8	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 1	1;2;3	26159375
10.2217/cer.15.33	methodology	8	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 2	12	26159375
10.2217/cer.15.33	methodology	8	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	8	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	8	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	8	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	8	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	8	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	8	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	8	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	8	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	8	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	8	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	methodology	9	NA	Treatment name 1	daclatasvir + asunaprevir	26159375
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 1	1;2;3	26159375
10.2217/cer.15.33	methodology	9	NA	Treatment name 2	peginterferon- + ribavirin	26159375
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 2	9;12	26159375
10.2217/cer.15.33	methodology	9	NA	Type of population-adjusted indirect comparisons performed	MAIC	26159375
10.2217/cer.15.33	methodology	9	NA	Anchored comparison?	No	26159375
10.2217/cer.15.33	methodology	9	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26159375
10.2217/cer.15.33	methodology	9	NA	Definition of a single primary outcome for the indirect comparison	Yes	26159375
10.2217/cer.15.33	methodology	9	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26159375
10.2217/cer.15.33	methodology	9	NA	Primary outcome: variable type	Binary (eg rates)	26159375
10.2217/cer.15.33	methodology	9	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26159375
10.2217/cer.15.33	methodology	9	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26159375
10.2217/cer.15.33	methodology	9	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26159375
10.2217/cer.15.33	methodology	9	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26159375
10.2217/cer.15.33	methodology	9	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26159375
10.2217/cer.15.33	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	1	NA	Primary outcome: adjusted treatment effect	8.7	26159375
10.2217/cer.15.33	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	368	26159375
10.2217/cer.15.33	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	2	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	2	NA	Primary outcome: adjusted treatment effect	16.5	26159375
10.2217/cer.15.33	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	521	26159375
10.2217/cer.15.33	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	3	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	3	NA	Primary outcome: adjusted treatment effect	0.4	26159375
10.2217/cer.15.33	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-8.9;9.7]	26159375
10.2217/cer.15.33	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	26159375
10.2217/cer.15.33	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	327	26159375
10.2217/cer.15.33	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	4	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	4	NA	Primary outcome: adjusted treatment effect	3	26159375
10.2217/cer.15.33	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-21.2;27.1]	26159375
10.2217/cer.15.33	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	988	26159375
10.2217/cer.15.33	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	5	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	5	NA	Primary outcome: adjusted treatment effect	39.6	26159375
10.2217/cer.15.33	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	26159375
10.2217/cer.15.33	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	6	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	6	NA	Primary outcome: adjusted treatment effect	17	26159375
10.2217/cer.15.33	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	162	26159375
10.2217/cer.15.33	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	7	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	7	NA	Primary outcome: adjusted treatment effect	22.8	26159375
10.2217/cer.15.33	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	8	NA	Sample size of the population of interest in the non IPD treatment arm	260	26159375
10.2217/cer.15.33	results	8	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	8	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	8	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	8	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	8	NA	Primary outcome: adjusted treatment effect	10.3	26159375
10.2217/cer.15.33	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	8	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	results	9	NA	Sample size of the population of interest in the non IPD treatment arm	213	26159375
10.2217/cer.15.33	results	9	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26159375
10.2217/cer.15.33	results	9	NA	Reporting of the list of the covariates adjusted for/matched on	No	26159375
10.2217/cer.15.33	results	9	NA	Primary outcome: treatment effect contrast	Rate difference	26159375
10.2217/cer.15.33	results	9	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	26159375
10.2217/cer.15.33	results	9	NA	Primary outcome: adjusted treatment effect	57.7	26159375
10.2217/cer.15.33	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26159375
10.2217/cer.15.33	results	9	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	26159375
10.2217/cer.15.33	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer.15.33	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834	NA
10.2217/cer.15.33	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2217/cer.15.33	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer.15.33	study_information	NA	10	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	10	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01289782	NA
10.2217/cer.15.33	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	10	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	10	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	11	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	11	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	11	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01290679	NA
10.2217/cer.15.33	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	11	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	11	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	12	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	12	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01281839	NA
10.2217/cer.15.33	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	12	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	12	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	13	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	13	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	13	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01641640	NA
10.2217/cer.15.33	study_information	NA	13	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/cer.15.33	study_information	NA	13	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	13	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer.15.33	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer.15.33	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01581203	NA
10.2217/cer.15.33	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	3	Patient-level data used	Yes	NA
10.2217/cer.15.33	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145	NA
10.2217/cer.15.33	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2217/cer.15.33	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00627926	NA
10.2217/cer.15.33	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	5	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01241760	NA
10.2217/cer.15.33	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	6	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	6	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00758043	NA
10.2217/cer.15.33	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	7	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	7	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00703118	NA
10.2217/cer.15.33	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.33	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	8	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	8	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00705432	NA
10.2217/cer.15.33	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.2217/cer.15.33	study_information	NA	9	Patient-level data used	No	NA
10.2217/cer.15.33	study_information	NA	9	Clinical Trial	Yes	NA
10.2217/cer.15.33	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00708500	NA
10.2217/cer.15.33	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.33	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.33	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
10.2217/cer.15.49	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c genotype 3	NA
10.2217/cer.15.49	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer.15.49	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer.15.49	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer.15.49	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer.15.49	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer.15.49	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer.15.49	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer.15.49	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir	26390233
10.2217/cer.15.49	methodology	1	NA	Study 'number(s)' for treatment 1	1	26390233
10.2217/cer.15.49	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin	26390233
10.2217/cer.15.49	methodology	1	NA	Study 'number(s)' for treatment 2	2	26390233
10.2217/cer.15.49	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	26390233
10.2217/cer.15.49	methodology	1	NA	Anchored comparison?	No	26390233
10.2217/cer.15.49	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	26390233
10.2217/cer.15.49	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	26390233
10.2217/cer.15.49	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26390233
10.2217/cer.15.49	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	26390233
10.2217/cer.15.49	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26390233
10.2217/cer.15.49	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26390233
10.2217/cer.15.49	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26390233
10.2217/cer.15.49	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	26390233
10.2217/cer.15.49	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26390233
10.2217/cer.15.49	methodology	2	NA	Treatment name 1	daclatasvir + sofosbuvir	26390233
10.2217/cer.15.49	methodology	2	NA	Study 'number(s)' for treatment 1	1	26390233
10.2217/cer.15.49	methodology	2	NA	Treatment name 2	NA	26390233
10.2217/cer.15.49	methodology	2	NA	Study 'number(s)' for treatment 2	3;4	26390233
10.2217/cer.15.49	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	26390233
10.2217/cer.15.49	methodology	2	NA	Anchored comparison?	No	26390233
10.2217/cer.15.49	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	26390233
10.2217/cer.15.49	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes	26390233
10.2217/cer.15.49	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26390233
10.2217/cer.15.49	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	26390233
10.2217/cer.15.49	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26390233
10.2217/cer.15.49	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26390233
10.2217/cer.15.49	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26390233
10.2217/cer.15.49	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	26390233
10.2217/cer.15.49	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26390233
10.2217/cer.15.49	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	250	26390233
10.2217/cer.15.49	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	144	26390233
10.2217/cer.15.49	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26390233
10.2217/cer.15.49	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26390233
10.2217/cer.15.49	results	1	NA	Number of covariates adjusted for/matched on	NA	26390233
10.2217/cer.15.49	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	26390233
10.2217/cer.15.49	results	1	NA	Primary outcome: treatment effect contrast	NA	26390233
10.2217/cer.15.49	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	26390233
10.2217/cer.15.49	results	1	NA	Primary outcome: unadjusted treatment effect	NA	26390233
10.2217/cer.15.49	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	26390233
10.2217/cer.15.49	results	1	NA	Primary outcome: adjusted treatment effect	NA	26390233
10.2217/cer.15.49	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26390233
10.2217/cer.15.49	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	492	26390233
10.2217/cer.15.49	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	74	26390233
10.2217/cer.15.49	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26390233
10.2217/cer.15.49	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26390233
10.2217/cer.15.49	results	2	NA	Number of covariates adjusted for/matched on	4	26390233
10.2217/cer.15.49	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)	26390233
10.2217/cer.15.49	results	2	NA	Primary outcome: treatment effect contrast	NA	26390233
10.2217/cer.15.49	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	26390233
10.2217/cer.15.49	results	2	NA	Primary outcome: unadjusted treatment effect	NA	26390233
10.2217/cer.15.49	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	26390233
10.2217/cer.15.49	results	2	NA	Primary outcome: adjusted treatment effect	NA	26390233
10.2217/cer.15.49	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	26390233
10.2217/cer.15.49	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer.15.49	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer.15.49	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032901	NA
10.2217/cer.15.49	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.49	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.49	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer.15.49	study_information	NA	2	Patient-level data used	No	NA
10.2217/cer.15.49	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer.15.49	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01682720	NA
10.2217/cer.15.49	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.49	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.49	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.49	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer.15.49	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer.15.49	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	ferenci et al. (2008)	NA
10.2217/cer.15.49	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.2217/cer.15.49	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.49	study_information	NA	4	Patient-level data used	No	NA
10.2217/cer.15.49	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/cer.15.49	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00077636	NA
10.2217/cer.15.49	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/cer.15.49	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4	NA
10.2217/cer.15.49	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer.15.69	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c virus genotype 1b	NA
10.2217/cer.15.69	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/cer.15.69	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/cer.15.69	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/cer.15.69	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/cer.15.69	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/cer.15.69	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/cer.15.69	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/cer.15.69	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir	26793987
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 1	NA	26793987
10.2217/cer.15.69	methodology	1	NA	Treatment name 2	NA	26793987
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 2	3	26793987
10.2217/cer.15.69	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	26793987
10.2217/cer.15.69	methodology	1	NA	Anchored comparison?	No	26793987
10.2217/cer.15.69	methodology	1	NA	Form of the indirect comparison	NA	26793987
10.2217/cer.15.69	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	26793987
10.2217/cer.15.69	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	26793987
10.2217/cer.15.69	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	26793987
10.2217/cer.15.69	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	26793987
10.2217/cer.15.69	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	26793987
10.2217/cer.15.69	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	26793987
10.2217/cer.15.69	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	26793987
10.2217/cer.15.69	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	26793987
10.2217/cer.15.69	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	171	26793987
10.2217/cer.15.69	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	252	26793987
10.2217/cer.15.69	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	26793987
10.2217/cer.15.69	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	26793987
10.2217/cer.15.69	results	1	NA	Number of covariates adjusted for/matched on	11	26793987
10.2217/cer.15.69	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)	26793987
10.2217/cer.15.69	results	1	NA	Primary outcome: treatment effect contrast	Rate difference	26793987
10.2217/cer.15.69	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	NA	26793987
10.2217/cer.15.69	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.004	26793987
10.2217/cer.15.69	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.398	26793987
10.2217/cer.15.69	results	1	NA	Primary outcome: unadjusted treatment effect	NA	26793987
10.2217/cer.15.69	results	1	NA	Primary outcome: adjusted treatment effect	NA	26793987
10.2217/cer.15.69	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/cer.15.69	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/cer.15.69	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834	NA
10.2217/cer.15.69	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2217/cer.15.69	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.69	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/cer.15.69	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/cer.15.69	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/cer.15.69	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145	NA
10.2217/cer.15.69	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2217/cer.15.69	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.69	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/cer.15.69	study_information	NA	3	Patient-level data used	No	NA
10.2217/cer.15.69	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/cer.15.69	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01975675	NA
10.2217/cer.15.69	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan	NA
10.2217/cer.15.69	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/cer.15.69	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/fon-2020-0823	general_information	NA	NA	Medical Condition of Interest Name	advanced cutaneous squamous cell carcinoma	NA
10.2217/fon-2020-0823	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.2217/fon-2020-0823	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/fon-2020-0823	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/fon-2020-0823	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/fon-2020-0823	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/fon-2020-0823	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/fon-2020-0823	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 2	erlotinib	33052055
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 2	2	33052055
10.2217/fon-2020-0823	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	1	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	1	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 2	gefitinib	33052055
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 2	6	33052055
10.2217/fon-2020-0823	methodology	10	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	10	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	10	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	10	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	10	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	10	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	10	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	10	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	10	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	10	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	10	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 2	dacomitinib	33052055
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 2	7	33052055
10.2217/fon-2020-0823	methodology	11	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	11	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	11	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	11	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	11	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	11	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	11	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	11	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	11	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	11	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	11	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 2	dacomitinib	33052055
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 2	7	33052055
10.2217/fon-2020-0823	methodology	12	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	12	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	12	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	12	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	12	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	12	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	12	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	12	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	12	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	12	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	12	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 2	panitumumab	33052055
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 2	8	33052055
10.2217/fon-2020-0823	methodology	13	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	13	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	13	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	13	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	13	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	13	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	13	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	13	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	13	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	13	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	13	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 2	panitumumab	33052055
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 2	8	33052055
10.2217/fon-2020-0823	methodology	14	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	14	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	14	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	14	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	14	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	14	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	14	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	14	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	14	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	14	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	14	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 2	pembrolizumab	33052055
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 2	9	33052055
10.2217/fon-2020-0823	methodology	15	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	15	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	15	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	15	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	15	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	15	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	15	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	15	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	15	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	15	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	15	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 2	pembrolizumab	33052055
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 2	9	33052055
10.2217/fon-2020-0823	methodology	16	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	16	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	16	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	16	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	16	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	16	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	16	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	16	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	16	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	16	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	16	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 2	pembrolizumab	33052055
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 2	10	33052055
10.2217/fon-2020-0823	methodology	17	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	17	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	17	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	17	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	17	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	17	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	17	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	17	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	17	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	17	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	17	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 2	pembrolizumab	33052055
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 2	10	33052055
10.2217/fon-2020-0823	methodology	18	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	18	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	18	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	18	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	18	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	18	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	18	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	18	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	18	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	18	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	18	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 2	11	33052055
10.2217/fon-2020-0823	methodology	19	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	19	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	19	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	19	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	19	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	19	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	19	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	19	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	19	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	19	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	19	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 2	erlotinib	33052055
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 2	2	33052055
10.2217/fon-2020-0823	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	2	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	2	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 2	11	33052055
10.2217/fon-2020-0823	methodology	20	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	20	NA	Anchored comparison?	NA	33052055
10.2217/fon-2020-0823	methodology	20	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	20	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	20	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	20	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	20	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	20	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	20	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	20	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	20	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 2	platinum-based chemotherapy	33052055
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 2	3	33052055
10.2217/fon-2020-0823	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	3	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	3	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 2	platinum-based chemotherapy	33052055
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 2	3	33052055
10.2217/fon-2020-0823	methodology	4	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	4	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	4	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 2	4	33052055
10.2217/fon-2020-0823	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	5	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	5	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 2	4	33052055
10.2217/fon-2020-0823	methodology	6	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	6	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	6	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 2	5	33052055
10.2217/fon-2020-0823	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	7	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	NA	33052055
10.2217/fon-2020-0823	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	7	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 2	cetuximab	33052055
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 2	5	33052055
10.2217/fon-2020-0823	methodology	8	NA	Type of population-adjusted indirect comparisons performed	STC	33052055
10.2217/fon-2020-0823	methodology	8	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	8	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	8	NA	Definition of a single primary outcome for the indirect comparison	NA	33052055
10.2217/fon-2020-0823	methodology	8	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	8	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	8	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	8	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	8	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	8	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	8	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 1	cemiplimab	33052055
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 1	1	33052055
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 2	gefitinib	33052055
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 2	6	33052055
10.2217/fon-2020-0823	methodology	9	NA	Type of population-adjusted indirect comparisons performed	MAIC	33052055
10.2217/fon-2020-0823	methodology	9	NA	Anchored comparison?	No	33052055
10.2217/fon-2020-0823	methodology	9	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33052055
10.2217/fon-2020-0823	methodology	9	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33052055
10.2217/fon-2020-0823	methodology	9	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33052055
10.2217/fon-2020-0823	methodology	9	NA	Primary outcome: variable type	Time-to-event	33052055
10.2217/fon-2020-0823	methodology	9	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33052055
10.2217/fon-2020-0823	methodology	9	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33052055
10.2217/fon-2020-0823	methodology	9	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	33052055
10.2217/fon-2020-0823	methodology	9	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33052055
10.2217/fon-2020-0823	methodology	9	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33052055
10.2217/fon-2020-0823	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	39	33052055
10.2217/fon-2020-0823	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	1	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	1	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	1	NA	Primary outcome: unadjusted treatment effect	0.28	33052055
10.2217/fon-2020-0823	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]	33052055
10.2217/fon-2020-0823	results	1	NA	Primary outcome: adjusted treatment effect	0.41	33052055
10.2217/fon-2020-0823	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.24;0.70]	33052055
10.2217/fon-2020-0823	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	10	NA	Sample size of the population of interest in the non IPD treatment arm	40	33052055
10.2217/fon-2020-0823	results	10	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	10	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	10	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	10	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	10	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	10	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	10	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	10	NA	Primary outcome: unadjusted treatment effect	0.27	33052055
10.2217/fon-2020-0823	results	10	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.44]	33052055
10.2217/fon-2020-0823	results	10	NA	Primary outcome: adjusted treatment effect	0.29	33052055
10.2217/fon-2020-0823	results	10	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.45]	33052055
10.2217/fon-2020-0823	results	11	NA	Sample size of the population of interest in the non IPD treatment arm	42	33052055
10.2217/fon-2020-0823	results	11	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	11	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	11	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	11	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	11	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	11	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	11	NA	Primary outcome: unadjusted treatment effect	0.2	33052055
10.2217/fon-2020-0823	results	11	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.33]	33052055
10.2217/fon-2020-0823	results	11	NA	Primary outcome: adjusted treatment effect	0.17	33052055
10.2217/fon-2020-0823	results	11	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33052055
10.2217/fon-2020-0823	results	11	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	12	NA	Sample size of the population of interest in the non IPD treatment arm	42	33052055
10.2217/fon-2020-0823	results	12	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	12	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	12	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	12	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	12	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	12	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	12	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	12	NA	Primary outcome: unadjusted treatment effect	0.2	33052055
10.2217/fon-2020-0823	results	12	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.33]	33052055
10.2217/fon-2020-0823	results	12	NA	Primary outcome: adjusted treatment effect	0.07	33052055
10.2217/fon-2020-0823	results	12	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.04;0.13]	33052055
10.2217/fon-2020-0823	results	13	NA	Sample size of the population of interest in the non IPD treatment arm	16	33052055
10.2217/fon-2020-0823	results	13	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	13	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	13	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	13	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	13	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	13	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	13	NA	Primary outcome: unadjusted treatment effect	0.27	33052055
10.2217/fon-2020-0823	results	13	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.54]	33052055
10.2217/fon-2020-0823	results	13	NA	Primary outcome: adjusted treatment effect	0.52	33052055
10.2217/fon-2020-0823	results	13	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.26;1.01]	33052055
10.2217/fon-2020-0823	results	13	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	14	NA	Sample size of the population of interest in the non IPD treatment arm	16	33052055
10.2217/fon-2020-0823	results	14	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	14	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	14	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	14	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	14	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	14	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	14	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	14	NA	Primary outcome: unadjusted treatment effect	0.27	33052055
10.2217/fon-2020-0823	results	14	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.54]	33052055
10.2217/fon-2020-0823	results	14	NA	Primary outcome: adjusted treatment effect	0.36	33052055
10.2217/fon-2020-0823	results	14	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.70]	33052055
10.2217/fon-2020-0823	results	15	NA	Sample size of the population of interest in the non IPD treatment arm	39	33052055
10.2217/fon-2020-0823	results	15	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	15	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	15	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	15	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	15	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	15	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	15	NA	Primary outcome: unadjusted treatment effect	0.41	33052055
10.2217/fon-2020-0823	results	15	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.20;0.87]	33052055
10.2217/fon-2020-0823	results	15	NA	Primary outcome: adjusted treatment effect	0.39	33052055
10.2217/fon-2020-0823	results	15	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.17;0.86]	33052055
10.2217/fon-2020-0823	results	15	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	16	NA	Sample size of the population of interest in the non IPD treatment arm	39	33052055
10.2217/fon-2020-0823	results	16	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	16	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	16	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	16	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	16	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	16	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	16	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	16	NA	Primary outcome: unadjusted treatment effect	0.41	33052055
10.2217/fon-2020-0823	results	16	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.20;0.87]	33052055
10.2217/fon-2020-0823	results	16	NA	Primary outcome: adjusted treatment effect	0.21	33052055
10.2217/fon-2020-0823	results	16	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.09;0.48]	33052055
10.2217/fon-2020-0823	results	17	NA	Sample size of the population of interest in the non IPD treatment arm	105	33052055
10.2217/fon-2020-0823	results	17	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	17	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	17	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	17	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	17	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	17	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	17	NA	Primary outcome: unadjusted treatment effect	0.4	33052055
10.2217/fon-2020-0823	results	17	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.25;0.63]	33052055
10.2217/fon-2020-0823	results	17	NA	Primary outcome: adjusted treatment effect	0.52	33052055
10.2217/fon-2020-0823	results	17	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.34;0.80]	33052055
10.2217/fon-2020-0823	results	17	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	18	NA	Sample size of the population of interest in the non IPD treatment arm	105	33052055
10.2217/fon-2020-0823	results	18	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	18	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	18	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	18	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	18	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	18	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	18	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	18	NA	Primary outcome: unadjusted treatment effect	0.4	33052055
10.2217/fon-2020-0823	results	18	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.25;0.63]	33052055
10.2217/fon-2020-0823	results	18	NA	Primary outcome: adjusted treatment effect	0.26	33052055
10.2217/fon-2020-0823	results	18	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.16;0.42]	33052055
10.2217/fon-2020-0823	results	19	NA	Sample size of the population of interest in the non IPD treatment arm	58	33052055
10.2217/fon-2020-0823	results	19	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	19	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	19	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	19	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	19	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	19	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	19	NA	Primary outcome: unadjusted treatment effect	0.34	33052055
10.2217/fon-2020-0823	results	19	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33052055
10.2217/fon-2020-0823	results	19	NA	Primary outcome: adjusted treatment effect	0.29	33052055
10.2217/fon-2020-0823	results	19	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.16;0.54]	33052055
10.2217/fon-2020-0823	results	19	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	39	33052055
10.2217/fon-2020-0823	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	2	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	2	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	2	NA	Primary outcome: unadjusted treatment effect	0.28	33052055
10.2217/fon-2020-0823	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]	33052055
10.2217/fon-2020-0823	results	2	NA	Primary outcome: adjusted treatment effect	0.23	33052055
10.2217/fon-2020-0823	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.14;0.39]	33052055
10.2217/fon-2020-0823	results	20	NA	Sample size of the population of interest in the non IPD treatment arm	58	33052055
10.2217/fon-2020-0823	results	20	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	20	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	20	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	20	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	20	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	20	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	20	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	20	NA	Primary outcome: unadjusted treatment effect	0.34	33052055
10.2217/fon-2020-0823	results	20	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33052055
10.2217/fon-2020-0823	results	20	NA	Primary outcome: adjusted treatment effect	0.19	33052055
10.2217/fon-2020-0823	results	20	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.11;0.31]	33052055
10.2217/fon-2020-0823	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	3	NA	Number of covariates adjusted for/matched on	4	33052055
10.2217/fon-2020-0823	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	33052055
10.2217/fon-2020-0823	results	3	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	3	NA	Primary outcome: unadjusted treatment effect	0.3	33052055
10.2217/fon-2020-0823	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.58]	33052055
10.2217/fon-2020-0823	results	3	NA	Primary outcome: adjusted treatment effect	0.19	33052055
10.2217/fon-2020-0823	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33052055
10.2217/fon-2020-0823	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	33052055
10.2217/fon-2020-0823	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	4	NA	Number of covariates adjusted for/matched on	4	33052055
10.2217/fon-2020-0823	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	33052055
10.2217/fon-2020-0823	results	4	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	4	NA	Primary outcome: unadjusted treatment effect	0.3	33052055
10.2217/fon-2020-0823	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.58]	33052055
10.2217/fon-2020-0823	results	4	NA	Primary outcome: adjusted treatment effect	0.17	33052055
10.2217/fon-2020-0823	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.09;0.33]	33052055
10.2217/fon-2020-0823	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	36	33052055
10.2217/fon-2020-0823	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	5	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	5	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	5	NA	Primary outcome: unadjusted treatment effect	0.25	33052055
10.2217/fon-2020-0823	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.46]	33052055
10.2217/fon-2020-0823	results	5	NA	Primary outcome: adjusted treatment effect	NA	33052055
10.2217/fon-2020-0823	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.49]	33052055
10.2217/fon-2020-0823	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	6	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	6	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	6	NA	Primary outcome: unadjusted treatment effect	0.25	33052055
10.2217/fon-2020-0823	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.46]	33052055
10.2217/fon-2020-0823	results	6	NA	Primary outcome: adjusted treatment effect	0.11	33052055
10.2217/fon-2020-0823	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.05;0.22]	33052055
10.2217/fon-2020-0823	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	31	33052055
10.2217/fon-2020-0823	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	7	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	7	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	7	NA	Primary outcome: unadjusted treatment effect	0.28	33052055
10.2217/fon-2020-0823	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]	33052055
10.2217/fon-2020-0823	results	7	NA	Primary outcome: adjusted treatment effect	0.37	33052055
10.2217/fon-2020-0823	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.69]	33052055
10.2217/fon-2020-0823	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	results	8	NA	Sample size of the population of interest in the non IPD treatment arm	31	33052055
10.2217/fon-2020-0823	results	8	NA	Initial sample size of the population of interest in the IPD treatment arm	193	33052055
10.2217/fon-2020-0823	results	8	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193	33052055
10.2217/fon-2020-0823	results	8	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	8	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	8	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	8	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	8	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	8	NA	Primary outcome: unadjusted treatment effect	0.28	33052055
10.2217/fon-2020-0823	results	8	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]	33052055
10.2217/fon-2020-0823	results	8	NA	Primary outcome: adjusted treatment effect	0.25	33052055
10.2217/fon-2020-0823	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.14;0.44]	33052055
10.2217/fon-2020-0823	results	9	NA	Sample size of the population of interest in the non IPD treatment arm	40	33052055
10.2217/fon-2020-0823	results	9	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	33052055
10.2217/fon-2020-0823	results	9	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33052055
10.2217/fon-2020-0823	results	9	NA	Number of covariates adjusted for/matched on	NA	33052055
10.2217/fon-2020-0823	results	9	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33052055
10.2217/fon-2020-0823	results	9	NA	Primary outcome: treatment effect contrast	HR	33052055
10.2217/fon-2020-0823	results	9	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33052055
10.2217/fon-2020-0823	results	9	NA	Primary outcome: unadjusted treatment effect	0.27	33052055
10.2217/fon-2020-0823	results	9	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.44]	33052055
10.2217/fon-2020-0823	results	9	NA	Primary outcome: adjusted treatment effect	0.47	33052055
10.2217/fon-2020-0823	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.29;0.75]	33052055
10.2217/fon-2020-0823	results	9	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	33052055
10.2217/fon-2020-0823	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/fon-2020-0823	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02760498	NA
10.2217/fon-2020-0823	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2020-0823	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	10	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	10	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03284424	NA
10.2217/fon-2020-0823	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2020-0823	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	10	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	11	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	11	Clinical Trial	No	NA
10.2217/fon-2020-0823	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	peyrade et al. (2018)	NA
10.2217/fon-2020-0823	study_information	NA	2	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01198028	NA
10.2217/fon-2020-0823	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/fon-2020-0823	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	3	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	3	Clinical Trial	No	NA
10.2217/fon-2020-0823	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jarkowski et al. (2016)	NA
10.2217/fon-2020-0823	study_information	NA	4	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00240682	NA
10.2217/fon-2020-0823	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.2217/fon-2020-0823	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	5	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	5	Clinical Trial	No	NA
10.2217/fon-2020-0823	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	picard et al. (2017)	NA
10.2217/fon-2020-0823	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.2217/fon-2020-0823	study_information	NA	6	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	6	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00054691	NA
10.2217/fon-2020-0823	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/fon-2020-0823	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	6	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	7	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	7	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02268747	NA
10.2217/fon-2020-0823	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/fon-2020-0823	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	7	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	8	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	8	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	foote et al. (2014)	NA
10.2217/fon-2020-0823	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	australia	NA
10.2217/fon-2020-0823	study_information	NA	8	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	8	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2020-0823	study_information	NA	9	Patient-level data used	No	NA
10.2217/fon-2020-0823	study_information	NA	9	Clinical Trial	Yes	NA
10.2217/fon-2020-0823	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02883556	NA
10.2217/fon-2020-0823	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.2217/fon-2020-0823	study_information	NA	9	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2020-0823	study_information	NA	9	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1102	general_information	NA	NA	Medical Condition of Interest Name	ros1-positive non-small-cell lung cancer	NA
10.2217/fon-2021-1102	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/fon-2021-1102	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/fon-2021-1102	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/fon-2021-1102	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/fon-2021-1102	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/fon-2021-1102	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/fon-2021-1102	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 1	crizotinib	35232230
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 1	1	35232230
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 2	entrectinib	35232230
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4	35232230
10.2217/fon-2021-1102	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	35232230
10.2217/fon-2021-1102	methodology	1	NA	Anchored comparison?	No	35232230
10.2217/fon-2021-1102	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	35232230
10.2217/fon-2021-1102	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35232230
10.2217/fon-2021-1102	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35232230
10.2217/fon-2021-1102	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	35232230
10.2217/fon-2021-1102	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35232230
10.2217/fon-2021-1102	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	35232230
10.2217/fon-2021-1102	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	35232230
10.2217/fon-2021-1102	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35232230
10.2217/fon-2021-1102	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35232230
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 1	crizotinib	35232230
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 1	1	35232230
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 2	crizotinib	35232230
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 2	5	35232230
10.2217/fon-2021-1102	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC	35232230
10.2217/fon-2021-1102	methodology	2	NA	Anchored comparison?	No	35232230
10.2217/fon-2021-1102	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35232230
10.2217/fon-2021-1102	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35232230
10.2217/fon-2021-1102	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	35232230
10.2217/fon-2021-1102	methodology	2	NA	Primary outcome: variable type	Time-to-event	35232230
10.2217/fon-2021-1102	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35232230
10.2217/fon-2021-1102	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35232230
10.2217/fon-2021-1102	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35232230
10.2217/fon-2021-1102	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35232230
10.2217/fon-2021-1102	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35232230
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 1	crizotinib	35232230
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 1	1	35232230
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 2	crizotinib	35232230
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 2	6	35232230
10.2217/fon-2021-1102	methodology	3	NA	Type of population-adjusted indirect comparisons performed	STC	35232230
10.2217/fon-2021-1102	methodology	3	NA	Anchored comparison?	No	35232230
10.2217/fon-2021-1102	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	35232230
10.2217/fon-2021-1102	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes	35232230
10.2217/fon-2021-1102	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	35232230
10.2217/fon-2021-1102	methodology	3	NA	Primary outcome: variable type	Time-to-event	35232230
10.2217/fon-2021-1102	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35232230
10.2217/fon-2021-1102	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35232230
10.2217/fon-2021-1102	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35232230
10.2217/fon-2021-1102	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35232230
10.2217/fon-2021-1102	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	NA	35232230
10.2217/fon-2021-1102	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	161	35232230
10.2217/fon-2021-1102	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	53	35232230
10.2217/fon-2021-1102	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53	35232230
10.2217/fon-2021-1102	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35232230
10.2217/fon-2021-1102	results	1	NA	Number of covariates adjusted for/matched on	4	35232230
10.2217/fon-2021-1102	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35232230
10.2217/fon-2021-1102	results	1	NA	Primary outcome: treatment effect contrast	RR	35232230
10.2217/fon-2021-1102	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35232230
10.2217/fon-2021-1102	results	1	NA	Primary outcome: unadjusted treatment effect	1.07	35232230
10.2217/fon-2021-1102	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	35232230
10.2217/fon-2021-1102	results	1	NA	Primary outcome: adjusted treatment effect	1.04	35232230
10.2217/fon-2021-1102	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35232230
10.2217/fon-2021-1102	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	69	35232230
10.2217/fon-2021-1102	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	53	35232230
10.2217/fon-2021-1102	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53	35232230
10.2217/fon-2021-1102	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35232230
10.2217/fon-2021-1102	results	2	NA	Number of covariates adjusted for/matched on	2	35232230
10.2217/fon-2021-1102	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35232230
10.2217/fon-2021-1102	results	2	NA	Primary outcome: treatment effect contrast	NA	35232230
10.2217/fon-2021-1102	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35232230
10.2217/fon-2021-1102	results	2	NA	Primary outcome: unadjusted treatment effect	10.8	35232230
10.2217/fon-2021-1102	results	2	NA	Primary outcome: adjusted treatment effect	8.3	35232230
10.2217/fon-2021-1102	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35232230
10.2217/fon-2021-1102	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	38	35232230
10.2217/fon-2021-1102	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	53	35232230
10.2217/fon-2021-1102	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53	35232230
10.2217/fon-2021-1102	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35232230
10.2217/fon-2021-1102	results	3	NA	Number of covariates adjusted for/matched on	4	35232230
10.2217/fon-2021-1102	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35232230
10.2217/fon-2021-1102	results	3	NA	Primary outcome: treatment effect contrast	NA	35232230
10.2217/fon-2021-1102	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35232230
10.2217/fon-2021-1102	results	3	NA	Primary outcome: unadjusted treatment effect	15.2	35232230
10.2217/fon-2021-1102	results	3	NA	Primary outcome: adjusted treatment effect	-10.5	35232230
10.2217/fon-2021-1102	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	NA	35232230
10.2217/fon-2021-1102	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/fon-2021-1102	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/fon-2021-1102	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195	NA
10.2217/fon-2021-1102	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1102	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	2	Patient-level data used	No	NA
10.2217/fon-2021-1102	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/fon-2021-1102	study_information	NA	2	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88	NA
10.2217/fon-2021-1102	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.2217/fon-2021-1102	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	3	Patient-level data used	No	NA
10.2217/fon-2021-1102	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/fon-2021-1102	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810	NA
10.2217/fon-2021-1102	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1102	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	4	Patient-level data used	No	NA
10.2217/fon-2021-1102	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/fon-2021-1102	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267	NA
10.2217/fon-2021-1102	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1102	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2021-1102	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1102	study_information	NA	5	Patient-level data used	No	NA
10.2217/fon-2021-1102	study_information	NA	5	Clinical Trial	No	NA
10.2217/fon-2021-1102	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	flatiron health	NA
10.2217/fon-2021-1102	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/fon-2021-1102	study_information	NA	6	Patient-level data used	No	NA
10.2217/fon-2021-1102	study_information	NA	6	Clinical Trial	No	NA
10.2217/fon-2021-1102	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	ontada (oncology insights & technology)	NA
10.2217/fon-2021-1102	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/fon-2021-1509	general_information	NA	NA	Medical Condition of Interest Name	advanced systemic mastocytosis	NA
10.2217/fon-2021-1509	general_information	NA	NA	Countries of first author affiliations	uk	NA
10.2217/fon-2021-1509	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.2217/fon-2021-1509	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/fon-2021-1509	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/fon-2021-1509	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/fon-2021-1509	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/fon-2021-1509	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/fon-2021-1509	methodology	1	NA	Treatment name 1	avapritinib	35114819
10.2217/fon-2021-1509	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	35114819
10.2217/fon-2021-1509	methodology	1	NA	Treatment name 2	midostaurin	35114819
10.2217/fon-2021-1509	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	35114819
10.2217/fon-2021-1509	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35114819
10.2217/fon-2021-1509	methodology	1	NA	Anchored comparison?	No	35114819
10.2217/fon-2021-1509	methodology	1	NA	Form of the indirect comparison	NA	35114819
10.2217/fon-2021-1509	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	NA	35114819
10.2217/fon-2021-1509	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	35114819
10.2217/fon-2021-1509	methodology	1	NA	Primary outcome: variable type	Time-to-event	35114819
10.2217/fon-2021-1509	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset	35114819
10.2217/fon-2021-1509	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	35114819
10.2217/fon-2021-1509	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	35114819
10.2217/fon-2021-1509	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35114819
10.2217/fon-2021-1509	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35114819
10.2217/fon-2021-1509	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	115	35114819
10.2217/fon-2021-1509	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	85	35114819
10.2217/fon-2021-1509	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35114819
10.2217/fon-2021-1509	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	NA	35114819
10.2217/fon-2021-1509	results	1	NA	Primary outcome: treatment effect contrast	HR	35114819
10.2217/fon-2021-1509	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35114819
10.2217/fon-2021-1509	results	1	NA	Primary outcome: unadjusted treatment effect	0.54	35114819
10.2217/fon-2021-1509	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.32;0.92]	35114819
10.2217/fon-2021-1509	results	1	NA	Primary outcome: adjusted treatment effect	0.44	35114819
10.2217/fon-2021-1509	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.25;0.76]	35114819
10.2217/fon-2021-1509	results	1	NA	Number of covariates adjusted for/matched on	NA	35114819
10.2217/fon-2021-1509	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35114819
10.2217/fon-2021-1509	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/fon-2021-1509	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/fon-2021-1509	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561988	NA
10.2217/fon-2021-1509	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1509	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1	NA
10.2217/fon-2021-1509	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1509	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/fon-2021-1509	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/fon-2021-1509	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03580655	NA
10.2217/fon-2021-1509	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1509	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2021-1509	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1509	study_information	NA	3	Patient-level data used	No	NA
10.2217/fon-2021-1509	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/fon-2021-1509	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00782067	NA
10.2217/fon-2021-1509	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/fon-2021-1509	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2021-1509	study_information	NA	3	Number of treatment arms (clinical trial only)	1	NA
10.2217/fon-2021-1509	study_information	NA	4	Patient-level data used	No	NA
10.2217/fon-2021-1509	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/fon-2021-1509	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00233454	NA
10.2217/fon-2021-1509	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.2217/fon-2021-1509	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/fon-2021-1509	study_information	NA	4	Number of treatment arms (clinical trial only)	1	NA
10.2217/imt-2018-0208	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma	NA
10.2217/imt-2018-0208	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/imt-2018-0208	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/imt-2018-0208	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/imt-2018-0208	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/imt-2018-0208	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/imt-2018-0208	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/imt-2018-0208	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.2217/imt-2018-0208	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab	30852924
10.2217/imt-2018-0208	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	30852924
10.2217/imt-2018-0208	methodology	1	NA	Treatment name 2	dabrafenib + trametinib	30852924
10.2217/imt-2018-0208	methodology	1	NA	Study 'number(s)' for treatment 2	3;4	30852924
10.2217/imt-2018-0208	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30852924
10.2217/imt-2018-0208	methodology	1	NA	Anchored comparison?	No	30852924
10.2217/imt-2018-0208	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30852924
10.2217/imt-2018-0208	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30852924
10.2217/imt-2018-0208	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	30852924
10.2217/imt-2018-0208	methodology	1	NA	Primary outcome: variable type	Time-to-event	30852924
10.2217/imt-2018-0208	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30852924
10.2217/imt-2018-0208	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30852924
10.2217/imt-2018-0208	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30852924
10.2217/imt-2018-0208	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30852924
10.2217/imt-2018-0208	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30852924
10.2217/imt-2018-0208	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab	30852924
10.2217/imt-2018-0208	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	30852924
10.2217/imt-2018-0208	methodology	2	NA	Treatment name 2	vemurafenib + cobimetinib	30852924
10.2217/imt-2018-0208	methodology	2	NA	Study 'number(s)' for treatment 2	5	30852924
10.2217/imt-2018-0208	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30852924
10.2217/imt-2018-0208	methodology	2	NA	Anchored comparison?	No	30852924
10.2217/imt-2018-0208	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30852924
10.2217/imt-2018-0208	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30852924
10.2217/imt-2018-0208	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	30852924
10.2217/imt-2018-0208	methodology	2	NA	Primary outcome: variable type	Time-to-event	30852924
10.2217/imt-2018-0208	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	30852924
10.2217/imt-2018-0208	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30852924
10.2217/imt-2018-0208	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30852924
10.2217/imt-2018-0208	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30852924
10.2217/imt-2018-0208	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30852924
10.2217/imt-2018-0208	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	563	30852924
10.2217/imt-2018-0208	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	124	30852924
10.2217/imt-2018-0208	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	106.3	30852924
10.2217/imt-2018-0208	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30852924
10.2217/imt-2018-0208	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30852924
10.2217/imt-2018-0208	results	1	NA	Number of covariates adjusted for/matched on	7	30852924
10.2217/imt-2018-0208	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest	30852924
10.2217/imt-2018-0208	results	1	NA	Primary outcome: treatment effect contrast	HR	30852924
10.2217/imt-2018-0208	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30852924
10.2217/imt-2018-0208	results	1	NA	Primary outcome: unadjusted treatment effect	0.58	30852924
10.2217/imt-2018-0208	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.001	30852924
10.2217/imt-2018-0208	results	1	NA	Primary outcome: adjusted treatment effect	0.64	30852924
10.2217/imt-2018-0208	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.009	30852924
10.2217/imt-2018-0208	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	247	30852924
10.2217/imt-2018-0208	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	124	30852924
10.2217/imt-2018-0208	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	59.2	30852924
10.2217/imt-2018-0208	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30852924
10.2217/imt-2018-0208	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30852924
10.2217/imt-2018-0208	results	2	NA	Number of covariates adjusted for/matched on	8	30852924
10.2217/imt-2018-0208	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)	30852924
10.2217/imt-2018-0208	results	2	NA	Primary outcome: treatment effect contrast	HR	30852924
10.2217/imt-2018-0208	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30852924
10.2217/imt-2018-0208	results	2	NA	Primary outcome: unadjusted treatment effect	0.53	30852924
10.2217/imt-2018-0208	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	30852924
10.2217/imt-2018-0208	results	2	NA	Primary outcome: adjusted treatment effect	0.56	30852924
10.2217/imt-2018-0208	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.014	30852924
10.2217/imt-2018-0208	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/imt-2018-0208	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/imt-2018-0208	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505	NA
10.2217/imt-2018-0208	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2018-0208	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2018-0208	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2018-0208	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/imt-2018-0208	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/imt-2018-0208	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01927419	NA
10.2217/imt-2018-0208	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2018-0208	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.2217/imt-2018-0208	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2018-0208	study_information	NA	3	Patient-level data used	No	NA
10.2217/imt-2018-0208	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/imt-2018-0208	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648	NA
10.2217/imt-2018-0208	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2018-0208	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2018-0208	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2018-0208	study_information	NA	4	Patient-level data used	No	NA
10.2217/imt-2018-0208	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/imt-2018-0208	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908	NA
10.2217/imt-2018-0208	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2018-0208	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2018-0208	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2018-0208	study_information	NA	5	Patient-level data used	No	NA
10.2217/imt-2018-0208	study_information	NA	5	Clinical Trial	Yes	NA
10.2217/imt-2018-0208	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519	NA
10.2217/imt-2018-0208	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2018-0208	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2018-0208	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2020-0266	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma	NA
10.2217/imt-2020-0266	general_information	NA	NA	Countries of first author affiliations	france	NA
10.2217/imt-2020-0266	general_information	NA	NA	Countries of last author affiliations	the netherlands	NA
10.2217/imt-2020-0266	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/imt-2020-0266	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/imt-2020-0266	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/imt-2020-0266	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/imt-2020-0266	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/imt-2020-0266	methodology	1	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	1	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	1	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	1	NA	Study 'number(s)' for treatment 2	2	33228440
10.2217/imt-2020-0266	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	1	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	1	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	33228440
10.2217/imt-2020-0266	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	methodology	2	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	2	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	2	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	2	NA	Study 'number(s)' for treatment 2	2	33228440
10.2217/imt-2020-0266	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	2	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	2	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)	33228440
10.2217/imt-2020-0266	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	methodology	3	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	3	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	3	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	3	NA	Study 'number(s)' for treatment 2	3	33228440
10.2217/imt-2020-0266	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	3	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	3	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33228440
10.2217/imt-2020-0266	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	methodology	4	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	4	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	4	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	4	NA	Study 'number(s)' for treatment 2	3	33228440
10.2217/imt-2020-0266	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	4	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	4	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33228440
10.2217/imt-2020-0266	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	methodology	5	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	5	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	5	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	5	NA	Study 'number(s)' for treatment 2	4	33228440
10.2217/imt-2020-0266	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	5	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	5	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33228440
10.2217/imt-2020-0266	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	methodology	6	NA	Treatment name 1	NA	33228440
10.2217/imt-2020-0266	methodology	6	NA	Study 'number(s)' for treatment 1	1	33228440
10.2217/imt-2020-0266	methodology	6	NA	Treatment name 2	NA	33228440
10.2217/imt-2020-0266	methodology	6	NA	Study 'number(s)' for treatment 2	NA	33228440
10.2217/imt-2020-0266	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC	33228440
10.2217/imt-2020-0266	methodology	6	NA	Anchored comparison?	No	33228440
10.2217/imt-2020-0266	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33228440
10.2217/imt-2020-0266	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33228440
10.2217/imt-2020-0266	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival	33228440
10.2217/imt-2020-0266	methodology	6	NA	Primary outcome: variable type	Time-to-event	33228440
10.2217/imt-2020-0266	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33228440
10.2217/imt-2020-0266	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33228440
10.2217/imt-2020-0266	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33228440
10.2217/imt-2020-0266	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33228440
10.2217/imt-2020-0266	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	543	33228440
10.2217/imt-2020-0266	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	NA	33228440
10.2217/imt-2020-0266	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	1	NA	Number of covariates adjusted for/matched on	4	33228440
10.2217/imt-2020-0266	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	33228440
10.2217/imt-2020-0266	results	1	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	1	NA	Primary outcome: unadjusted treatment effect	0.48	33228440
10.2217/imt-2020-0266	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	1	NA	Primary outcome: adjusted treatment effect	0.47	33228440
10.2217/imt-2020-0266	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	542	33228440
10.2217/imt-2020-0266	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	515	33228440
10.2217/imt-2020-0266	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	2	NA	Number of covariates adjusted for/matched on	4	33228440
10.2217/imt-2020-0266	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)	33228440
10.2217/imt-2020-0266	results	2	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	2	NA	Primary outcome: unadjusted treatment effect	1.07	33228440
10.2217/imt-2020-0266	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.655	33228440
10.2217/imt-2020-0266	results	2	NA	Primary outcome: adjusted treatment effect	1.13	33228440
10.2217/imt-2020-0266	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.419	33228440
10.2217/imt-2020-0266	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	543	33228440
10.2217/imt-2020-0266	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	206	33228440
10.2217/imt-2020-0266	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	3	NA	Number of covariates adjusted for/matched on	12	33228440
10.2217/imt-2020-0266	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33228440
10.2217/imt-2020-0266	results	3	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	3	NA	Primary outcome: unadjusted treatment effect	0.4	33228440
10.2217/imt-2020-0266	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	3	NA	Primary outcome: adjusted treatment effect	0.35	33228440
10.2217/imt-2020-0266	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	542	33228440
10.2217/imt-2020-0266	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	211	33228440
10.2217/imt-2020-0266	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	4	NA	Number of covariates adjusted for/matched on	12	33228440
10.2217/imt-2020-0266	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33228440
10.2217/imt-2020-0266	results	4	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	4	NA	Primary outcome: unadjusted treatment effect	NA	33228440
10.2217/imt-2020-0266	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	NA	33228440
10.2217/imt-2020-0266	results	4	NA	Primary outcome: adjusted treatment effect	NA	33228440
10.2217/imt-2020-0266	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	33228440
10.2217/imt-2020-0266	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	543	33228440
10.2217/imt-2020-0266	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	416	33228440
10.2217/imt-2020-0266	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	5	NA	Number of covariates adjusted for/matched on	7	33228440
10.2217/imt-2020-0266	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33228440
10.2217/imt-2020-0266	results	5	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	5	NA	Primary outcome: unadjusted treatment effect	0.37	33228440
10.2217/imt-2020-0266	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	5	NA	Primary outcome: adjusted treatment effect	0.42	33228440
10.2217/imt-2020-0266	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	33228440
10.2217/imt-2020-0266	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	542	33228440
10.2217/imt-2020-0266	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	393	33228440
10.2217/imt-2020-0266	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33228440
10.2217/imt-2020-0266	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33228440
10.2217/imt-2020-0266	results	6	NA	Number of covariates adjusted for/matched on	7	33228440
10.2217/imt-2020-0266	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	NA	33228440
10.2217/imt-2020-0266	results	6	NA	Primary outcome: treatment effect contrast	HR	33228440
10.2217/imt-2020-0266	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33228440
10.2217/imt-2020-0266	results	6	NA	Primary outcome: unadjusted treatment effect	0.82	33228440
10.2217/imt-2020-0266	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.222	33228440
10.2217/imt-2020-0266	results	6	NA	Primary outcome: adjusted treatment effect	0.94	33228440
10.2217/imt-2020-0266	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.738	33228440
10.2217/imt-2020-0266	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	NA	33228440
10.2217/imt-2020-0266	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/imt-2020-0266	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/imt-2020-0266	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02541383	NA
10.2217/imt-2020-0266	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2020-0266	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2020-0266	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2020-0266	study_information	NA	2	Patient-level data used	No	NA
10.2217/imt-2020-0266	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/imt-2020-0266	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01191060	NA
10.2217/imt-2020-0266	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.2217/imt-2020-0266	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2020-0266	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2020-0266	study_information	NA	3	Patient-level data used	No	NA
10.2217/imt-2020-0266	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/imt-2020-0266	study_information	NA	3	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2010-019173-16	NA
10.2217/imt-2020-0266	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	germany	NA
10.2217/imt-2020-0266	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2020-0266	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2020-0266	study_information	NA	4	Patient-level data used	No	NA
10.2217/imt-2020-0266	study_information	NA	4	Clinical Trial	Yes	NA
10.2217/imt-2020-0266	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00200681	NA
10.2217/imt-2020-0266	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.2217/imt-2020-0266	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2020-0266	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2021-0273	general_information	NA	NA	Medical Condition of Interest Name	metastatic non-small-cell lung cancer with pd-l1	NA
10.2217/imt-2021-0273	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.2217/imt-2021-0273	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.2217/imt-2021-0273	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.2217/imt-2021-0273	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.2217/imt-2021-0273	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.2217/imt-2021-0273	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.2217/imt-2021-0273	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 1	pembrolizumab	35073727
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 1	NA	35073727
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab	35073727
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 2	3	35073727
10.2217/imt-2021-0273	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	35073727
10.2217/imt-2021-0273	methodology	1	NA	Anchored comparison?	Yes	35073727
10.2217/imt-2021-0273	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	35073727
10.2217/imt-2021-0273	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	35073727
10.2217/imt-2021-0273	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	35073727
10.2217/imt-2021-0273	methodology	1	NA	Primary outcome: variable type	Time-to-event	35073727
10.2217/imt-2021-0273	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	35073727
10.2217/imt-2021-0273	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No	35073727
10.2217/imt-2021-0273	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	35073727
10.2217/imt-2021-0273	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	35073727
10.2217/imt-2021-0273	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	35073727
10.2217/imt-2021-0273	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	793	35073727
10.2217/imt-2021-0273	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1428	35073727
10.2217/imt-2021-0273	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	993	35073727
10.2217/imt-2021-0273	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	35073727
10.2217/imt-2021-0273	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	35073727
10.2217/imt-2021-0273	results	1	NA	Number of covariates adjusted for/matched on	8	35073727
10.2217/imt-2021-0273	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	35073727
10.2217/imt-2021-0273	results	1	NA	Primary outcome: treatment effect contrast	HR	35073727
10.2217/imt-2021-0273	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	35073727
10.2217/imt-2021-0273	results	1	NA	Primary outcome: unadjusted treatment effect	0.98	35073727
10.2217/imt-2021-0273	results	1	NA	Primary outcome: adjusted treatment effect	1.07	35073727
10.2217/imt-2021-0273	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	35073727
10.2217/imt-2021-0273	study_information	NA	1	Patient-level data used	Yes	NA
10.2217/imt-2021-0273	study_information	NA	1	Clinical Trial	Yes	NA
10.2217/imt-2021-0273	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02142738	NA
10.2217/imt-2021-0273	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2021-0273	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2021-0273	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2021-0273	study_information	NA	2	Patient-level data used	Yes	NA
10.2217/imt-2021-0273	study_information	NA	2	Clinical Trial	Yes	NA
10.2217/imt-2021-0273	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02220894	NA
10.2217/imt-2021-0273	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2021-0273	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2021-0273	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.2217/imt-2021-0273	study_information	NA	3	Patient-level data used	No	NA
10.2217/imt-2021-0273	study_information	NA	3	Clinical Trial	Yes	NA
10.2217/imt-2021-0273	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826	NA
10.2217/imt-2021-0273	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.2217/imt-2021-0273	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.2217/imt-2021-0273	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.3111/13696998.2013.768530	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.3111/13696998.2013.768530	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.3111/13696998.2013.768530	methodology	1	NA	Treatment name 1	adalimumab	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Study 'number(s)' for treatment 1	1	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Treatment name 2	etanercept	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Study 'number(s)' for treatment 2	2	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Anchored comparison?	Yes	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	23339434
10.3111/13696998.2013.768530	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Treatment name 1	adalimumab	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Study 'number(s)' for treatment 1	1	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Treatment name 2	infliximab	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Study 'number(s)' for treatment 2	3	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Anchored comparison?	Yes	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	23339434
10.3111/13696998.2013.768530	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	23339434
10.3111/13696998.2013.768530	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	101	23339434
10.3111/13696998.2013.768530	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	104	23339434
10.3111/13696998.2013.768530	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	142	23339434
10.3111/13696998.2013.768530	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	154	23339434
10.3111/13696998.2013.768530	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23339434
10.3111/13696998.2013.768530	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23339434
10.3111/13696998.2013.768530	results	1	NA	Number of covariates adjusted for/matched on	NA	23339434
10.3111/13696998.2013.768530	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	23339434
10.3111/13696998.2013.768530	results	1	NA	Primary outcome: treatment effect contrast	NA	23339434
10.3111/13696998.2013.768530	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	23339434
10.3111/13696998.2013.768530	results	1	NA	Primary outcome: adjusted treatment effect	NA	23339434
10.3111/13696998.2013.768530	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	NA	23339434
10.3111/13696998.2013.768530	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	100	23339434
10.3111/13696998.2013.768530	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	100	23339434
10.3111/13696998.2013.768530	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	108	23339434
10.3111/13696998.2013.768530	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	126	23339434
10.3111/13696998.2013.768530	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	23339434
10.3111/13696998.2013.768530	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	23339434
10.3111/13696998.2013.768530	results	2	NA	Number of covariates adjusted for/matched on	NA	23339434
10.3111/13696998.2013.768530	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	NA	23339434
10.3111/13696998.2013.768530	results	2	NA	Primary outcome: treatment effect contrast	NA	23339434
10.3111/13696998.2013.768530	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	23339434
10.3111/13696998.2013.768530	results	2	NA	Primary outcome: adjusted treatment effect	18.9	23339434
10.3111/13696998.2013.768530	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.034	23339434
10.3111/13696998.2013.768530	study_information	NA	1	Patient-level data used	Yes	NA
10.3111/13696998.2013.768530	study_information	NA	1	Clinical Trial	Yes	NA
10.3111/13696998.2013.768530	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689	NA
10.3111/13696998.2013.768530	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.3111/13696998.2013.768530	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.3111/13696998.2013.768530	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.3111/13696998.2013.768530	study_information	NA	2	Patient-level data used	No	NA
10.3111/13696998.2013.768530	study_information	NA	2	Clinical Trial	Yes	NA
10.3111/13696998.2013.768530	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	mease et al. (2004)	NA
10.3111/13696998.2013.768530	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.3111/13696998.2013.768530	study_information	NA	2	Phase of the clinical trial (clinical trial only)	NA	NA
10.3111/13696998.2013.768530	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.3111/13696998.2013.768530	study_information	NA	3	Patient-level data used	No	NA
10.3111/13696998.2013.768530	study_information	NA	3	Clinical Trial	Yes	NA
10.3111/13696998.2013.768530	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	NA	NA
10.3111/13696998.2013.768530	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.3111/13696998.2013.768530	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.3111/13696998.2013.768530	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.3111/13696998.2013.768530	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623	NA
10.3390/biom11060780	general_information	NA	NA	Medical Condition of Interest Name	metastatic pancreatic cancer	NA
10.3390/biom11060780	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.3390/biom11060780	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.3390/biom11060780	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.3390/biom11060780	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.3390/biom11060780	general_information	NA	NA	Mentioned sources of funding	No fundings	NA
10.3390/biom11060780	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None	NA
10.3390/biom11060780	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.3390/biom11060780	methodology	1	NA	Treatment name 1	NA	34067288
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 1	1	34067288
10.3390/biom11060780	methodology	1	NA	Treatment name 2	NA	34067288
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 2	2	34067288
10.3390/biom11060780	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34067288
10.3390/biom11060780	methodology	1	NA	Anchored comparison?	No	34067288
10.3390/biom11060780	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34067288
10.3390/biom11060780	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	34067288
10.3390/biom11060780	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34067288
10.3390/biom11060780	methodology	1	NA	Primary outcome: variable type	Time-to-event	34067288
10.3390/biom11060780	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34067288
10.3390/biom11060780	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34067288
10.3390/biom11060780	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34067288
10.3390/biom11060780	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34067288
10.3390/biom11060780	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34067288
10.3390/biom11060780	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	NA	34067288
10.3390/biom11060780	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	NA	34067288
10.3390/biom11060780	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34067288
10.3390/biom11060780	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	NA	34067288
10.3390/biom11060780	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	NA	34067288
10.3390/biom11060780	results	1	NA	Primary outcome: treatment effect contrast	HR	34067288
10.3390/biom11060780	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference	34067288
10.3390/biom11060780	results	1	NA	Primary outcome: adjusted treatment effect	1.1	34067288
10.3390/biom11060780	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.527	34067288
10.3390/biom11060780	study_information	NA	1	Patient-level data used	Yes	NA
10.3390/biom11060780	study_information	NA	1	Clinical Trial	No	NA
10.3390/biom11060780	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	local retrospective cohort from ehr	NA
10.3390/biom11060780	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.3390/biom11060780	study_information	NA	2	Patient-level data used	No	NA
10.3390/biom11060780	study_information	NA	2	Clinical Trial	Yes	NA
10.3390/biom11060780	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00112658	NA
10.3390/biom11060780	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france	NA
10.3390/biom11060780	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.3390/biom11060780	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.3390/cancers12123648	general_information	NA	NA	Medical Condition of Interest Name	metastatic non small cell lung cancer	NA
10.3390/cancers12123648	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.3390/cancers12123648	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.3390/cancers12123648	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.3390/cancers12123648	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.3390/cancers12123648	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.3390/cancers12123648	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.3390/cancers12123648	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.3390/cancers12123648	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy	33291810
10.3390/cancers12123648	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	33291810
10.3390/cancers12123648	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab	33291810
10.3390/cancers12123648	methodology	1	NA	Study 'number(s)' for treatment 2	4	33291810
10.3390/cancers12123648	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	33291810
10.3390/cancers12123648	methodology	1	NA	Anchored comparison?	Yes	33291810
10.3390/cancers12123648	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	33291810
10.3390/cancers12123648	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	33291810
10.3390/cancers12123648	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival	33291810
10.3390/cancers12123648	methodology	1	NA	Primary outcome: variable type	Time-to-event	33291810
10.3390/cancers12123648	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	33291810
10.3390/cancers12123648	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	33291810
10.3390/cancers12123648	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	NA	33291810
10.3390/cancers12123648	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33291810
10.3390/cancers12123648	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33291810
10.3390/cancers12123648	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	33291810
10.3390/cancers12123648	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33291810
10.3390/cancers12123648	results	1	NA	Number of covariates adjusted for/matched on	8	33291810
10.3390/cancers12123648	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)	33291810
10.3390/cancers12123648	results	1	NA	Primary outcome: treatment effect contrast	HR	33291810
10.3390/cancers12123648	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33291810
10.3390/cancers12123648	results	1	NA	Primary outcome: unadjusted treatment effect	0.84	33291810
10.3390/cancers12123648	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.218	33291810
10.3390/cancers12123648	results	1	NA	Primary outcome: adjusted treatment effect	0.8	33291810
10.3390/cancers12123648	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.152	33291810
10.3390/cancers12123648	study_information	NA	1	Patient-level data used	Yes	NA
10.3390/cancers12123648	study_information	NA	1	Clinical Trial	Yes	NA
10.3390/cancers12123648	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674	NA
10.3390/cancers12123648	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.3390/cancers12123648	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2	NA
10.3390/cancers12123648	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.3390/cancers12123648	study_information	NA	2	Patient-level data used	Yes	NA
10.3390/cancers12123648	study_information	NA	2	Clinical Trial	Yes	NA
10.3390/cancers12123648	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680	NA
10.3390/cancers12123648	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.3390/cancers12123648	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.3390/cancers12123648	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.3390/cancers12123648	study_information	NA	3	Patient-level data used	Yes	NA
10.3390/cancers12123648	study_information	NA	3	Clinical Trial	Yes	NA
10.3390/cancers12123648	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02775435	NA
10.3390/cancers12123648	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown	NA
10.3390/cancers12123648	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.3390/cancers12123648	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.3390/cancers12123648	study_information	NA	4	Patient-level data used	No	NA
10.3390/cancers12123648	study_information	NA	4	Clinical Trial	Yes	NA
10.3390/cancers12123648	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826	NA
10.3390/cancers12123648	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.3390/cancers12123648	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.3390/cancers12123648	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.3390/cancers13102406	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma	NA
10.3390/cancers13102406	general_information	NA	NA	Countries of first author affiliations	italy	NA
10.3390/cancers13102406	general_information	NA	NA	Countries of last author affiliations	italy	NA
10.3390/cancers13102406	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic	NA
10.3390/cancers13102406	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned	NA
10.3390/cancers13102406	general_information	NA	NA	Mentioned sources of funding	No fundings	NA
10.3390/cancers13102406	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None	NA
10.3390/cancers13102406	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.3390/cancers13102406	methodology	1	NA	Treatment name 1	NA	34067521
10.3390/cancers13102406	methodology	1	NA	Study 'number(s)' for treatment 1	1	34067521
10.3390/cancers13102406	methodology	1	NA	Treatment name 2	NA	34067521
10.3390/cancers13102406	methodology	1	NA	Study 'number(s)' for treatment 2	2	34067521
10.3390/cancers13102406	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	34067521
10.3390/cancers13102406	methodology	1	NA	Anchored comparison?	No	34067521
10.3390/cancers13102406	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	34067521
10.3390/cancers13102406	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	34067521
10.3390/cancers13102406	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	34067521
10.3390/cancers13102406	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	34067521
10.3390/cancers13102406	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	NA	34067521
10.3390/cancers13102406	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables	34067521
10.3390/cancers13102406	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables	34067521
10.3390/cancers13102406	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	34067521
10.3390/cancers13102406	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	34067521
10.3390/cancers13102406	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	74	34067521
10.3390/cancers13102406	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	191	34067521
10.3390/cancers13102406	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	34067521
10.3390/cancers13102406	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No	34067521
10.3390/cancers13102406	results	1	NA	Primary outcome: treatment effect contrast	NA	34067521
10.3390/cancers13102406	study_information	NA	1	Patient-level data used	Yes	NA
10.3390/cancers13102406	study_information	NA	1	Clinical Trial	No	NA
10.3390/cancers13102406	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua.	NA
10.3390/cancers13102406	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.3390/cancers13102406	study_information	NA	2	Patient-level data used	No	NA
10.3390/cancers13102406	study_information	NA	2	Clinical Trial	Yes	NA
10.3390/cancers13102406	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01387503	NA
10.3390/cancers13102406	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy	NA
10.3390/cancers13102406	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3	NA
10.3390/cancers13102406	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Medical Condition of Interest Name	steroid-refractory acute graft-versus-host disease	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of last author affiliations	usa	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company	NA
10.36469/jheor.2021.19008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Mentioned sources of funding	None mentioned	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	No such section presenting competing interest/conflict of interest	NA
10.36469/jheor.2021.19008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No	NA
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 1	remestemcel-l-rknd	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 1	1	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 2	ruxolitinib	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 2	2	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Anchored comparison?	No	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	33768123
10.36469/jheor.2021.19008	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	33768123
10.36469/jheor.2021.19008	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	49	33768123
10.36469/jheor.2021.19008	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	55	33768123
10.36469/jheor.2021.19008	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55	33768123
10.36469/jheor.2021.19008	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	33768123
10.36469/jheor.2021.19008	results	1	NA	Number of covariates adjusted for/matched on	3	33768123
10.36469/jheor.2021.19008	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity	33768123
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: treatment effect contrast	RR	33768123
10.36469/jheor.2021.19008	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	33768123
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: unadjusted treatment effect	1.21	33768123
10.36469/jheor.2021.19008	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.21	33768123
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: adjusted treatment effect	1.13	33768123
10.36469/jheor.2021.19008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.45	33768123
10.36469/jheor.2021.19008	study_information	NA	1	Patient-level data used	Yes	NA
10.36469/jheor.2021.19008	study_information	NA	1	Clinical Trial	Yes	NA
10.36469/jheor.2021.19008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336230	NA
10.36469/jheor.2021.19008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.36469/jheor.2021.19008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.36469/jheor.2021.19008	study_information	NA	1	Number of treatment arms (clinical trial only)	1	NA
10.36469/jheor.2021.19008	study_information	NA	2	Patient-level data used	No	NA
10.36469/jheor.2021.19008	study_information	NA	2	Clinical Trial	Yes	NA
10.36469/jheor.2021.19008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02953678	NA
10.36469/jheor.2021.19008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.36469/jheor.2021.19008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2	NA
10.36469/jheor.2021.19008	study_information	NA	2	Number of treatment arms (clinical trial only)	1	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Medical Condition of Interest Name	ankylosing spondylitis	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of first author affiliations	canada	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of last author affiliations	switzerland	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.5152/eurjrheum.2018.18162	methodology	1	NA	Treatment name 1	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Study 'number(s)' for treatment 1	1;2	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Treatment name 2	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Study 'number(s)' for treatment 2	3	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Anchored comparison?	Yes	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30388073
10.5152/eurjrheum.2018.18162	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Treatment name 1	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Study 'number(s)' for treatment 1	1;2	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Treatment name 2	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Study 'number(s)' for treatment 2	3	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Anchored comparison?	No	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	NA	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	30388073
10.5152/eurjrheum.2018.18162	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	208	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	107	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	197	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	120	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	196	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	120	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Number of covariates adjusted for/matched on	5	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Primary outcome: treatment effect contrast	OR	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	Primary outcome: adjusted treatment effect	0.91	30388073
10.5152/eurjrheum.2018.18162	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.795	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	208	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	197	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	120	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Number of covariates adjusted for/matched on	5	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Primary outcome: treatment effect contrast	OR	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	Primary outcome: adjusted treatment effect	1.6	30388073
10.5152/eurjrheum.2018.18162	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.047	30388073
10.5152/eurjrheum.2018.18162	study_information	NA	1	Patient-level data used	Yes	NA
10.5152/eurjrheum.2018.18162	study_information	NA	1	Clinical Trial	Yes	NA
10.5152/eurjrheum.2018.18162	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358175	NA
10.5152/eurjrheum.2018.18162	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.5152/eurjrheum.2018.18162	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2018.18162	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	Patient-level data used	Yes	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	Clinical Trial	Yes	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01649375	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2018.18162	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	Patient-level data used	No	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	Clinical Trial	Yes	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00085644	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2018.18162	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of first author affiliations	usa	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of last author affiliations	uk	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes	NA
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes	NA
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 1	secukinumab 150 mg	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 2	etanercept	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 2	4	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Anchored comparison?	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 12	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 1	secukinumab 150 mg	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 1	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 2	etanercept	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 2	4	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Anchored comparison?	No	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 24	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 1	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 2	etanercept	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 2	4	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Anchored comparison?	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 12	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 1	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 2	etanercept	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 2	4	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Anchored comparison?	No	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 24	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	NA	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No	31364979
10.5152/eurjrheum.2019.19057	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	101	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	104	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	458	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	567	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	159	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Number of covariates adjusted for/matched on	11	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Primary outcome: treatment effect contrast	OR	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	Primary outcome: adjusted treatment effect	0.57	31364979
10.5152/eurjrheum.2019.19057	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.186	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	101	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	458	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Number of covariates adjusted for/matched on	11	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Primary outcome: treatment effect contrast	OR	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	Primary outcome: adjusted treatment effect	1.47	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.173	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	101	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	104	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	461	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	567	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	159	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Number of covariates adjusted for/matched on	11	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Primary outcome: treatment effect contrast	OR	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	Primary outcome: adjusted treatment effect	0.86	31364979
10.5152/eurjrheum.2019.19057	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.722	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	101	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	461	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Number of covariates adjusted for/matched on	11	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Primary outcome: treatment effect contrast	OR	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	Primary outcome: adjusted treatment effect	3.28	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA	31364979
10.5152/eurjrheum.2019.19057	study_information	NA	1	Patient-level data used	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	1	Clinical Trial	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634	NA
10.5152/eurjrheum.2019.19057	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.5152/eurjrheum.2019.19057	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2019.19057	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	Patient-level data used	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	Clinical Trial	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2019.19057	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	Patient-level data used	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	Clinical Trial	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02404350	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2019.19057	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	Patient-level data used	No	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	Clinical Trial	Yes	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00317499	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more	NA
10.5152/eurjrheum.2019.19057	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	NA	NA
